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ABSTRACT OF DISSERTATION 
LYMPHOCYTE-MEDIATED INFLAMM-AGING IN THE HORSE 
Senior horses (≥20 years) exhibit inflamm-aging, or chronic, low-grade 
inflammation that occurs systemically with aging, similarly to humans. Inflamm-aging has 
previously been characterized in the horse in circulation as well as specifically being 
mediated by lymphocytes and monocytes. In humans, inflamm-aging has been associated 
with increased morbidity and mortality. However, in the horse, relatively little about 
inflamm-aging is known regarding clinical effects or factors influencing severity. The 
contribution of lymphocytes to inflamm-aging of senior horses was examined, specifically 
through determining the relationships of inflamm-aging with various other health 
parameters, effects of seasonality, and the extent to which inflamm-aging can be modulated 
by anti-inflammatory phytonutrient curcumin. The overall hypothesis of this research is 
that lymphocyte-mediated inflamm-aging of the senior horse is associated with various 
factors including season, endocrine function, body composition, and nutritional status, and 
may be modulated by polyphenol curcumin. The effect of season on lymphocyte-mediated 
inflamm-aging was examined, and senior horses exhibited elevated inflammation 
compared to adult horse as expected, while also exhibiting changes in inflammatory 
cytokine production and gene expression throughout the year. In addition to season, 
pituitary pars intermedia dysfunction (PPID), a common endocrinopathy in senior horses 
that is associated with immunosuppression, was examined in a group of senior horses to 
determine any effects on degree of inflamm-aging. Results indicated no significant 
differences between age-matched PPID and non-PPID horses for lymphocyte-mediated 
inflammatory cytokine production or gene expression. The immunosuppressive aspect of 
PPID does not appear to be associated with the degree of lymphocyte-mediated 
inflammation of the aged horse. Additionally, an expansive correlative study was 
undertaken to determine relationships between inflamm-aging and basal nutritional status, 
body composition, age, and PPID within a similarly-managed senior horse population. 
Results showed various relationships between inflammatory markers and nutritional status, 
particularly yielding positive associations with serum folate and with serum fatty acids 
C22:2n6c and C22:5n3c. Inflammation was also associated with age itself but was not 
associated with body composition parameters and showed mild association with PPID (and 
serum inflammatory C-reactive protein). As a whole, this study demonstrates that 
nutritional status can be associated with inflammatory markers. Similarly, many 
phytonutrients have exhibited anti-inflammatory properties, which may be beneficial to the 
senior horse exhibiting inflamm-aging. Specifically, the effects of polyphenols including 
curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene on 
lymphocyte production of inflammatory cytokines by senior horses were examined in vitro 
and found to significantly reduce inflammation similarly to common non-steroidal anti-
inflammatory drugs. This study led to the in vivo investigation of the effectiveness of 
curcumin in modulating chronic inflammation of the senior horse. No significant 
differences were seen between groups receiving curcumin and placebo for the various 
inflammatory parameters, which may be due to the dose or low bioavailability of curcumin. 
As a whole, this research provides further understanding of factors associated with 
inflamm-aging of the senior horse. 
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CHAPTER 1 
LITERATURE REVIEW 
Senior horses generally refer to those ≥ 20 years old, which similar to the senior 
human population, is a demographic of increasing importance as numbers continue to rise. 
Senior horses (≥20 years) comprise approximately 11.4% of the equine population in the 
United States (USDA, 2016), while those ≥15 years compose approximately 29% of the 
horses in the United Kingdom (≥15 years) (Ireland et al., 2011a). This USDA estimate of 
senior horses (≥20 years) comprising 11.4% of the US equine population (USDA, 2016) is 
increased from the 7.6% estimated only ten years prior (USDA, 2006), indicating the 
growth of the senior demographic among equids. Furthermore, among equine facilities in 
the United States, 44.6% possessed one or more senior horse (≥20 years) (USDA, 2016). 
These senior horses are frequently ridden for pleasure or kept as companion animals, while 
some continue engaging in athletic competitions and breeding into their late teens and 
twenties (Ireland et al., 2011a). Causes of mortality among horses aged 20 or older in the 
United States include: other (26.6%, with old age as the most common specified cause), 
colic (13.4%), cancer (13.2%), neurologic problems (12.1%), and chronic weight loss 
(11.7%) (USDA, 2016).  
An Overview of Inflamm-aging 
The onset of old age is associated with multiple physiological changes, particularly 
those associated with the immune system. Horses, like humans, exhibit the phenomenon 
of inflamm-aging (chronic, systemic, low-grade inflammation that is associated with 
advanced age), in addition to exhibiting immunosenescence (decreased immune response 
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associated with old age). Initially the occurrence of inflamm-aging appears somewhat 
paradoxical in the face of the existence of immunosenescence; however, this phenomenon 
of inflamm-aging has traditionally been thought to occur as an overload response of the 
immune system being subjected to countless mitogens over the course of a lifetime. 
(Adams et al., 2008; Franceschi et al., 2000; Vasto et al., 2007). More recently, inflamm-
aging has specifically been thought to derive from at least some of the following factors: 
1) increased cell debris due to potential accumulation time and/or deficient elimination, 2) 
senescent cells and their secretory pro-inflammatory cytokines, 3) immunosenescence, 
which is likely exacerbated by persistent infections, 4) endogenous microbiota of the 
digestive tract potentially leaking into the surrounding tissues with age, causing chronic 
inflammation, or a shift toward more pro-inflammatory types of microbiota with age, and 
5) increased coagulation with aging (Franceschi and Campisi, 2014). 
 Given the variety of stimuli thought to trigger inflamm-aging, it is not surprising 
that quite a few mechanisms may be involved in this phenomenon. The classic 
inflammatory cascade is regulated by nuclear factor(NF)-κβ and is thought to be the 
primary pathway by which inflamm-aging is mediated (Salminen et al., 2008; Xia et al., 
2016). However, the target of rapamycin (TOR) pathway has also been researched in 
regards to inflamm-aging, as it regulates longevity through a variety of means (Stanfel et 
al., 2009) and also is associated with NF-κB activation, suggesting a regulatory role in 
inflamm-aging (Temiz-Resitoglu et al., 2017; Xia et al., 2016). Other pathways that may 
be involved in inflamm-aging either due to their effects on aging as a whole or due to their 
effects specifically on inflammation (whether pro- or anti-inflammatory) include: Retinoic-
3 
acid-inducible gene-I (RIG-I), Notch, Sirtuin, Transforming growth factor(TGF)-β, and 
Ras pathways (Xia et al., 2016).  
Inflamm-aging manifests itself by increased gene expression and protein 
production of various inflammatory cytokines, both systemically and specifically mediated 
by peripheral blood mononuclear cells (PBMC) (Adams et al., 2008; Adams et al., 2009; 
Fagiolo et al., 1993). In humans, old age has been linked to increases in pro-inflammatory 
interleukin(IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), 
and serum amyloid A (SAA) (Franceschi et al., 2000; Ostan et al., 2015). Similarly, in the 
horse, inflamm-aging has been characterized by increased production of IFN-γ and TNF-
α mediated by lymphocytes and monocytes as well as increased serum TNF-α protein 
levels and increased whole blood gene expression of IL-1β, IL-15, IL-18, and TNF-α 
(Adams et al., 2008; Adams et al., 2009). More recently, inflamm-aging in the horse has 
also been characterized by increased PBMC-mediated IFN-γ gene expression (Adams et 
al., 2015).  
In humans, inflamm-aging is associated with morbidity and mortality (Franceschi 
and Campisi, 2014). Furthermore, inflamm-aging underlies various maladies including 
Alzheimer’s disease, Parkinson’s disease, macular degeneration, osteoporosis, 
cardiovascular diseases such as atherosclerosis, and various others (Xia et al., 2016). 
Chronic inflammation even appears to be associated with cancer and diabetes (Freund et 
al., 2010; Vasto et al., 2009; Xia et al., 2016), two maladies particularly rampant in the 
United States currently. Given the association of inflamm-aging with numerous diseases 
in aged humans, it is anticipated that inflamm-aging has negative implications on equine 
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health; however, specific clinical conditions associated with inflamm-aging in the horse 
have not yet been identified. 
Inflamm-aging and Season 
It is unknown whether external conditions, such as season, exacerbate inflamm-
aging. Seasonal immune changes in other species have been demonstrated (Bilbo et al., 
2002; Bowden et al., 2007; McFarlane et al., 2012). Seasonality in cytokine levels both 
circulating in serum and mediated by PBMC have been demonstrated in baboons 
(McFarlane et al., 2012). Particularly, pro-inflammatory serum C-reactive protein and 
mitogen-stimulated PBMC production of TNF-α and IL-6 have exhibited lowest levels in 
December, while serum IL-6 levels for baboons housed outdoors were actually highest in 
December, indicating that different types of cells may be producing cytokines quite 
differentially at a given time of year  (McFarlane et al., 2012). Siberian hamsters subjected 
to lipopolysaccharide injection also exhibited decreased inflammatory response (IL-6 and 
IL-1β) in addition to decreased fever and anorexia duration, when exposed to photoperiods 
reflecting winter in comparison to summer (Bilbo et al., 2002). 
 In the horse specifically, a few studies have been performed regarding seasonal 
changes in immune parameters; however, several of these studies primarily examined 
horses in diseased states known to have seasonal elements. For example, in a study 
examining summer pasture-associated obstructive pulmonary disease (SPAOPD), PBMC-
mediated gene expression of IFN-γ was higher in summer compared to winter in both 
diseased (p<0.05) and control (p<0.10) horses (Beadle et al., 2002). In a large-scale 
retrospective study examining lower airway inflammation of racehorses, bronchoalveolar 
lavage (BAL) revealed influences of season on cell profiles; specifically, lower airway 
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inflammation was associated with an increase in mast cell percentage, which occurred most 
commonly in spring (Secombe et al., 2015). Another study examining stable air quality 
seasonally found that BAL samples from trotting horses in training had elevated levels of 
IL-6 expression in winter compared to summer, however the horses were stabled all but 4-
7 hours of the day during winter, while only around 12 hours during summer which may 
have also affected the immune system aside from season alone (Riihimaki et al., 2008). 
Additionally, serum IL-4 has been shown to be elevated in winter compared to late spring 
in ponies (Wray et al., 2013). Thus, the horse has demonstrated some seasonal variations 
in immune parameters, but specifically examining inflamm-aging seasonally has not yet 
been investigated. 
 Several inflammatory diseases in humans have demonstrated seasonal fluctuations 
(Araki et al., 2017; Feldthusen et al., 2016; Vinnik et al., 2016). Inflamm-aging itself has 
not been examined seasonally to determine whether it appears exacerbated at certain times 
of year. However, given the prevalence of seasonality in inflammatory human diseases, 
seasonal fluctuations associated with inflamm-aging are likely.  
Additionally, although little is known regarding seasonal changes in inflammation 
in the horse, seasonal rhythms in various hormones are known to occur in horses. In healthy 
horses, α-melanocyte stimulating hormone (α-MSH) and adrenocorticotropin hormone 
(ACTH) both display rather marked seasonal patterns, with levels of both these hormones 
peaking in fall as horses prepare for winter (McFarlane et al., 2011). These seasonal 
hormonal patterns appear to derive from both the hypothalamus and the pituitary, as 
demonstrated by a sheep model in which the neural tissue connecting the two organs was 
surgically removed (Lincoln and Richardson, 1998). Although ACTH does not have a 
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clearly defined relationship with either pro- or anti-inflammatory cytokines, α-MSH has 
demonstrated numerous anti-inflammatory, antioxidant effects (Bhardwaj et al., 1996; 
Catania et al., 1999; Luger and Brzoska, 2007; Oktar et al., 2004). Specifically, α-MSH 
increases anti-inflammatory IL-10 production by monocytes (Bhardwaj et al., 1996) and 
also downregulates LPS-activated NF-κB (Luger et al., 2000). Thus, the seasonal rhythm 
of anti-inflammatory α-MSH in the horse may influence inflammatory cytokine production 
over the course of the year. 
Inflamm-aging and Pituitary Pars Intermedia Dysfunction (PPID) 
 ACTH and α-MSH hormones are elevated in horses with the endocrinopathy 
known as pituitary pars intermedia dysfunction (PPID) or equine Cushing’s disease 
(McFarlane et al., 2011). PPID is prevalent among aged horses, affecting 15-30% of this 
demographic, and is characterized by the presence of hypertrichosis (McFarlane et al., 
2011). Other clinical signs of PPID include polydipsia, polyuria, hyperhidrosis, muscle 
atrophy, laminitis, regionalized adiposity, immunosuppression and increased susceptibility 
to disease, behavioral abnormalities (such as lethargy), reproductive infertility, and 
neurologic impairment (McFarlane, 2011). PPID is thought to be caused by dopaminergic 
neurodegeneration of the pituitary pars intermedia, compromising the natural negative 
feedback loop such that the PPID horse produces elevated levels of pro-opiomelanocortin 
(POMC)-derived hormones ACTH and α-MSH (McFarlane, 2011). These elevated levels 
of ACTH and/or α-MSH are likely the mediators of the clinical signs that characterize 
PPID. Although exact mechanisms are not clear (Hart et al., 2016), these POMC-derived 
hormones have demonstrated preliminary effects on hair pigmentation in humans (Bohm 
et al., 2006; Tobin, 2008), and may affect hair growth in the horse, leading to the 
7 
characteristic hypertrichosis. As previously discussed, α-MSH also has many anti-
inflammatory properties (Bhardwaj et al., 1996; Catania et al., 1999; Luger and Brzoska, 
2007; Oktar et al., 2004), which when produced at the elevated levels seen in PPID, may 
lead to the clinical symptoms of immunosuppression and increased susceptibility to disease 
characterizing PPID. Specifically, PPID horses have been reported to exhibit increased 
bacterial infections causing dermatophilosis, pneumonia, and abscesses (McFarlane, 
2011). This decreased ability of the PPID horse to respond to pathogens may be 
exacerbated by the fact that the senior horse is already immune-compromised, exhibiting 
the age-related phenomena of inflamm-aging and immunosenescence.  
 A few studies have been performed to determine immune changes associated with 
PPID. PPID horses have demonstrated decreased neutrophil function, evidence by 
decreased oxidative burst activity as well as decreased adhesion (McFarlane et al., 2015). 
In examining oxidative burst activity, a positive association was shown for the ratio of 
insulin:α-MSH, indicating a potential role for hormones in immune function of the PPID 
horse (McFarlane et al., 2015). Another study reported that PPID horses exhibit total 
leukocyte cytokine dysregulation, in which cytokines varied as to whether they reflected 
age-matched non-PPID (IL-8) or adult non-PPID horses (IFN-γ, IL-6) depending on the 
cytokine, although the spread of much of the data for each cytokine was quite large 
(McFarlane and Holbrook, 2008). Still, this differential expression of cytokines in the PPID 
horse suggests that the aged, PPID horse may exhibit inflamm-aging differently from the 
non-PPID, aged horse. 
Although some research regarding PPID has been performed, studies to better 
understand the pathogenesis of this endocrine disease, particularly as it relates to 
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immunosuppression and susceptibility to opportunistic infections, need to be undertaken. 
Furthermore, inflamm-aging of the senior horse has been established both in whole blood 
as well as being mediated by PBMC. Thus, it would be of interest to determine if PPID 
specifically affects PBMC function of the senior horse exhibiting inflamm-aging. 
Inflamm-aging and General Health  
 In addition to the effects of PPID on the immune system of the senior horse, little 
is known regarding the implications of inflamm-aging of the horse in relation to overall 
health, specifically regarding nutritional status and muscle composition. Given the 
prevalence of senior horses, with nearly half of the equine operations in the US having a 
least one senior horse (USDA, 2016), promoting healthspan in addition to lifespan is key. 
And, given that inflamm-aging appears to underlie most age-associated diseases in humans 
(Freund et al., 2010; Vasto et al., 2009; Xia et al., 2016), understanding physiological 
relationships of other health parameters with inflamm-aging will likely help promote better 
quality of life through improved management of the senior horse.  
 Loss of muscle mass is associated not only with the occurrence of PPID, as 
previously mentioned, but is also associated with advanced aging. This old age-associated 
loss of muscle mass is termed sarcopenia. In humans, sarcopenia occurs at a rate of 
approximately 6% per decade starting mid-life (Janssen, 2010; Janssen and Ross, 2005). 
Although longitudinal studies examining rates of sarcopenia have not been performed in 
the horse, the occurrence of sarcopenia in the horse is a known phenomenon (Lehnhard et 
al., 2004; Reed et al., 2015). In fact, an owner-reported survey of over 900 horses in the 
United Kingdom found that 23.9% of horses aged 15 years or older have exhibited loss of 
muscle tone (Ireland et al., 2011b). 
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 Some studies have found an inverse relationship between inflammation and mass 
and strength of skeletal muscle. Various human studies have found increased pro-
inflammatory cytokines (TNF-α, IL-6, and CRP) associated with decreased muscle mass 
and strength, including in the elderly (Schaap et al., 2009; Schaap et al., 2006; Visser et 
al., 2002). Additionally, sarcopenia in cattle appears to be associated with lymphocyte 
(primarily CD8+) inflammation (Costagliola et al., 2016).  
 In the horse, specific muscle changes associated with age include: shifts in muscle 
fiber types (increased percentage of myosin heavy chain types I and IIA) (Li et al., 2016), 
decreased density of mitochondria (Li et al., 2016), and decreased satellite cell activity in 
response to exercise (Reed et al., 2015). This decreased satellite cell activity in response to 
exercise is thought to be associated with the increased inflammatory state of the senior 
horse experiencing inflamm-aging. It is thought that inflamm-aging may diminish the 
ability of the senior horse to experience hypertrophy and acute exercise-associated 
inflammation similarly to their younger counterparts during strenuous exercise (Reed et 
al., 2015), making the maintenance of physical fitness more difficult in the senior horse. 
As exercise is key for prevention and treatment of sarcopenia and considering regular 
exercise in humans and mice tends to be anti-inflammatory, including in regards to 
inflamm-aging (Lesniewski et al., 2011; Montero-Fernandez and Serra-Rexach, 2013; 
Sallam and Laher, 2016; Woods et al., 2012), further research should be performed to better 
understand any connections between sarcopenia and inflamm-aging in the horse in order 
to better manage the senior horse. 
In relation to nutritional status of the senior horse and potential relationships with 
inflamm-aging, various vitamins, minerals, and fatty acids have demonstrated biological 
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effects on immunity and specifically inflammation. Vitamin D has well-established anti-
inflammatory properties (Abbas, 2016; Capri et al., 2006; Moore et al., 2005). Vitamin C 
has been shown to downregulate IL-6 in bone marrow mononuclear cells of adults aged 67 
± 6.8 years, another population of cells where inflamm-aging has been demonstrated 
(Pangrazzi et al., 2017). Vitamin E has also been shown to mitigate inflamm-aging, 
downregulating the elevated levels of pro-inflammatory prostaglandin E2 (PGE2) in aged 
mice (Wu et al., 2001). In the aged horse, supplementation with Vitamin E has improved 
bacterial killing capacity of monocytes and neutrophils (Petersson et al., 2010). The 
immunity of the horse also appears to be affected by some minerals, such as deficiencies 
in selenium (Brummer et al., 2013). 
Poly-unsaturated fatty acids (PUFA) have been associated with anti-inflammatory 
activity as well. Independent of age, PUFA, especially n-3 fatty acids, exhibited positive 
correlations with anti-inflammatory cytokines (IL-10, transforming growth factor[TGF]-β) 
and negative correlations with pro-inflammatory cytokines (IL-6, TNF-α) in a large-scale 
human population study primarily focused on the aged population (78.9% ≥65 yrs; age 
range = 20-98 yrs) (Ferrucci et al., 2006). This suggests that increased levels of dietary 
PUFA may decrease the degree of inflamm-aging (Ferrucci et al., 2006). Another short-
term study found that an infusion of fish oil-based n-3 fatty acids decreased endotoxin-
stimulated production of TNF-α, IL-1, IL-6, and IL-8 by monocytes, again indicating an 
anti-inflammatory capacity of n-3 fatty acids (Mayer et al., 2003). Furthermore, in horses 
with chronic lower airway inflammatory disease, supplementation with n-3 fatty acids has 
also demonstrated clinical benefits (Nogradi et al., 2015). Clearly nutrition has 
demonstrated clinical effects on inflammation and specifically inflamm-aging (Dasilva et 
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al., 2016; Dato et al., 2016) and should therefore be explored specifically in the senior 
horse experiencing inflamm-aging. 
Inflamm-aging and Mitigation by Polyphenols, Particularly Curcumin 
In addition to vitamins, minerals, and fatty acids, various plant-derived bioactive 
polyphenols have anti-inflammatory, antioxidant effects that may benefit the senior horse 
exhibiting inflamm-aging. Some polyphenols of interest include resveratrol, quercetin, 
pterostilbene, hydroxypterostilbene, and curcumin.  
Resveratrol, a phytoalexin and sirtuin-1 activator found in red wine, has 
demonstrated anti-inflammatory effects both in vitro and in vivo (Kelly, 2010; Knutson and 
Leeuwenburgh, 2008). Resveratrol mediates anti-inflammatory effects through both the 
NF-κB and MAPK pathways, decreasing expression of TNF-α and IL-1β while also 
decreasing activity of myeloperoxidase, a marker of oxidative stress (Zhang et al., 2017). 
Furthermore, resveratrol has exhibited various anti-inflammatory and anti-oxidant effects 
in an aged mouse model, including decreasing age-related inflammatory profiles (Gines et 
al., 2017; Wong et al., 2011), indicating that resveratrol is able to modulate the degree of 
inflamm-aging. In the horse, in vitro work has demonstrated the ability of resveratrol to 
decrease neutrophil-mediated oxidative stress (Kohnen et al., 2007). Additionally, oral 
supplementation of horses with resveratrol has reportedly decreased some measures of 
lameness (Watts et al., 2016) and also increased antioxidant capacity of older horses 
(Ememe et al., 2015), indicating that resveratrol is biologically active in the horse and may 
be able to decrease inflamm-aging. 
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Quercetin, a flavonoid commonly found in various fruits, vegetables and tea, has 
exhibited anti-inflammatory and antioxidant effects both in vitro and in vivo, as well. 
Quercetin has particularly been successful in mitigating inflammation induced by high-fat 
and high-fructose diets in rodents (Das et al., 2013; Vazquez Prieto et al., 2015). Quercetin 
has been shown to exert anti-inflammatory effects by downregulating the NF- κβ and p38 
MAPK signaling pathways (Wang et al., 2017). In a model of age-associated macular 
degeneration, which has an underlying inflammatory component, quercetin was shown to 
decrease inflammation (IL-6, IL-8) (Hytti et al., 2015), showing potential for the capability 
of quercetin to decrease age-associated inflammation.  
Pterostilbene, an analog of resveratrol found in blueberries, and 
hydroxypterostilbene, an analog of pterostilbene found in the plant Sphaerophysa salsula, 
have likewise demonstrated anti-inflammatory and antioxidant effects. Pterostilbene acts 
as a nuclear factor erythroid 2-related factor-2 (Nrf2) activator, decreasing inflammatory 
cytokines in a mouse model of diabetes (Sireesh et al., 2017). Pterostilbene as well as 
resveratrol and quercetin have been shown to decrease pro-inflammatory expression of 
TNF-α, IL-1β, IL-6, and iNOS, while also decreasing NF-κB activation in macrophage 
and kidney cell lines, respectively. Hydroxypterostilbene has demonstrated anti-
inflammatory activity as well by decreasing pro-inflammatory COX-2 protein levels 
(Cheng et al., 2014; Takemoto et al., 2015). Hydroxypterostilbene mediated these effects 
through the PI3K/Akt, MAPK, and mTOR signaling pathways (Cheng et al., 2014). 
Curcumin, the primary anti-inflammatory component of the turmeric spice derived 
from the rhizomes of Curcuma longa (Kumar et al., 2010), is of particular interest 
regarding anti-inflammatory capacity. In addition to the extensive evidence of its various 
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anti-inflammatory, anti-oxidant, anti-tumor, and various other health-promoting effects 
(Franck et al., 2008; Schaaf et al., 2009; Venkatesan and Chandrakasan, 1995), curcumin 
has specifically demonstrated effects in the horse. Several equine studies in vivo and ex 
vivo have shown the potential of curcumin as an anti-inflammatory, antioxidant agent 
(Clutterbuck et al., 2009; Derochette et al., 2013; Franck et al., 2006; Franck et al., 2008; 
Siard et al., 2016). In a preliminary study, horses supplemented orally with curcumin 
demonstrated anti-inflammatory effects, showing decreased levels of whole blood IL-1β 
and IL-1RN expression (Farinacci et al., 2009b). Taken together, curcumin in particular 
appears a prime candidate to mitigate inflamm-aging of the senior horse.  
Curcumin is a pleiotropic agent, exerting various biological effects by a vast 
number of mechanisms, with even anti-inflammatory effects being mediated through quite 
a variety of different ways (Di Pierro et al., 2013). Primary signaling pathways through 
which curcumin suppresses inflammation include NF-κB and COX. Specifically, curcumin 
inhibits IκB kinase (IKK) activity, decreasing phosphorylation of IκBα, thereby 
sequestering more NF-κB outside of the nucleus and keeping NF-κB from acting as a 
transcription factor, leading to decreased production of inflammatory cytokines, such as 
IL-6, IL-12, and TNF-α (Bharti et al., 2003; Nanji et al., 2003). Curcumin modulates the 
COX pathway, which may actually be a caveat of the NF-κB pathway (Kim et al., 2006), 
by selectively inhibiting COX-2 activity (Goel et al., 2001), such that it cannot convert 
arachidonic acid into pro-inflammatory PGE2 (Chizzolini and Brembilla, 2009; Park and 
Conteas, 2010), thereby suppressing inflammation. 
Curcumin has mediated these anti-inflammatory effects extensively in vitro 
(Derochette et al., 2013; Lin et al., 2014) while also having numerous biological effects in 
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vivo, including decreased inflammation (Venkatesan and Chandrakasan, 1995). In addition 
to the previously mentioned small-scale study in horses examining curcumin 
supplementation on inflammation (Farinacci et al., 2009b), several other studies in vivo 
and ex vivo have demonstrated the potential of curcumin as an anti-inflammatory, 
antioxidant agent in the horse (Clutterbuck et al., 2009; Derochette et al., 2013; Franck et 
al., 2006; Franck et al., 2008; Siard et al., 2016).  
Although free curcumin is readily metabolized following oral administration 
(Kumar et al., 2010) and therefore not biologically active, many formulations have been 
engineered to enable curcumin to remain bioavailable and bioactive. Some of the most 
researched formulations that have been shown to increase bioavailability include solid lipid 
curcumin particle™ technology (Longvida®) (Gota et al., 2010) and phosphatidylcholine 
curcumin phytosomes (Meriva®) (Cuomo et al., 2011). In older humans, Longvida® 
administered orally has demonstrated biological effects by improving mood and working 
memory (Cox et al., 2015) as well as improving vascular endothelial function (Santos-
Parker et al., 2017). Additionally, Longivda® has decreased pathology associated with 
Alzheimer’s disease in an aged mouse model (Ma et al., 2013). Furthermore, Longvida has 
recently demonstrated anti-inflammatory effects, reducing serum TNF-α and IL-8, as well 
as decreasing circulating marker of muscle damage creatine kinase following exercise 
(McFarlin et al., 2016). Oral administration of Meriva® has also resulted in various anti-
inflammatory effects, ranging from improvements in inflammatory ocular conditions 
(Mazzolani and Togni, 2013) to decreased levels of pain, similarly to acetaminophen (Di 
Pierro et al., 2013). In a study of osteoarthritic patients, all markers of inflammation 
[interleukin(IL)-1β, IL-6, soluble CD40 ligand, soluble vascular adhesion molecule-1 
15 
(sVCAM-1), and erythrocyte sedimentation rate (ESR)] were significantly reduced in the 
treatment group (n=50) but not the control group (n=50) over the course of the 8 month 
study (Belcaro et al., 2010a). A previous study from the same group had also shown a 
decrease in elevated levels of CRP when treated with curcumin phytosomes over the course 
of 3 months (Belcaro et al., 2010b). Thus, these studies show that curcumin can certainly 
mediate biological effects, including decreasing inflammation, when administered orally 
using an enhanced bioavailability formulation. 
Given the bioavailability and bioactivity of various curcumin formulations and the 
fact that polyphenols including curcumin have been shown to decrease PBMC- and 
specifically lymphocyte-mediated inflammation (Afman et al., 2014; Ford et al., 2016; 
Literat et al., 2001; Siard et al., 2016), it is therefore likely that curcumin may be able to 
modulate lymphocyte-mediated inflamm-aging of the senior horse.  
Furthermore, inflamm-aging of the senior horse would provide a good model in 
which to test the anti-inflammatory nature of these phytonutrients, like curcumin, not only 
for potential benefits to the senior horse experiencing inflamm-aging but also for the many 
chronic inflammatory conditions common in the horse. Chronic inflammation is frequently 
treated with nonsteroidal anti-inflammatory drugs (NSAIDs), despite the fact that many 
NSAIDs have adverse side effects and/or are not indicated for chronic treatment of 
inflammation (Bessone, 2010; Ingrasciotta et al., 2015; Martinez Aranzales et al., 2015; 
McConnico et al., 2008; Monreal et al., 2004; Reed et al., 2006). Thus, the potential of 
polyphenols, such as curcumin, to attenuate inflammation in the senior horse may provide 
an alternative to the use of NSAIDs in treating chronic inflammation, while also benefiting 
the health of the senior horse as a whole by decreasing the degree of inflamm-aging. 
16 
Hypothesis and Specific Aims 
The overall hypothesis of this research is that lymphocyte-mediated inflamm-aging 
of the senior horse is associated with various factors including season, endocrine function, 
body composition, and nutritional status, and may be modulated by curcumin, a plant-
derived polyphenol. 
Specific aims are as follows: 
1. To determine the effects of season on lymphocyte-mediated inflamm-aging of
the senior horse.
2. To determine the relationship between lymphocyte-mediated inflamm-aging of
the senior horse and nutrient status, body composition,
hematology/biochemistry, and pituitary pars intermedia dysfunction (PPID).
3. To determine the relationship between lymphocyte-mediated inflamm-aging
and the age-associated endocrinopathy PPID in the senior horse.
4. To determine effects of polyphenols curcumin, resveratrol, pterostilbene,
hydroxypterostilbene, and quercetin on lymphocyte-mediated inflamm-aging
of the senior horse in vitro.
5. To determine the effectiveness of curcumin as an anti-inflammatory
supplement to modulate inflamm-aging of the senior horse.
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CHAPTER 2 
EFFECT OF SEASON ON LYMPHOCYTE-MEDIATED INFLAMM-AGING 
AND IMMUNOSENESCENCE IN THE HORSE 
Abstract 
Senior horses (≥20 years) exhibit changes in the immune system associated with 
advanced age, similarly to those evidenced in humans. Specifically, senior horses 
experience inflamm-aging or systemic, chronic, low-grade inflammation and 
immunosenescence or decreased immune response, particularly evidenced by decreased 
response to vaccination and decreased lymphocytes proliferation. While age is a factor 
known to impact immune responses, season has also been shown to influence immune 
responses of many species including fish, rodents, and primates. Although a few studies 
examining diseased horses have explored seasonal relationships with immune function, 
healthy horses have not yet been examined to determine if they display seasonal variations. 
Furthermore, the senior horse is of interest to gain a better understanding of when these 
immunosuppressed horses may be more prone to disease.  
In this study, peripheral blood mononuclear cells (PBMC) were collected from n=8 
senior (mean age = 23.38±1.66 yr) and n=8 adult horses (mean age = 10.75 ± 0.83 yr) 
monthly for one year. PBMC to be used for lymphocyte proliferation assay using 
carboxyfluorescein succinimidyl ester (CFSE) staining were stimulated with concanavalin 
A for 96 hours prior to flow cytometry analysis. PBMC for all other assays were stimulated 
with phorbol 12-myristate 13-acetate (PMA) for 4 hours. PBMC were then intracellularly 
stained for inflammatory cytokines interferon(IFN)-γ and tumor necrosis factor(TNF)-α 
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and analyzed using flow cytometry to determine the percent of lymphocytes producing 
each cytokine (%) as well as the mean fluorescence intensity (MFI). PBMC were also 
analyzed seasonally (January, April, July, and October) using RNA isolation, reverse 
transcription, and real-time polymerase chain reaction (RT-PCR) to determine gene 
expression of IFN-γ, TNF-α, interleukin(IL)-4, IL-6, and IL-10. Cortisol, 
adrenocorticotropin hormone (ACTH), and body weights were analyzed seasonally 
(January, April, July, and October) as well. Statistical analyses were performed using SAS 
9.4 software mixed procedures with repeated measures, and significance was set at p<0.05. 
 Results showed significant differences between senior and adult horses for all flow 
cytometry measures of inflammation and for lymphocyte proliferation (p<0.05), as 
expected. Seasonal differences were identified for IFN-γ MFI, %TNF-α, and TNF-α MFI 
(p<0.05). Gene expression of IL-6 varied seasonally, being significantly decreased in July 
(p<0.05), while TNF-α gene expression was highest in July compared to January and April 
(p<0.05). Gene expression of IFN-γ and TNF-α was also significantly greater for senior 
horses than adult horses (p<0.05). Body weight appeared to have some effects on immune 
parameters, but these seasonal changes are likely due to a wide and complex variety of 
mechanisms. In general, inflammation was decreased during winter and elevated in spring 
and summer. Furthermore, senior horses exhibited overall increased inflammation and 
decreased lymphocyte proliferation in comparison to adult horses, demonstrating the 
immune-compromising effects of aging. Thus, the senior horse exhibiting inflamm-aging 
and immunosenescence appears to be affected by seasonal immune changes, which may 
have management implications to best promote health. 
 
19 
Introduction 
In multiple species, old age is associated with various alterations in immune 
function, which can have negative implications on health. The horse is no exception, 
experiencing both inflamm-aging (systemic, chronic low-grade inflammation) and 
immunosenescence (decreased immune response) similar to elderly humans (Adams et al., 
2008; Franceschi et al., 2000). Inflamm-aging in the horse has been characterized as 
increased circulating pro-inflammatory cytokines, whole blood gene expression of 
inflammatory cytokines, and peripheral blood mononuclear cell (PBMC)-mediated 
production of inflammatory cytokines (Adams et al., 2008; Adams et al., 2009). 
Immunosenescence has also been characterized in the horse, encompassing both decreased 
response to vaccination and decreased lymphocyte proliferation of old horses in relation to 
young horses (Adams et al., 2008; Goto et al., 1993; Horohov et al., 1999). The occurrence 
of these age-associated changes in immune function have been well-established; however, 
the potential effect of season on the aged immune system merits investigation in the horse. 
Many species are known to exhibit seasonal changes in various parameters 
including immune response, body weight, adipose tissue content, voluntary food intake, 
metabolic rate, heat production, reproductive activity, length and color of hair coat, and 
hormone levels (McFarlane et al., 2012). Some of the species exhibiting seasonal changes, 
particularly in immune response, include various types of fish, rodents, and primates (Bilbo 
et al., 2002; Bowden et al., 2007; Mann et al., 2000; McFarlane et al., 2012). In a baboon 
study specifically examining seasonal changes in inflammation in the northern hemisphere, 
serum C-reactive protein (CRP), an acute phase protein, was decreased in December 
compared to June (p<0.05), and serum interleukin(IL)-6 also showed an effect of season 
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(p<0.001) (McFarlane et al., 2012). In another study, Siberian hamsters injected with 
lipopolysaccharide and subjected to short vs. long day length (to mimic winter and summer, 
respectively) experienced decreased inflammatory cytokine production (IL-6 and IL-1β) 
as well as decreased duration of fever and anorexia during short day length, indicating that 
immune response may be diminished during winter (Bilbo et al., 2002). 
 A few studies have also demonstrated effects of season on immune parameters in 
the horse (Riihimaki et al., 2008; Secombe et al., 2015; Wray et al., 2013). Peripheral blood 
mononuclear cells have been examined in equids to determine the effects on seasonal 
allergy-related changes in cytokine production (Beadle et al., 2002; Hamza et al., 2007). 
For example, a study examining equine insect bite hypersensitivity in Icelandic horses 
showed increased PBMC-mediated interferon(IFN)-γ and decreased IL-4 production and 
mRNA expression in winter compared to summer (Hamza et al., 2007). A study examining 
summer pasture-associated obstructive pulmonary disease (SPAOPD), another malady 
thought to have an allergic component, showed seasonal changes in PBMC-mediated IFN-
γ expression as well; however, in this study, IFN-γ expression was lower in the winter 
compared to summer, for both control and diseased horses (Beadle et al., 2002).  
The present study was performed to determine seasonal changes in lymphocyte-
mediated inflammatory cytokine production of senior horses (which are known to 
experience inflamm-aging and immunosenescence) compared to adult horses. We 
hypothesized that season will affect immune function in both senior and adult horses, with 
senior horses experiencing elevated inflammation and diminished lymphocyte proliferation 
relative to adult horses overall. Determining seasonal effects on immunity will provide a 
better understanding of when senior horses, which are already immunocompromised, may 
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be more prone to disease. Furthermore, determining whether season may be a potential 
confounding factor may aid in improving experimental design of future studies. 
Methods and Materials 
2.1. Animals 
Eight senior horses (mean age ± SD = 23.38 ± 1.77 yr) and eight adult horses (mean 
age ± SD = 10.75 ± 0.89) were housed at the University of Kentucky, Department of 
Veterinary Science Maine Chance Farm. Horses were maintained on pasture throughout 
the year, receiving mixed grass hay ad libitum during winter months. The horses also had 
access to salt and mineral blocks. All horses were free of clinical signs of infectious disease 
and did not exhibit signs of lameness throughout the study, and all sixteen horses enrolled 
completed the study. All procedures were in accordance with the University of Kentucky 
Institute of Animal Care and Use Committee.  
Due to the fact that the study duration was a year (April 2013 – March 2014), the 
diets of horses varied, with some horses receiving concentrates during the study. 
Specifically, all horses received the same isocaloric diet for the first 2 months of the study 
(50% oats, 50% alfalfa pellets). However, since the adult horses were gaining weight, for 
management purposes, the adult horses did not receive feed for the following 10 months 
of the study. The senior horses continued to receive the 50% oats, 50% alfalfa pellets 
mixture through September; however amounts changed in order to maintain body weight. 
The senior horses then received a senior feed October through December, then were 
returned to the maintenance diet of oats and alfalfa pellets, also receiving an additional 
balancer pellet in February and March. Although diet could not be accounted for in the 
model as a covariate because it was confounded with month, analysis was performed on 
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the 2 months at the beginning of the study when all horses received the same diet, as well 
as during the 10 months for the adult horses in which they received only forage, and similar 
results were found for these subsets in relation to analyzing all the data. Thus, it is unlikely 
that differences in feed afforded a significant role in the results of this study (see Section 
2.8 & 3.4). 
2.2. Data and Sample Collection 
Over the course of one year, the body weights of the horses were recorded monthly 
using a weight tape to determine any changes. Air temperatures were also collected using 
the data reported by the UK Ag Weather Center for Spindletop Farm (adjacent to Maine 
Chance Farm) at 1000 h on the days of blood collections, and hours of daylight were found 
on the Weather Underground website for Lexington, Kentucky. Heparinized blood was 
collected monthly in the morning (at approximately 1000 hours) via jugular venipuncture, 
from which PBMC were then isolated. Gene expression from PBMC was then examined 
seasonally (January, April, July, October). Serum and EDTA plasma was collected 
seasonally (January, April, July, October) to measure basal cortisol and 
adrenocorticotropin hormone (ACTH), respectively. 
2.3. PBMC Isolation and Freezing 
PBMC were isolated using a Ficoll-Paque Plus™ (Amersham Biosciences, 
Piscataway, NJ) density gradient and counted using a VICELLTM Counter-XR (Beckman 
Coulter, Miami, FL), as previously described (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006; Siard et al., 2016). Each month over the course of the year-long 
study, PBMCs were frozen in liquid nitrogen at a concentration of 2-5x107 in freeze media 
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(50% RPMI 1640 [Gibco, Grand Island, NY], 40% fetal bovine serum [Sigma-Aldrich, St. 
Louis, MO], and 10% dimethyl sulfoxide [Sigma]). 
2.4. Culture Preparation 
At the completion of the study, PBMC were thawed by horse for all months (n=12 
samples per horse), washed in cRPMI media (RPMI 1640 [Gibco, Grand Island, NY] 
supplemented with 2.5% fetal equine serum [FES; BioWest, Nuaillé, France], 55 μM 2-
mercaptoethanol [Gibco], and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL 
streptomycin [HyClone Pen/Strep/Glutamine solution; Thermo Scientific]), spun at 300g 
x 10 minutes, and resuspended in cRPMI. PBMC were then counted using the VICELL to 
attain desired plating concentrations.  
Prior to intracellular staining and RNA isolation, PBMC were plated at a 
concentration of 4x106 cells/mL in cRPMI media (in duplicate), stimulated with phorbol 
12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma) (single 
well per sample), and incubated 4 hours at 37oC, 5% CO2 (Adams et al., 2008; Adams et 
al., 2009; Breathnach et al., 2006; Siard et al., 2016). Brefeldin A (10 μg/mL; Sigma) was 
also added to all wells (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; 
Siard et al., 2016).  
Prior to proliferation analysis, PBMC were fluorescently tagged with 
carboxyfluorescein succinimidyl ester (CFSE), as previously described (Adams et al., 
2008), with the exception that the reaction was quenched with FES and washed with 10% 
FES, (instead of FBS). PBMC were then plated (in duplicate) at a concentration of 2x106 
cells/mL in cRPMI media, stimulated with concanavalin A (2.5 µg/mL; Sigma) (single 
well per sample), and incubated 96 hours at 37oC, 5% CO2 (Adams et al., 2008).  
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2.5. IFN-γ and TNF-α Intracellular Staining and Flow Cytometry 
Prior to intracellular staining, PBMC were transferred to duplicate 96-well V-
bottom plates, fixed with 2% paraformaldehyde (Sigma), and incubated at 4oC overnight. 
Intracellular staining for IFN-γ and TNF-α was performed as has previously been described 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016). Briefly, 
PBMC were washed in saponin buffer [PBS supplemented with 1% fetal bovine serum 
(FBS), 0.1% saponin (Sigma), and 0.1% sodium azide (Sigma)] and intracellularly stained 
with IFN-γ FITC mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg; 1:100 
dilution) or TNF-α anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob 
MacKay, University of Florida; 1:10 dilution) and secondary antibody FITC-conjugated 
goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL; 1:1000 dilution) (Adams et al., 
2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016). PBMC from both 
IFN-γ and TNF-α plates were resuspended in FACS Flow (Becton Dickinson, Franklin 
Lakes, NJ) and transferred to 5-mL round-bottom tubes prior to analysis using a FACS 
Calibur flow cytometer (Becton Dickinson) and Cell Quest® software (Becton Dickinson) 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016). 
Lymphocyte populations were gated on cell size and granularity to determine the percent 
of lymphocytes producing IFN-γ and TNF-α as well as mean fluorescence intensities (MFI) 
of lymphocytes for each cytokine (Adams et al., 2008; Adams et al., 2009; Breathnach et 
al., 2006). 
2.6. RNA Isolation, Reverse Transcription, and Polymerase Chain Reaction  
Following the incubation in 24-well plates, PBMC for all horses in each season 
(January, April, July, October) were stored at -80oC in Trizol® solution, until RNA was 
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isolated by phenol-chloroform extraction (Breathnach et al., 2006) and quantified using an 
Epoch microplate spectrophotometer (BioTek, Winooski, VT). RNA was reverse 
transcribed with master mix reagents (16 μL avian myeloblastosis virus [AMV] buffer 5X, 
16 μL MgCl2, 4 μL dNTP, 1 μL RNasin, 1 μL oligo dT primer, and 0.5 μL AMV reverse 
transciptase per sample; Promega, Madison, WI) and a thermocycler (Applied Biosystems, 
Foster City, CA),  incubating samples at 42oC for 15 minutes and 95oC for 5 minutes 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). cDNA samples were 
then stored at -20oC until real time-polymerase chain reaction (RT-PCR) analysis. To 
ensure accuracy and precision in aliquoting, an epMotion 5070 (Eppendorf) loaded plates 
with cDNA samples and 5 equine specific intron-spanning primers and probes including 
IFN-γ, IL-4, IL-6, IL-10, and TNF-α, (Applied Biosystems) in addition to Beta-
glucuronidase (β-GUS), the housekeeping gene (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). The 7900HT Fast RT-PCR System (Applied Biosystems) was 
used to perform RT-PCR, incubating samples at 95oC for 10 minutes, followed by 40 
cycles of 95oC for 15s and 60oC for 60s (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). Linear regression was used to determine cycle threshold (CT) 
values, with relative changes in cytokine gene expression being quantified using the ΔΔCT 
method (Livak and Schmittgen, 2001). The calibrator for each cytokine was the average 
ΔCT of all media alone samples. Data are reported as relative quantity (RQ) values 
according to the equation RQ = 2 -ΔΔCT (Livak and Schmittgen, 2001). 
2.7. Endocrine Analysis. 
Basal cortisol and basal ACTH were examined for all horses in each season 
(January, April, July, October). Serum cortisol and EDTA plasma ACTH were analyzed 
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by Cornell Animal Health Diagnostic Center, Endocrinology Laboratory using 
chemiluminescence immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et 
al., 2010). 
2.8. Statistical Analysis.  
 Statistical analysis was performed using SAS 9.4 software (SAS Institute Inc., 
Cary, NC). Flow cytometry data from each month was grouped into seasons and averaged 
according to the following: winter (December, January, February); spring (March, April, 
May); summer (June, July, August); fall (September, October, November). Flow cytometry 
data was analyzed using a mixed procedure with age category (senior or adult) and season 
as well as the interaction between age category and season as the fixed effects, with season 
as the repeated variable. Gene expression, hormone, and body weight data was analyzed 
similarly but using month (January, April, July, and October) instead of seasonal averages.  
Additionally, modeling was then performed with cortisol, ACTH, and body weight 
data to determine whether these variables may be potential influencing factors on the 
various immune parameters. Data was blocked by age category and analyzed individually 
with each of the potential influencing factors (cortisol, ACTH, and body weight), month, 
and the interaction of month and potential influencing factor as the fixed effects when 
modeling for each of the immune parameters (%IFN-γ, IFN-γ MFI, %TNF-α, TNF-α MFI, 
lymphocyte proliferation, IFN-γ RQ, TNF-α RQ, IL-4 RQ, IL-6 RQ, IL-10 RQ). Ambient 
temperature was modeled over time (January, April, July, October) to determine 
differences between months.  
Due to some changes in diet over the course of the year-long study, additional 
analysis was performed. Data from the first two months (April & May) in which all horses 
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received the same isocaloric diet was modeled with age category, month, and age x month 
to determine whether differences between adult and senior horses were similar to the results 
of the entire dataset when diets were the same. Additionally, adult horses did not receive 
feed (forage only) the last 10 months of the study, so those horses were analyzed by month 
to determine if seasonal effects were similar for this subset as the entire dataset.  
All data met skewness and kurtosis requirements, (although ACTH required log-
transformation). Analyses with p<0.05 were considered statistically significant.  
Results 
3.1. Inflammatory cytokine production. 
Senior horses exhibited elevated inflammation when compared to adult horses, as 
expected. Specifically, senior horses exhibited a higher percentage of lymphocytes 
producing IFN-γ (% IFN-γ) (Fig. 2.1A), as well as higher mean fluorescence intensity 
(MFI) of lymphocytes intracellularly stained for IFN-γ (Fig. 2.1B) (p<0.001). Senior 
horses also exhibited higher percentage of lymphocytes producing TNF-α (% TNF-α) (Fig. 
2.2A), as well as higher TNF-α MFI (Fig. 2.2B) (p<0.001). 
Some seasonal changes were observed in lymphocyte-mediated production of IFN-
γ. While the percent of lymphocytes producing IFN-γ did not significantly differ seasonally 
(p>0.05) (Fig. 2.1A), IFN-γ MFI did vary seasonally (p<0.001) (Fig. 2.1B). Specifically, 
IFN-γ MFI was lower in winter and fall than in spring and summer (p<0.05) (Fig. 2.1B). 
Seasonal changes were also observed in lymphocyte-mediated production of TNF-
α. The percent of lymphocytes producing TNF-α and TNF-α MFI both significantly varied 
with season (p<0.01). Specifically, %TNF- α was lower in winter than in spring and 
summer (p<0.01), and %TNF-α was also lower in fall than spring (Fig. 2.2) (p<0.05). TNF-
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α MFI was lowest in winter compared to all seasons (p<0.01) (Fig. 2.2B). No significant 
interactions of season and age category were present for any of the lymphocyte-mediated 
inflammatory cytokine parameters (p>0.05).  
3.2. Lymphocyte proliferation.  
 Lymphocyte proliferation also significantly differed between senior and adult 
horses (p=0.023), with adult horses having higher proliferation than senior horses (Fig. 
2.3). Lymphocyte proliferation did not differ significantly between seasons (p>0.05) (Fig. 
2.3). No significant interaction of age category and season was present (p>0.05). 
3.3. Cytokine gene expression. 
  Gene expression of various pro- and anti-inflammatory cytokines was examined 
using PCR to examine any differences seasonally for senior and adult horses. January, 
April, July, and October were analyzed to determine gene expression of IFN-γ, TNF-α, IL-
4, IL-6, and IL-10, as each of these months was considered the middle month for each 
season (winter, spring, summer, and fall, respectively) (Fig. 2.4). For the cytokines 
analyzed, significant differences between senior and adult horses were found for IFN-γ and 
TNF-α (p<0.01) (Fig. 2.4).  
A significant overall effect of month was found for IL-6 (p<0.05), while a trend for 
an effect of month was determined for TNF-α (p=0.055) (Fig. 2.4B&C). Specifically, IL-
6 gene expression was lower in July than in all other months analyzed, showing diminished 
levels in summer (p<0.05). Meanwhile, TNF-α was higher in July than in January or April 
(p<0.05) but did not significantly differ from October, showing that gene expression of 
TNF-α is greater in summer than in winter or spring. There were no other significant effects 
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of month (p>0.05), and there were not significant interactions of age category and month 
for any of the cytokines analyzed (p>0.05). 
3.4. Potential influencing factors.  
 Serum cortisol, plasma ACTH, body weight, ambient air temperatures, and length 
of daylight were examined seasonally (in January, April, July, and October) to determine 
whether they may affect inflammatory and proliferative parameters. Serum cortisol 
significantly differed between months, with an overall p-value of <0.0001, but did not 
differ between age groups (Fig. 2.5A). Cortisol was lowest in January and October and 
highest in April (Fig. 2.5A). Plasma ACTH was statistically significant for differences both 
between age groups and months (p<0.01) (Fig. 2.5B). Senior horses exhibited elevated 
plasma ACTH concentrations compared to adult horses (Fig. 2.5B). Overall, ACTH was 
lowest in January and April and highest in October (Fig. 2.5B). Body weight did not vary 
by month (p>0.05) and did not differ between senior and adult horses (p>0.05) (Fig. 2.6). 
Ambient temperatures varied as expected with January (winter) being lowest and July 
(summer) being highest (compared to all seasons) (p<0.05) (Table 2.1). Likewise, length 
of daylight followed a similar pattern with January being shortest and July being longest 
(Table 2.1). 
 For each of the immune parameters modeling with cortisol, ACTH, and body 
weight for the months of January, April, July, and October was performed to determine 
any influence on specific markers of the immune system. In a model incorporating month 
and month interactions while also blocking for age category, it was found that IFN-γ MFI 
and ACTH were positively associated (p=0.038). Weight was also individually associated 
with %IFN-γ (p=0.018; negative), %TNF-α (p=0.003; negative), and lymphocyte 
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proliferation (p=0.008; positive). No other relationships were found between cortisol, 
ACTH, or body weight and immune parameters (%IFN-γ, IFN-γ MFI, %TNF-α, TNF-α 
MFI, lymphocyte proliferation, IFN-γ RQ, TNF-α RQ, IL-4 RQ, IL-6 RQ, IL-10 RQ) 
(p>0.05) in the aforementioned model.  
 Although diet was a confounding factor, the adult horses did not receive any feed 
(only forage) for 10 months and still exhibited various seasonal changes in inflammatory 
cytokine production. While the forage changed throughout the year, as horses were kept 
on pasture and fed mixed-grass hay ad libitum during winter months, this is a common 
management practice of equine facilities and arguably is part of a seasonal effect. In this 
group of adult horses not receiving feed, seasonal changes were specifically seen for IFN-
γ MFI (p<0.0001), %TNF-α (p=0.003), and TNF-α MFI (p<0.001), quite similarly to the 
results of the complete dataset (Fig. 2.1&2.2). Furthermore, although all horses were only 
on the same diet for the first two months of the study due to differences in energy needs to 
keep adult vs. senior horses at maintenance, differences in cytokine production were seen 
between senior and adult horses. Specifically, differences between senior and adult horses 
were seen for % IFN-γ (p=0.002), IFN-γ MFI (p=0.051), %TNF-α (p=0.002), and TNF-α 
MFI (p=0.016), although lymphocyte proliferation did not demonstrate significant effects 
of age (p=0.283). Additionally, for the full dataset, there were no interactions between age 
category and month/season. Therefore, seasonal inflammatory changes likely are not due 
to changes in feed.  
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Discussion 
Many species are known to undergo physiological changes seasonally as an 
adaptation to varying conditions. These changes in physiology affect everything from 
hormones to hair coat (McFarlane et al., 2012). Not surprisingly, immune function has also 
demonstrated seasonal variations in many species as well (Bilbo et al., 2002; Bowden et 
al., 2007; Mann et al., 2000; McFarlane et al., 2012). Few studies have been conducted in 
the horse to determine seasonal effects, though some seasonal effects on immune response 
of allergy-related conditions have been determined (Beadle et al., 2002; Hamza et al., 
2007). However, a longitudinal study to determine the effects of season on senior horses 
in comparison to adult horses has not previously been performed. 
Senior horses are known to experience inflamm-aging (chronic, low-grade 
inflammation occurring systemically during old age) and immunosenescence (aging of the 
immune system including decreased lymphocyte proliferation and decreased response to 
vaccination) (Adams et al., 2008; Adams et al., 2009; Adams et al., 2011). The current 
study determined the effects of season on function of PBMC in these already immune-
compromised senior horses in comparison to adult horses.  
As hypothesized, season affected lymphocyte-mediated inflammatory cytokine 
production for multiple parameters examined. IFN-γ MFI, %TNF-α, and TNF-α MFI all 
exhibited seasonal patterns. Specifically, IFN-γ MFI was lowest in winter and fall and 
highest in spring and summer. Percent of lymphocytes producing TNF-α was lowest in 
winter compared to spring and summer, and TNF-α MFI was lowest in winter compared 
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to all seasons. As a whole, inflammation was diminished in the winter and elevated in the 
spring and summer.  
This general decrease in inflammation during winter is similar to what has been seen 
in rhesus monkeys and baboons (Mann et al., 2000; McFarlane et al., 2012). Specifically, 
Mann et al. (2000) showed a decrease in IFN-γ+ PBMC during winter compared to 
summer (Mann et al., 2000). McFarlane et al. (2012) showed a decrease in pro-
inflammatory serum CRP in December compared to June as well as a decrease of 
inflammatory cytokine production in December following stimulation with both LPS and 
CpG (deoxynucleotide found in viral, bacterial, fungal and parasitic DNA) (McFarlane et 
al., 2012). However, the study also showed an increase in serum IL-6 in December 
compared to June for baboons housed outdoors (McFarlane et al., 2012), showing that 
various inflammatory cytokines can be expressed differentially from each other 
dependent on the season.  
Senior horses also exhibited elevated levels of inflammatory cytokine protein 
production relative to adult horses in all measures, as expected. This was likewise seen in 
the 2 month subset when horses were all receiving the same diet. Inflamm-aging in the 
horse is a well-characterized phenomenon (Adams et al., 2008; Adams et al., 2009) that 
was evidenced again in this study.  
Senior horses had decreased lymphocyte proliferation compared to adult horses, as 
expected. Functionally, these results indicate a decreased adaptive response of senior 
horses to pathogen invasion in comparison to adult horses. Although the two month subset 
when all horses received the same diet did not exhibit a significant difference between 
senior and adult horses, previous studies examining lymphocyte proliferation of senior 
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horses in comparison with adult horses have observed lower levels in senior horses as an 
aspect of immunosenescence (Adams et al., 2008). It is expected that these differences in 
lymphocyte proliferation between senior and adult horses would be more pronounced if 
using a younger population of adult horses for comparison, similarly to previous studies 
(in which the mean age was 4.5 years as compared to 10.8 years in the current study) 
(Adams et al., 2008).   
Lymphocyte proliferation did not significantly differ with seasonal. The lack of 
seasonal differences was also seen in the 10 month subset of adult horses maintained on 
forage. Lymphocyte proliferation has minimally been examined in regards to season, thus 
the lack of seasonal differences is not entirely surprising. However, a study in rhesus 
monkeys showed that lymphocyte proliferation was elevated in winter compared to 
summer (Mann et al., 2000). Conversely, a study in humans had found that lymphocyte 
proliferation was lower in patients with seasonal affective disorder (SAD) than in healthy 
patients (Song et al., 2015a). This decreased lymphocyte proliferation in SAD patients was 
corrected by light therapy, suggesting a potential role of photoperiod in lymphocyte 
proliferation, although the effect of light therapy was only examined in SAD patients (Song 
et al., 2015a). In the present study, equine lymphocyte proliferation did not appear to be 
affected by season. 
Gene expression of various cytokines including IFN-γ, TNF-α, IL-4, IL-6, and IL-10 
mediated by PBMC was also examined to determine any differences seasonally as well as 
between senior and adult horses. A significant effect of season was seen for IL-6, with July 
being decreased relative to the other months examined (January, April, October). Despite 
the deviation of these results compared to the other parameters in which inflammation was 
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decreased most in winter, this decrease of IL-6 in summer is similar to the results seen by 
McFarlane et al., 2012 in baboons (McFarlane et al., 2012), as previously mentioned. 
However, gene expression of TNF-α was significantly increased in July compared to 
January and April. Overall differences for senior and adult horses were also seen for gene 
expression of IFN-γ and TNF-α, which are not surprising, given the differences in these 
cytokine proteins determine by flow cytometry. Additionally, differences in PBMC-
mediated gene expression of IFN-γ between senior and adult horses have been found 
previously, although differences in TNF-α were not significant (Adams et al., 2015).  
No differences were seen seasonally or regarding age category for gene expression of 
any other cytokines. Initially the lack of similarity in results between anti-inflammatory 
IL-10 and the pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) may appear 
unexpected. However, despite the fact that IL-10 is regulated in part by NF-κB (Cao et al., 
2006), which also regulates many of the pro-inflammatory cytokines including IFN-γ (Sica 
et al., 1997), TNF-α (Collart et al., 1990), and IL-6 (Son et al., 2008), the IL-10 regulation 
by NF-κB is primarily mediated by dendritic cells and macrophages (Cao et al., 2006; 
Saraiva and O'Garra, 2010). In the present study, PBMC gene expression was analyzed, 
where IL-10 is primarily regulated by the MAF/ERK pathway (in T-cells) (Saraiva and 
O'Garra, 2010). Also, IL-10 gene expression of PBMC has previously been examined with 
no differences between senior and adult horses being found (Adams et al., 2015). 
Stress hormone levels of cortisol and ACTH were also analyzed to determine any 
seasonal differences which may be potentially influencing factors on immune parameters. 
Cortisol exhibited seasonal effects, being highest in April and lowest in January and 
October. This aligns with the results of Cordero et al. (2012) in which cortisol was highest 
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in spring for healthy horses (Cordero et al., 2012), although a study the following year 
demonstrated no seasonal cortisol changes in ponies (Borer-Weir et al., 2013). ACTH was 
most elevated in October and lowest in January and April, as expected. ACTH is known to 
exhibit robust seasonal patterns, becoming quite elevated in the fall (McFarlane et al., 
2011). Additionally, ACTH was significantly higher in senior horses, which again was 
expected, particularly since many senior horses develop pituitary pars intermedia 
dysfunction (PPID), an endocrine disorder causing hypertrichosis and resulting in excess 
production of ACTH (McFarlane, 2011). Since basal ACTH is used clinically to diagnose 
PPID, it was included in the potential influencing factors model in order to determine 
whether circulating levels of ACTH and potentially the presence of PPID are influencing 
factors on immune function. Among the various immune parameters, ACTH appeared to 
significantly affect only IFN-γ MFI, thus ACTH does not appear to have a significant role 
in regulating immune function in general. 
Body weight also appeared to have significant effects on each of the following: %IFN-
γ, %TNF-α, and lymphocyte proliferation. Specifically, body weight exhibited a negative 
relationship with %IFN-γ and %TNF-α, which was unexpected, given that changes in body 
weight and body fat in the old horse have been positively associated with PBMC-mediated 
inflammation (Adams et al., 2009). In the present study however the negative relationships 
were only slight (with every kg of increased body weight resulting in a decrease of %IFN-
γ and %TNF-α by 0.025 and 0.063, respectively), and body weights were determined using 
a weight tape, which may not have been the most accurate measure of changes in weight. 
The low temperatures in winter and/or short length of daylight also may contribute to 
the decreased inflammation in winter. Short day length has been shown to decrease 
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immune response in Siberian hamsters (Bilbo et al., 2002). However, these are not likely 
to be primary contributing factors, as robust seasonal rhythms in other species have been 
found for animals housed indoors at room temperature year-round (McFarlane et al., 2012). 
Another potential factor that may affect the seasonal changes in inflammation is the 
variation in forage the horses consumed throughout the year. Horses were maintained on 
pasture but were fed mixed-grass hay in the winter months. Although forage was not tested 
throughout the year, it is thought that perhaps the nonstructural carbohydrate (NSC) content 
of the hay was lower than what the horses received from the grass pasture, yielding lower 
levels of inflammation in winter, as horses fed higher levels of NSC were found to have 
increased serum TNF-α (Suagee et al., 2011). 
In conclusion, this study demonstrates seasonal patterns in pro-inflammatory cytokines 
of both the adult horse and the senior horse exhibiting inflamm-aging and 
immunosenescence. It appears that body weight may play a role, but the seasonal control 
of the immune system appears quite complex and likely involves various aspects of the 
immune-neuro-endocrine system (Weil et al. 2015; Haldar & Ahmad 2010) and may also 
include forage type. The seasonal variations of inflammatory cytokine production, 
particularly for the already immune-compromised senior horses, may yield understanding 
of when horses may be more prone to infectious disease. For example, horses may be at 
greater risk for disease in spring following the decreased inflammation in winter, as has 
been shown in rhesus monkeys (Mann et al., 2000). These seasonal variations in 
inflammatory cytokines may also have management implications, such as not vaccinating 
during winter, as the immune system appears to be suppressed during those months and 
would likely not elicit as strong of a protective response. However, more research needs to 
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be performed to determine what these seasonal inflammatory changes may specifically 
mean for the health of the senior horse.  
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Table 2.1. Ambient temperatures and length of daylight by representative month from 
each season. 
Season Ambient Temperature (oC) Length of Daylight (h) 
January -10 10h 09m 
April 17.5 13h 29m 
July 25 14h 21m 
October 4.2 10h 51m 
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Figure 2.1. Lymphocyte production of pro-inflammatory cytokine interferon(IFN)-γ after 
stimulation with PMA/ionomycin for n=8 senior (≥20 years) and n=8 adult (9-12 years) 
horses for each season. Both (A) percent of lymphocytes producing IFN-γ (%IFN-γ) and 
(B) IFN-γ mean fluorescence intensity (MFI) are shown, with significant differences 
(p<0.05) between seasons being signified by different lettering (a, b). Page denotes the p-
value for overall differences between senior and adult horses for IFN-γ production, while 
Pseason denotes the overall p-value for differences between seasons. 
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Figure 2.2. Lymphocyte production of pro-inflammatory cytokine tumor necrosis 
factor(TNF)-α after stimulation with PMA/ionomycin for n=8 senior (≥20 years) and n=8 
adult (9-12 years) horses for each season. Both (A) percent of lymphocytes producing 
TNF-α and (B) TNF-α mean fluorescence intensity (MFI) are shown, with significant 
differences (p<0.05) between seasons being signified by different lettering (a, b, c). Page 
denotes the p-value for overall differences between senior and adult horses for TNF-α 
production, while Pseason denotes the overall p-value for differences between seasons. 
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Figure 2.3. Lymphocyte proliferation of n=8 senior (≥20 years) and n=8 adult (9-12 years) 
horses for each season. Peripheral blood mononuclear cells were stimulated with mitogen 
concanavalin A and incubated 96 hours to determine lymphocyte proliferation index. Page 
denotes the p-value for overall differences between senior and adult horses in lymphocyte 
proliferation index, while Pseason denotes the overall p-value for differences between 
seasons. 
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Figure 2.5. Potential hormone influences on seasonal inflammatory changes of n=8 
senior (≥20 years) and n=8 adult (9-12 years) horses. Serum cortisol (A) and plasma 
adrenocorticotropin hormone (ACTH) (B) were examined throughout the year (January, 
April, July, and October) to determine whether these factors may influence any seasonal 
inflammatory changes. Significant differences (p<0.05) between seasons are denoted by 
different lettering (a, b, c). Page denotes the p-value for overall differences between 
senior and adult horses in gene expression, while Pmonth denotes the overall p-value for 
differences between months. 
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Figure 2.6. Body weights of n=8 senior (≥20 years) and n=8 adult (9-12 years) horses 
seasonally. Body weights were examined throughout the year (January, April, July, and 
October) to determine whether it may influence any seasonal inflammatory changes. Any 
significant differences (p<0.05) between seasons are denoted by different lettering. Page 
denotes the p-value for overall differences between senior and adult horses in gene 
expression, while Pmonth denotes the overall p-value for differences between months. 
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CHAPTER 3 
RELATIONSHIPS OF INFLAMM-AGING WITH NUTRITIONAL STATUS, 
BODY COMPOSITION, AGE, AND PITUITARY PARS INTERMEDIA 
DYSFUNCTION IN A SENIOR HORSE POPULATION. 
Abstract 
Similar to aged humans, senior horses (≥20 years) exhibit chronic low-grade 
inflammation systemically, known as inflamm-aging. In addition to inflamm-aging, senior 
horses present with sarcopenia and often the endocrinopathy pituitary pars intermedia 
dysfunction (PPID). Despite the concurrence of these phenomena, the relationships 
inflamm-aging may have with measures of nutritional status, body composition, age, and 
pituitary function in the horse remain unknown. Thus, an exploratory study of a population 
of n=42 similarly-managed senior horses was conducted. Serum was collected to determine 
vitamin, mineral, and fatty acid content. Peripheral blood mononuclear cells were also 
isolated to determine inflammatory cytokine production of interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) following stimulation with a mitogen, as well as to determine 
gene expression of interleukin(IL)-1β, IL-6, IL-10, IFN-γ, and TNF-α. Serum IL-6 and C-
reactive protein were determined by enzyme-linked immunosorbent assay. Whole blood 
was collected for hematological and biochemical analysis. Body composition was 
evaluated via ultrasound and muscle scoring for all 42 horses as well as by deuterium oxide 
dilution for a subset of n=10 horses. Pituitary function was determined by measuring basal 
adrenocorticotropin hormone concentrations as well as by thyrotropin releasing hormone 
stimulation testing (to determine PPID status). Results showed various relationships 
between inflammatory markers and the other variables measured. Most notably, 
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docosadienoic acid (C22:2n6c), docosapentaenoic acid (C22:5n3c), and folate were 
positively associated with numerous inflammatory parameters (P≤0.05). Being positive for 
PPID was negatively associated with vitamin B12 and positively associated with 
percentage of eosinophils (P≤0.05). No relationships between inflammation and body 
composition were found, however age was associated with multiple parameters, 
particularly with numerous inflammatory cytokines and fatty acids. In summary, inflamm-
aging exhibited relationships with various other parameters examined, particularly with 
certain fatty acids. This exploratory study provides insights into physiological changes 
associated with inflamm-aging in the senior horse. 
Introduction 
Senior horses (≥20 years), like aged humans, exhibit chronic low-grade 
inflammation that occurs systemically; this phenomenon is known as inflamm-aging 
(Franceschi et al., 2000). In humans, the term inflamm-aging was coined (Franceschi et al., 
2000) after discovering that despite the generalized immunodepression previously known 
to occur with aging, peripheral blood mononuclear cells (PBMC) produced elevated levels 
of inflammatory cytokines in the elderly when compared to their younger counterparts 
(Fagiolo et al., 1993). Various other systemic increases in markers of inflammation such 
as interleukin(IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), 
and serum amyloid A (SAA) have also been associated with old age in humans (Franceschi 
et al., 2000; Ostan et al., 2015). These increases in pro-inflammatory cytokines and other 
inflammatory markers in turn increase systemic inflammation. Inflamm-aging in the horse 
is likewise characterized by increased pro-inflammatory cytokine production by 
monocytes and lymphocytes of old horses when compared to young horses. Specifically, 
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old horses have increased levels of circulating IL-1β, IL-15, IL-18, and TNF-α in whole 
blood, as well as increased production of IFN-γ and TNF-α by lymphocytes and monocytes 
after stimulation with a mitogen (Adams et al., 2008; Adams et al., 2009). A vast body of 
human literature has shown systemic inflammation to be  an underlying condition 
predisposing people to various diseases including Alzheimer’s disease, atherosclerosis, 
macular degeneration, and degenerative arthritis (Franceschi and Campisi, 2014). 
Inflamm-aging, therefore, is considered to be a key predictor of morbidity and mortality 
(Franceschi and Campisi, 2014); however, what exactly inflamm-aging means for the 
physiology of the horse remains unknown. Furthermore, the causes of inflamm-aging in 
both humans and horses remain relatively unknown (Franceschi and Campisi, 2014). 
In many species, various vitamins, minerals, and fatty acids have been associated 
with inflammation, whether pro- or anti-inflammatory. Many studies have shown Vitamin 
D to be anti-inflammatory in humans and rats (Abbas, 2016; Capri et al., 2006; Moore et 
al., 2005). A recent human study in China showed folic acid, the synthetic form of folate, 
to be anti-inflammatory as well, even improving cognition of patients with Alzheimer’s 
disease (Chen et al., 2016). Mineral supplements including zinc (Zhu et al., 2016) and 
selenium (Brummer et al., 2013) in piglets and horses, respectively, have also exhibited 
various effects on immunity. In human patients experiencing a systemic inflammatory 
response, most micronutrients decreased with the exception of iron, which was shown to 
increase (Thurnham and Northrop-Clewes, 2016). In a human population study, many 
polyunsaturated fatty acids (PUFAs) were associated with a lower inflammatory profile, in 
that a negative correlation was found between PUFAs and pro-inflammatory cytokines, 
while a positive correlation was found between PUFAs and anti-inflammatory cytokines 
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(Ferrucci et al., 2006). Additionally, omega-3 supplementation in the horse has 
demonstrated potential immunomodulatory effects at a clinical level (Nogradi et al., 2015). 
Nutrition has implications for healthspan and life span; however, this relationship requires 
further elucidation (Dato et al., 2016), particularly in the old horse, where much currently 
remains unknown (Siciliano, 2002). Furthermore, the numerous associations between 
inflammation and vitamins, minerals, and fatty acids in various species indicate that 
nutritional intervention has the potential to alter inflammatory profiles (Dasilva et al., 2016; 
Dato et al., 2016), which may extend to the senior horse. 
In addition to inflamm-aging, old horses experience sarcopenia (age-associated 
muscle wasting), similarly to other species including humans (Lehnhard et al., 2004; Reed 
et al., 2015; Schaap et al., 2009; Schaap et al., 2006). In longitudinal human studies, 
increased inflammatory markers, particularly TNF-α, IL-6, and CRP, were associated with 
decreased muscle mass and strength (Schaap et al., 2009; Schaap et al., 2006). In a study 
of over 3000 healthy, aged (70-79 yrs) adults, IL-6 and TNF-α were associated with 
decreased muscle mass and strength (Visser et al., 2002). In aged cattle, lymphocyte-
mediated (primarily CD8+) inflammation was also associated with sarcopenia (Costagliola 
et al., 2016). In the old horse, decreased muscle mitochondrial density and shifted fiber 
types (toward a higher percentage of myosin heavy chain types I and IIA) have been 
associated with aging (Li et al., 2016). Furthermore, a recent study suggests that the pro-
inflammatory status associated with inflamm-aging in old horses may decrease exercise-
induced satellite cell activity, thereby decreasing the normal process of hypertrophy 
associated with exercise (Reed et al., 2015). This, in turn, may indicate why maintaining 
physical fitness in senior horses is more challenging (Reed et al., 2015), a key issue in the 
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equine industry due to the number of equine athletes competing into their senior years 
(Malinowski et al., 1997; McKeever, 2016). The relationship between inflamm-aging and 
sarcopenia therefore requires further study. 
While there is little evidence that senior horses have different hematological or 
biochemical reference ranges than adult horses (Silva and Furr, 2013), it was of interest to 
determine whether inflammation in the older animal was associated with any particular 
clinical biomarkers. For example bilirubin, a biomarker of liver function, has variable 
associations with inflammation in other species, exhibiting anti-inflammatory properties 
(Moreno-Otero et al., 1994) and even protecting against inflamm-aging in some studies 
(Zelenka et al., 2016), while exhibiting pro-inflammatory effects in other studies (Qaisiya 
et al., 2016).  
Senior horses also frequently exhibit pituitary pars intermedia dysfunction (PPID), 
commonly known as equine Cushing’s disease. This endocrinopathy is caused by 
dopaminergic neurodegeneration of the hypothalamic neurons, causing hypertrophy, 
hyperplasia, and often adenomas of the pituitary pars intermedia (Durham, 2016; Miller et 
al., 2008b) and frequently results in hypertrichosis, polydipsia, polyuria, hyperhidrosis, 
laminitis, muscle atrophy, and abnormal fat distribution (McFarlane, 2011). 
Endocrinologically this frequently results in increased basal levels of circulating 
adrenocorticotropin hormone (ACTH), while also resulting in a decreased ability of horses 
to return to resting levels of ACTH after intravenous injection of thyrotropin releasing 
hormone (TRH) (Beech et al., 2007). ACTH has been associated with increased gene 
expression of pro-inflammatory IL-6 in septic foals (Gold et al., 2012); however, the 
relationship of ACTH with inflammation is not well-characterized. PPID has been 
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associated with total leukocyte-mediated cytokine dysregulation (McFarlane and 
Holbrook, 2008). Therefore, it was of interest to examine whether various circulating 
serum and PBMC-mediated markers of inflammation would be associated with PPID. 
Further, the exact mechanisms that result in this hypothalamic dopaminergic 
neurodegeneration found in many old horses remain unknown, and specific markers of 
inflamm-aging being differentially associated with PPID may yield understanding of 
underlying mechanisms involved in this pathology.  
Thus, an exploratory study to examine the potential relationships between 
inflammatory parameters and various vitamin, mineral, fatty acid, hematology, 
biochemistry, body composition, and PPID parameters in senior horses was undertaken. It 
was hypothesized that inflamm-aging would be inversely associated with markers of 
muscle mass and with levels of known anti-inflammatory nutrients. It was also 
hypothesized that specific markers of inflamm-aging would be differentially associated in 
relation to PPID status and that inflamm-aging would not be associated with hematology 
or blood biochemistry markers.  
Methods and Materials 
2.1. Animals and Study Design 
Forty-two senior horses (mean age = 24.4 ± 3.0 yr [SD]; range = 18-29 yr) were 
used in this study. Horses were of mixed-breeds and sex (33 mares, 11 geldings) with a 
mean body condition score (BCS; according to the Henneke scale 1-9) (Henneke et al., 
1983) of 5.2 ± 0.8 and body weight (BW) of 531.2 ± 86.9 kg. All horses were free of 
clinical signs of infectious disease and housed at the University of Kentucky, Department 
of Veterinary Science Maine Chance Farm in Lexington, Kentucky on pasture during the 
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winter season. Horses received a diet of 50% oats and 50% vitamin and mineral fortified 
alfalfa pellets (5.5 kg per day, divided equally into meals fed at 0830 and 1400 h) with 
mixed grass hay provided ad libitum (Table 3.1). All procedures were approved by the 
University of Kentucky Institute of Animal Care and Use Committee. 
Samples and measurements collected for all (n=42) horses included the following: 
BW, BCS, muscle mass score, rump ultrasound, and blood samples. A subset of n=10 of 
these horses also had deuterium oxide assessment of percent body fat and fat free mass 
(FFM) performed. Horses were weighed (using a portable calibrated large-animal scale) 
and assessed for BCS using the Henneke scale (1-9) (Henneke et al., 1983) by two 
experienced assessors. Muscle mass was scored by two assessors using the previously 
established 1-5 scale (Graham-Thiers and Kronfeld, 2005). Blood was collected within 2 
hours after horses had eaten their morning meal. Percent body fat and fat free mass were 
estimated using  ultrasound (Kane, 1987; Lehnhard et al., 2004) and deuterium oxide 
(Dugdale et al., 2011) methods within one week post blood collection. Furthermore, 
thyrotropin releasing hormone (TRH) stimulation testing was performed on all horses 
within 3 hours of their morning meal, with adrenocorticotropin hormone (ACTH) being 
measured prior to and 10 minutes post intravenous TRH injection, to determine pituitary 
function, as further described below. Twenty-eight of the 42 horses tested positive for 
pituitary pars intermedia dysfunction (PPID) according to results from TRH stimulation.  
2.2. Blood Sampling 
All blood was collected from the jugular vein using an aseptic technique. 
Heparinized blood was collected to isolate peripheral blood mononuclear cells (PBMCs), 
which were processed fresh after collection. Serum was collected for analysis of vitamins, 
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fatty acids, and inflammatory proteins (interleukin [IL]-6, tumor necrosis factor-alpha 
[TNF-α], and C-reactive protein [CRP]), centrifuged (800g x 10 min x 22oC), and frozen 
at -20oC until analysis. Serum was also collected to analyze trace mineral content (in royal 
blue top, serum clot activator [silicone coated] tubes with hemogard closure to enable zinc 
analysis [Fisher Scientific, Waltham, MA]), centrifuged (800g x 10 min x 22oC), and 
frozen at -20oC until analysis. EDTA plasma was collected for ACTH analysis, centrifuged 
(800g x 10 min x 22oC), and frozen at -20oC until analysis. Lithium heparinized whole 
blood was collected and immediately analyzed for complete blood count with differential 
and blood chemistry panel analysis.  
2.3. PBMC Isolation, IFN-γ and TNF-α Intracellular Staining, and Flow Cytometry 
Peripheral blood mononuclear cells were isolated from the collected heparinized 
blood using a Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ) density 
gradient, as has been previously described (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). PBMC were counted using a VICELL™ Counter-XR (Beckman 
Coulter, Miami, FL) and plated at a concentration of 4x106 cells/mL in complete media 
(RPMI 1640 [Gibco, Grand Island, NY] with 2.5% fetal equine serum [FES; BioWest, 
Nuaillé, France], 55 μM 2-mercaptoethanol [Gibco], and 2 mM L-glutamine, 100 U/ml 
penicillin, 0.1 mg/mL streptomycin [HyClone Pen/Strep/Glutamine solution; Thermo 
Scientific]) (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). PBMC were 
aliquoted in duplicate into 24-well plates, with brefeldin A (10 μg/mL; Sigma) added to all 
wells, and phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 
μM; Sigma) added to one well per sample. PBMC were incubated 4 hours at 37oC, 5% 
CO2, then fixed with 2% paraformaldehyde overnight. To determine pro-inflammatory 
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cytokine production, PBMC were stained intracellularly with IFN-γ FITC mouse anti-
bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg) and with TNF-α anti-equine 
monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay, University of Florida) 
and secondary antibody FITC-conjugated goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen, 
Carlsbad, CA; 2 mg/mL) (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). 
Flow cytometry was performed using a FACS Calibur flow cytometer (Becton Dickinson) 
and Cell Quest® software (Becton Dickinson) (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006).  
 2.4. RNA Isolation and Reverse Transcription 
Following the incubation in 24-well plates, aliquots (500 μL) of PBMC were 
centrifuged in 1.5 mL microcentrifuge tubes, resuspended in 1 mL of Trizol® solution, and 
stored at -80oC, following the manufacturer’s protocol. RNA was isolated by phenol-
chloroform extraction and stored at -80oC (Breathnach et al., 2006). Using an Epoch 
microplate spectrophotometer (BioTek, Winooski, VT), RNA was quantified. Reverse 
transcription was performed on 1 μg RNA in RNase-free water (41.5 μL total) using Master 
Mix (16 μL avian myeloblastosis virus [AMV] buffer 5X, 16 μL MgCl2, 4 μL dNTP, 1 μL 
RNasin, 1 μL oligo dT primer, and 0.5 μL AMV reverse transciptase per sample; Promega, 
Madison, WI) and a thermocycler (Bio-Rad, Hercules, CA), with samples incubated at 
42oC for 15 minutes and 95oC for 5 minutes (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). Samples of cDNA were stored at -20oC until real time-polymerase 
chain reaction (RT-PCR) analysis.     
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2.5. Determination of Cytokine Gene Expression  
cDNA samples were thawed at room temperature and loaded into the epMotion 
5070 (Eppendorf) with 5 equine specific intron-spanning primers and probes including 
IFN-γ, IL-1β, IL-6, IL-10, and TNF-α, (Applied Biosystems, Foster City, CA) in addition 
to Beta-glucuronidase (β-GUS), the housekeeping gene (Adams et al., 2008; Adams et al., 
2009; Breathnach et al., 2006). RT-PCR was performed using the 7900HT Fast RT-PCR 
System (Applied Biosystems), which incubated samples at 95oC for 10 minutes, followed 
by 40 cycles of 95oC for 15s and 60oC for 60s (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). The reaction volume for each sample was 10 µL of master mix, 
with 5 µL Sensimix II Probe Kit (Bioline), 0.5 µL assay mix for the gene of interest 
(primer/probe sets; Applied Biosystems), and 4.5 µL cDNA template (Adams et al., 2008; 
Adams et al., 2009; Breathnach et al., 2006). Relative changes in cytokine gene expression 
were quantified using the ΔΔCT method (Livak and Schmittgen, 2001). The average ΔCT 
of all the wells treated with media alone served as the calibrator for each cytokine. Data 
are reported as natural logs of relative quantity (RQ) values (RQ = 2 -ΔΔCT) (Livak and 
Schmittgen, 2001).  
2.6. Inflammatory protein ELISAs 
Using enzyme-linked immunosorbent assay (ELISA) methods previously 
described in the horse, serum inflammatory protein concentrations of IL-6 (Burton et al., 
2009) and CRP (Lavoie-Lamoureux et al., 2012) were quantified in duplicate. Briefly, IL-
6 was measured by coating ELISA plates (Immunoplate Maxisorp, Nalge Nunc Int., 
Rochester, NY) with a polyclonal goat anti-horse IL-6 antibody (AF1886, R&D Systems, 
Inc., Minneapolis, MN), blocking plates with phosphate buffered saline (PBS, pH 7.2) 
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supplemented with 0.5% bovine serum albumin, washing with phosphate buffer (2.5 mmol 
NaH2PO4, 7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1% (v/v) Tween 20, pH 7.2), and 
tagging with biotinylated goat anti-horse IL-6 (AF1886, R&D Systems, Inc., Minneapolis, 
MN) and a streptavidin–horseradish peroxidase solution (Jackson ImmunoResearch Lab., 
West Grove, PA) (Burton et al., 2009). A recombinant equine IL-6 (1886-EL, R&D 
Systems, Inc., Minneapolis, MN) in two-fold dilutions was used to create a standard curve, 
ranging from 500-4 ng/mL (Burton et al., 2009). Reactions were pigmented and stopped 
with TMB substrate solution (Thermo Scientific, Rockford, IL) & TMB stop solution 
(KPL, Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD), respectively and 
analyzed in duplicate colorimetrically at 450 nm of absorbance using an ELISA reader 
(Bio-Rad Laboratories, Inc., Philadelphia, PA). The serum sample dilution was 1:50 or 
1:100, with dilution factor taken into account when calculating protein concentrations. The 
mean intra-assay coefficient of variation was 6.4%. 
Serum CRP was quantified using a commercially available equine-specific CRP 
ELISA kit (Kamiya Biomedical, Seattle, WA), according to manufacturer instructions 
(Lavoie-Lamoureux et al., 2012), except all serum samples were diluted 1:300 instead of 
1:100. The standard curve ranged from 200-6.25 ng/mL. ELISA reader (Bio-Rad) analysis 
was performed at an absorbance of 450 nm. The mean intra-assay coefficient of variation 
was 2.5%, while the mean inter-assay coefficient of variation was 0.8%.  
2.7. Circulating vitamins and minerals 
Serum vitamins and minerals were analyzed at Michigan State University 
Diagnostic Center for Population and Animal Health (MSU DCPAH), except Vitamin B12 
and folate, which were analyzed at Cornell University Animal Health Diagnostic Center 
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(AHDC) Endocrinology Laboratory using American Association of Veterinary Laboratory 
Diagnosticians (AAVLD) validated assays. Serum 25-hydroxyvitamin D was analyzed via 
radioimmunoassay (RIA) using a commercially available 125 iodine-RIA kit (Dia Sorin, 
Stillwater, MN). Vitamins A (retinol), E (α-tocopherol), and β-carotene were measured via 
ultra high pressure liquid chromatography with a C18 column and photodiode array 
detection (Waters, Milford, MA), following liquid-liquid extraction. Fatty acids, including 
saturated and unsaturated, were measured via gas chromatography with a SP2556 column 
and flame ionization detection (PerkinElmer Inc., Waltham, MA), following methyl 
esterification preparation. Trace minerals including total zinc, selenium, cobalt, copper, 
iron, manganese, and molybdenum were measured in serum via inductively coupled 
plasma mass spectrometry (Agilent Technologies, Santa Clara, CA), following direct 
dilution preparation. Serum vitamin B12 and folate were analyzed via chemiluminescence 
immunoassay using an Immulite® 2000 (Siemens, Berlin, Germany). 
2.8. Muscle measures 
Estimated percent body fat, fat weight, and fat free mass (FFM) were determined 
using ultrasound measurements of rump fat thickness at approximately 11 cm caudal from 
the tail head and 10 cm off the midline. This measurement of rump fat was then used to 
calculate the estimated percent body fat according to the equation: % body fat = 
5.4*(ultrasound rump fat thickness in cm) + 2.47 (Kane, 1987; Lehnhard et al., 2004). 
Estimated fat weight and FFM were calculated in turn using the equations: fat weight = 
body weight*(% body fat); FFM = body weight – fat weight (Lehnhard et al., 2004). 
Muscle mass scores were also determined by two assessors using the previously published 
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scale of 1-5 (where 1=lowest; 5=highest), and scores were averaged prior to statistical 
analysis (Graham-Thiers and Kronfeld, 2005).  
Furthermore, percent body fat and fat free mass were determined in ten horses using 
the deuterium oxide (D2O) dilution method previously validated in ponies (Dugdale et al., 
2011). (The horses assessed were n=5 with high inflammation and n=5 with low 
inflammation, as determined by %IFN-γ.) Briefly, feed and water were removed from horse 
pens, and a dose of 0.12 g/kg BW D2O (Cambridge Isotope Laboratories, Tewksbury, MA) 
was administered through a temporary catheter in the left jugular vein. (All horses analyzed 
had a BCS of 4-6, therefore, 0.12*BW could be used for all horses.) Blood samples were 
collected by venipuncture of the right jugular vein immediately before and 4 hours after 
D2O infusion. D2O was administered into the catheter (16Gx5 ½”; Hospira, Inc.; Lake 
Forest, IL) with a 0.22 mm filter (Millex®GP Filter Unit, EMD Millipore, Darmstadt, 
Germany) on the syringe tip to ensure sterility of the procedure, followed by immediate 
administration of sterile saline (100 mL). Syringes were weighed to determine the exact 
weight of D2O administered to each animal. Blood was immediately spun at 2000xg for 10 
minutes at 4oC and placed on ice. Plasma was aliquoted with limited air exposure into air-
tight, o-ring screw cap vials (Fisher Scientific, Waltham, MA) and immediately placed in 
freezer. Samples were stored at -80oC until analysis.  
Metabolic Solutions (Nashua, NH) performed D2O content analysis in triplicate 
using cavity ring-down spectroscopy (CRDS) with a liquid water isotope analyzer 
automated injection system, version 2 upgrade (Los Gatos Research, Mountain View, CA) 
as has previously been published (Thorsen et al., 2011). To remove plasma proteins: zinc 
sulfate monohydrate (5 mg) was added to plasma (25-50 µL), samples were vortexed, and 
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samples were spun at 6000g for 10 minutes at room temperature (22oC) to precipitate 
proteins. The supernatant was injected six times, with the last three being averaged to 
determine values. A standard curve was generated using known values of D2O. Values 
were determined as deltas relative to the V-SMOW (Vienna Standard Mean Ocean Water) 
standard in parts per thousand (ppt). Intra-run variation was <2 delta ppt/mL and inter-run 
variation is <3.5 delta ppt/mL. D2O analysis was performed on samples pre and post D2O 
administration as well as on D2O infusate. The calculation of total body water (TBW) 
adapted from Dugdale et al. (2011) was conducted as follows (Dugdale et al., 2011): 
TBW (kg) = W*A/a*[(delta of dose – delta of dilution tap water)/(delta of post – delta of 
pre)]/1000/1.04 
Here, W= water needed to dilute the D2O infusate dose to enable CRDS measurement 
(58.9225 mg), A= amount of D2O (g) administered to the horse, a= amount of D2O infusate 
dose diluted and measured via CRDS (0.0276 mg), delta of D2O infusate dose relative to 
VSMOW (2595.79 ppt/mL), delta of dilution tap water relative to VSMOW (-81.38 
ppt/mL), 1000= necessary to convert g to kg, and 1.04= factor of overestimation of D2O 
method due to deuterium binding to protein and non-exchangeable areas.  
Using the adjustment factor of 0.723 adapted by Pace and Rathbun (Pace and Rathbun, 
1945), equations were also used to determine percent body fat and fat free mass:  
% Body fat = 100 – (TBW / BW / 0.732)  
Fat Free Mass (FFM) = TBW / 0.732 
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2.9. Pituitary Function 
ACTH levels were determined by Cornell AHDC Endocrinology Laboratory via 
chemiluminescence immunoassay using an Immulite® 1000 (Siemens, Berlin, Germany), 
as previously published in the horse (Place et al., 2010).  
As a dynamic measure of pituitary function, TRH stimulation was also performed. 
TRH (Sigma-Aldrich, St. Louis, MO) was stored at -20oC until dissolved in saline. Using 
sterile techniques in a biochemical hood, TRH was dissolved in 0.9% saline (1 mg/mL), 
aliquoted into sterile microcentrifuge tubes, and immediately frozen at -80oC (Beech et al., 
2007; McFarlane et al., 2006). The morning of TRH testing, the aliquots were thawed at 
room temperature, and using sterile techniques in a chemical hood 1 mL of TRH solution 
was drawn into each of the syringes, which were immediately placed on ice. Blood was 
collected aseptically from the jugular vein in EDTA-containing tubes prior to and 10 
minutes post intravenous TRH administration and placed on ice (Diez de Castro et al., 
2014). The blood was then centrifuged at 800g for 10 minutes at room temperature and 
placed back on ice. Plasma was aliquoted and stored at -20oC until shipment on dry ice to 
Cornell AHDC for ACTH analysis. Horses with ACTH values 10 minutes post TRH 
injection of >110 pg/mL were considered PPID, as recommended by the Equine 
Endocrinology Group (Restifo et al., 2016). 
2.10. Hematological and Biochemical Analyses 
Blood was analyzed by Rood and Riddle Equine Hospital Laboratory, Lexington, 
Kentucky to determine complete blood count (CBC) with differential and blood chemistry 
panel. A Beckman Coulter ACT/DIFF hematology machine and Beckman Coulter AU480 
serum chemistry analyzer were used to determine CBC and blood chemistry, respectively. 
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Specifically measured were: hemoglobin (Hgb), packed cell volume (PCV), red blood cells 
(RBC), white blood cells (WBC), total protein, mature neutrophils (segs), immature 
neutrophils (bands), lymphocytes (lymph), monocytes (mono), eosinophils (eos), sodium, 
potassium, chloride, albumin, serum glutamic oxaloacetic 
transaminase/aspartate aminotransferase (SGOT/AST), alkaline phosphatase, total 
bilirubin, direct bilirubin, creatine kinase (CK), creatinine, glucose, gamma-glutamyl 
transferase (GGT), blood urea nitrogen (BUN), phosphorus, calcium, sorbitol 
dehydrogenase (SDH), and lactate dehydrogenase (LDH). 
2.11. Statistical Analysis  
Prior to data analysis, WINPEPI DESCRIBE (version 3.07) computer program for 
epidemiologists (Abramson, 2011) was used to determine outliers. Non-normally 
distributed data were natural log-transformed to achieve a normal distribution. Outliers at 
each end of the distribution, defined as values further than five times the median absolute 
deviation (MAD) from the median were then excluded prior to analysis to achieve normal 
distribution. 
Data were analyzed with SPSS version 24 (IBM Corp, Armonk, 
NY). Bivariate Pearson correlations were performed among the various parameter 
values. Partial correlations among the various parameters were also analyzed with age as a 
covariate. (Breed and sex were not included as covariates, given the population of horses 
examined were predominantly female [79%] and over half of the horses were 
Thoroughbreds, with quite a variety of other breeds composing the rest of the population.) 
The few variables that were not normally distributed following log-transformation (IL-6 
ELISA, C22:2n6c, and C22:6n3c) were analyzed using non-parametric 
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tests: bivariate Spearman correlations and partial Spearman correlations with age as a 
covariate. For comparisons of deuterium oxide method with ultrasound and muscle scoring 
to determine body composition, data were analyzed via partial Pearson correlations and 
with both age and body weight as covariates for n=10 horses that underwent D2O analysis. 
For all analyses, data with P≤0.05 was considered significant. Results tables depict 
significant relationships between variables. 
Results 
3.1. Relationships of Inflammation to Serum Levels of Vitamins, Minerals, and Fatty Acids 
Lymphocyte production of IFN-γ and TNF-α were correlated with various serum 
vitamins, minerals, and fatty acids. Specifically, the percent of lymphocytes producing 
IFN-γ (% IFN-γ) exhibited a positive correlation with serum folate and selenium and with 
fatty acids C20:2n6c, C20:4n6c, C22:2n6c, C22:5n3c, and C24:1n9c (P≤0.05), while % 
IFN-γ exhibited a negative correlation with serum C16, C18:1n9c, and iron (P≤0.05); 
however, when the model was adjusted for age, only relationships with C22:2n6c and 
C22:5n3c remained significant (P≤0.05) (Table 3.2). The IFN-γ MFI was positively 
correlated with folate, selenium, and fatty acids C20:2n6c, C20:4n6c, C22:5n3c, and 
C24:1n9c (P≤0.05) and was negatively correlated with fatty acid C16 (P≤0.05) (Table 3.2). 
After adjusting for age, only zinc, C22:2n6c, and C22:5n3c were significant (P≤0.05) 
(Table 3.2). The percent of lymphocytes producing TNF-α (% TNF-α) exhibited a positive 
correlation with serum folate, selenium, C20:2n6c, C22:2n6c, C22:5n3c, and C24:1n9c 
(P≤0.05), and % TNF-α exhibited a negative correlation with C16 and C18:1n9c (P≤0.05). 
After adjusting for age, only folate, C20:2n6c, C22:2n6c, and C22:5n3c exhibited a 
significant relationship with % TNF-α (P≤0.05) (Table 3.2). Tumor necrosis factor-α MFI 
62 
was positively correlated with serum folate and fatty acid C22:2n6c and negatively 
correlated with C16 (P≤0.05); after adjusting for age, the relationship of TNF-α MFI with 
folate and C22:2n6c remained significant (P≤0.05) (Table 3.2). 
Peripheral blood mononuclear cell gene expression of various inflammatory 
cytokines was also correlated with various serum vitamins, minerals, and fatty acids. Gene 
expression of IFN-γ was positively correlated with serum folate, C20:4n6c, and C22:5n3c 
(P≤0.05) and was negatively correlated with C16 and C18:1n9c (P≤0.05); after the model 
was adjusted for age folate, C22:2n6c, and C22:5n3c were significantly associated with 
IFN-γ RQ (P≤0.05) (Table 3.2). Gene expression of IL-10 (IL-10 RQ) was positively 
correlated (P≤0.05) with serum folate, selenium, C20:2n6c, C20:4n6c, C22:5n3c, and 
C24:1n9c and negatively correlated (P≤0.05) with iron, C16, and C18:1n9c (Table 3.2). 
Folate and C22:5n3c were still positively associated (P≤0.05) with IL-10 RQ after 
adjusting for age (Table 3.2). Interleukin-1β RQ was negatively correlated (P≤0.05) with 
zinc (Table 3.2). After adjusting the model for age, zinc remained negatively associated 
with IL-1β RQ, and fatty acid C16 became positively associated with IL-1β RQ (P≤0.05) 
(Table 3.2). Interleukin-6 RQ exhibited a positive correlation with fatty acids C18, 
C18:3n3c, and C22:5n3c and showed a negative correlation with C16. Upon including age 
in the model, C16:1n7c, C18, C18:3n3c, and C22:5n3c were positively correlated with IL-
6, while C18:1n9c exhibited a negative correlation with IL-6 (P≤0.05) (Table 3.2). Tumor 
necrosis factor-α RQ was positively correlated (P≤0.05) with folate, selenium, C20:2n6c, 
C22:2n6c, C22:4n6c, and C22:5n3c; upon including age in the model, all of these 
correlations remained significant except with selenium and C22:4n6c (P>0.05). 
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Serum inflammatory proteins also correlated with some vitamins, minerals, and 
fatty acids. Specifically, Serum CRP exhibited a directly proportional relationship (P≤0.05) 
with copper and an inverse relationship (P≤0.05) with vitamin B12 and selenium; after 
adjusting for age, copper and vitamin B12 retained significant relationships with CRP 
(P≤0.05). IL-6 exhibited a directly proportional relationship (P≤0.05) with folate, 
C16:1n7c, C18:3n6c, C20:1n9c, and C22:3n3c, with all relationships remaining significant 
(P≤0.05) after adjusting for age, as well as C22:2n6c and C20:3n3c become positively and 
negatively correlated (P≤0.05) with serum IL-6, respectively.  
In summary, C22:2n6c, C22:5n3c, and folate particularly stood out as being 
positively associated with markers of inflammation after taking age into account as a 
covariate. Docosadienoic acid (C22:2n6c) exhibited a positive correlation with % IFN-γ, 
IFN-γ MFI, % TNF-α, TNF-α MFI, IFN-γ RQ, TNF-α RQ, and serum IL-6. 
Docosapentaenoic acid (DPA; C22:5n3c) was positively correlated with % IFN-γ, IFN-
γ MFI, % TNF-α, IFN-γ RQ, IL-10 RQ, IL-6 RQ, and TNF-α RQ. Folate was also 
positively correlated with % TNF-α, TNF-α MFI, IFN-γ RQ, IL-10 RQ, TNF-α RQ, and 
serum IL-6. Some other fatty acids were correlated (P≤0.05) with two inflammatory 
parameters, including: C20:2n6c with % TNF-α and TNF-α RQ (positive correlation) and 
C16:1n7c with IL-6 RQ and serum IL-6 (positive).  
3.2. Relationships of Inflammation to Hematological (Complete Blood Count [CBC]) and 
Biochemical Parameters 
 Lymphocyte production of IFN-γ and TNF-α were correlated with various 
measures of overall health, as determined by CBC and blood chemistry panel measures. 
Specifically, % IFN-γ was positively correlated (P≤0.05) with direct bilirubin, hemoglobin, 
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total bilirubin, and WBC counts (Table 3.3). Upon adjusting the model for age, all 
parameters remained positively associated with % IFN-γ (P≤0.05) (Table 3.3). Interferon-
γ MFI exhibited a negative correlation (P≤0.05) with eosinophils; this relationship was 
retained when adjusted for age, and mature neutrophils also became negatively correlated 
(P≤0.05) with IFN-γ MFI upon age-adjustment (Table 3.3). Interferon-γ MFI exhibited a 
positive correlation (P≤0.05) with calcium, lymphocytes, direct bilirubin, and total 
bilirubin, which was also retained when adjusted for age for all parameters except calcium 
(Table 3.3). Percent TNF-α was positively correlated with direct bilirubin, total bilirubin, 
and WBC, while % TNF-α was negatively correlated with eosinophils (P≤0.05) (Table 
3.3). After adjusting the model for age, the relationships of % TNF-α with WBC and total 
bilirubin as well as between % TNF-α and eosinophils remained significant (P≤0.05) 
(Table 3.3). Tumor necrosis factor-α MFI was negatively correlated (P≤0.05) with sodium, 
SDH, and SGOT/AST and was positively correlated (P≤0.05) with direct and total 
bilirubin. Only the relationships of TNF- α MFI with SGOT/AST and total bilirubin 
remained after adjusting for age (P≤0.05) (Table 3.3). 
Peripheral blood mononuclear cell gene expression of inflammatory cytokines was 
also correlated with various measures examined by CBC and chemistry panel. Interferon-
γ RQ was positively correlated (P≤0.05) with WBC, direct bilirubin, and total bilirubin, 
and was negatively correlated with eosinophils. All relationships except total bilirubin were 
retained following age adjustment, and the positive correlation between IFN-γ RQ and 
lymphocytes became significant (P≤0.05) (Table 3.3). Interleukin-10 RQ was positively 
associated (P≤0.05) with WBC, direct bilirubin, and total bilirubin and was negatively 
associated with SDH. Following age adjustment, the relationship of IL-10 RQ with 
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eosinophils became significant in addition to the relationship between IL-10 and WBC 
remaining significant (P≤0.05). Interleukin-1β RQ was positively associated with mature 
neutrophils and negatively associated with CK, hemoglobin, and lymphocytes (P≤0.05); 
following age adjustment, all relationships remained significant, as well as the negative 
correlation between IL-1β RQ and creatinine becoming significant (P≤0.05). Interleukin-6 
RQ was positively correlated (P≤0.05) with WBC and lymphocytes and negatively 
correlated (P≤0.05) with neutrophils and SDH, with all relationships except WBC (P≤0.05) 
being retained following age adjustment. Tumor necrosis factor-α RQ was positively 
associated with direct bilirubin and negatively correlated with LDH, SDH, and SGOT/AST 
(P≤0.05); only the relationship with SGOT/AST remained significant following age-
adjustment (P≤0.05).  
 Additionally, serum inflammatory proteins exhibited relationships with various 
aspects of immune health examined via CBC and chemistry panel. Serum CRP was 
positively correlated with SDH and negatively correlated with BUN and creatinine. After 
model adjustment for age, relationships with BUN and creatinine remained significant, 
with the negative correlation between CRP and SGOT/AST also becoming significant 
(P≤0.05) (Table 3.3). Serum IL-6 was negatively correlated (P≤0.05) with alkaline 
phosphatase, CK, LDH, and SGOT/AST, and was positively correlated with phosphorus, 
neutrophils, and total protein (P≤0.05). All relationships were retained (P≤0.05) following 
model adjustment for age, as well as the negative correlation between serum IL-6 and RBC 
becoming significant (P≤0.05) (Table 3.3).  
 In summary, various CBC and chemistry measures were significantly correlated 
with inflammation following age-adjustment. Specifically, inflammation was positively 
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correlated with total bilirubin (% IFN-γ, IFN-γ MFI, % TNF-α, TNF-α MFI), WBC (% 
IFN-γ, % TNF-α, IFN-γ RQ, IL-10), and direct bilirubin (% IFN-γ, IFN-γ MFI, IFN-γ RQ) 
(P≤0.05). Inflammation was negatively correlated with eosinophils (IFN-γ MFI, % TNF-
α, IFN-γ RQ, IL-10), SGOT/AST (TNF-α MFI, CRP, TNF-α RQ, serum IL-6), and CK 
(IL-1β & serum IL-6) (P≤0.05). Lymphocytes, neutrophils, and hemoglobin all exhibited 
both negative and positive relationships with inflammatory markers, specifically: 
lymphocytes (IFN-γ MFI, IFN-γ RQ, IL-6 RQ – positive correlation; IL-1β – negative 
correlation), neutrophils (IL-1β RQ, serum IL-6 – positive; IFN-γ MFI, IL-6 RQ – 
negative), and hemoglobin (% IFN-γ -positive; IL-1β RQ-negative).  
3.3. Relationships of Inflammation to Body Composition Measures 
Relationships between inflammation and body composition were also determined. 
Serum IL-6 exhibited a directly proportional relationship with body weight both prior to 
(R=0.321; p=0.038) and following age-adjustment (R=0.551; P≤0.001). Serum IL-6 also 
appeared to be positively correlated with fat free mass as estimated by ultrasound prior to 
(R=0.322; p=0.037) and following age-adjustment of the model (R=0.534; P≤0.001); 
however, upon taking body weight into the model as a covariate in addition to age, the 
association between IL-6 and FFM disappeared (R=0.011; p=0.947). No other measures of 
body composition (including average muscle score, BCS, body weight, % body fat via 
ultrasound, FFM via ultrasound, and for the subset of n=10 horses % body fat via D2O and 
FFM via D2O) exhibited relationships (P>0.05) with the inflammatory measures examined. 
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3.4. Relationships of PPID to Inflammation, Vitamins, Minerals, Fatty Acids, 
Hematological, Biochemical, and Body Composition Measures 
The presence or absence of the endocrinopathy PPID was associated with various 
vitamin, mineral, fatty acid, CBC, chemistry panel, and body composition parameters 
examined. Pituitary pars intermedia dysfunction status was positively associated (P≤0.05) 
with basal ACTH and folate and was negatively associated with vitamin B12 (Table 3.4). 
Adjusting the model for age yielded directly proportional relationships (P≤0.05) between 
PPID status and basal ACTH, serum CRP, and eosinophils (Table 3.4). After adjusting for 
age, PPID status was also negatively correlated (P≤0.05) with RBC, creatinine, vitamin 
B12, and fatty acid C20:4n6c (Table 3.4).    
Basal ACTH, a known indicator of pituitary function, also exhibited some 
relationships with the various parameters examined. Basal ACTH was negatively 
correlated (P≤0.05) with vitamin B12. When age adjustment was taken into account, basal 
ACTH exhibited a significant positive correlation with fatty acid C16, while exhibiting a 
significant negative correlation with direct bilirubin (P≤0.05) (Table 3.4). 
3.5. Relationships of Age to Inflammation, Vitamins, Minerals, Fatty Acids, Complete 
Blood Count, Chemistry Panel, Body Composition, and PPID Measures 
 Even within this population of senior horses, age was associated with various 
vitamin, mineral, fatty acid, hematological, biochemical, body composition, and PPID 
parameters. Among the inflammatory parameters, age was positively correlated with the 
percent of lymphocytes producing IFN-γ and TNF-α, as well as with gene expression of 
IFN-γ, IL-10, and TNF-α (P≤0.05) (Table 3.5). Vitamin E, selenium, and fatty acids 
C18:2n6c, C20:4n6c, and C24:1n9c also exhibited positive correlations with age, while 
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fatty acids C16, C16:1n7c, C18:1n7c, C18:1n9c, and C20:1n9c exhibited negative 
correlations with age (P≤0.05) (Table 3.5). Among CBC and chemistry panel parameters, 
only SDH was inversely proportional to age (P≤0.05) (Table 3.5). Various measures of 
body composition exhibited negative correlations with age including BCS, body weight, 
FFM as estimated by ultrasound, and muscle score (P≤0.05) (Table 3.5). And within this 
group of old horses, both PPID status and basal ACTH were directly proportional to age 
(P≤0.05) (Table 3.5). 
3.6. Comparison of D2O Methods with Ultrasound and Muscle Scoring in Determining 
Body Composition  
When examining D2O methods vs. ultrasound for the subset of 10 horses with age 
and body weight as covariates, results generally showed poor correlation (P>0.05) (Table 
3.6). However, FFM measurements via D2O and muscle score were strongly correlated 
(R=0.895; p=0.001) (Table 3.6).  
Discussion 
The occurrence of inflamm-aging in senior horses has been well-established 
(Adams et al., 2008; Adams et al., 2009). However, what remains to be determined are the 
implications of inflamm-aging on the overall health of the horse and how markers of 
inflamm-aging may be related to other parameters associated with nutritional status, health, 
and wellbeing. It was expected that inflamm-aging would be inversely associated with 
muscle measures and known anti-inflammatory nutrients, while specific markers of 
inflammation would be differentially associated with PPID status due to cytokine 
dysregulation. Thus, an old horse population was examined to determine whether various 
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vitamin, mineral, fatty acid, hematological, biochemical, body composition, and PPID 
parameters showed any significant associations with certain inflammatory measures. 
 In this study docosadienoic acid (C22:2n6c), docosapentaenoic acid (DPA; 
C22:5n3c), and folate were all positively associated with numerous inflammatory 
parameters. Docosadienoic acid has exhibited antioxidant activity in previous in vitro 
research, exhibiting some of the highest cyclooxygenase enzyme inhibition among the 
numerous fatty acids examined (Henry et al., 2002). The results showing that C22:2n6c 
then is positively associated with inflammation is somewhat surprising, given that 
oxidative stress and inflammation frequently occur together; however, little research on 
C22:2n6c has been conducted thus far. Docosapentaenoic acid was also positively 
associated with various inflammatory markers despite being an omega-3 fatty acid, which 
are generally considered to be anti-inflammatory. In a study examining metabolic 
syndrome in obese adolescents, changes in DPA specifically were positively associated 
with changes in anti-inflammatory adiponectin and were negatively associated with pro-
inflammatory leptin and leptin/adiponectin ratio, indicating that DPA tends to be associated 
with an anti-inflammatory status (Masquio et al., 2016). A recent human study of ulcerative 
colitis (a type of inflammatory bowel disease), showed an interesting caveat in that serum 
DPA concentrations were higher in patients with pro-inflammatory ulcerative colitis 
compared to healthy controls, although the opposite relationship was found at the tissue 
level (Wiese et al., 2016). Similarly to these studies involving other inflammatory 
conditions, inflamm-aging appears to be associated with altered fatty acid metabolism. 
Additionally, in this study, markers of inflammation were positively associated with folate 
concentrations, although some previous studies have suggested folate to have anti-
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inflammatory properties (Chen et al., 2016; Cianciulli et al., 2016), whereas other studies 
have found no association (Cao et al., 2016). One possible explanation for these perhaps 
unexpected associations between markers of inflammation and (anti-inflammatory) folate 
and fatty acid concentrations is that these anti-inflammatory compounds have been released 
from tissues into the bloodstream in an effort to moderate the elevated systemic 
inflammation inherent with inflamm-aging, i.e. a compensatory effect.  
 Some hematological and biochemical parameters were also associated with 
markers of inflammation in this study. Specifically direct bilirubin, total bilirubin, and 
WBC were positively associated with various inflammatory parameters, while 
SGOT/AST, eosinophils, and CK were negatively associated with inflammatory 
parameters.  The positive correlations between bilirubin and inflammation are somewhat 
expected, as some studies have shown bilirubin to be associated with neuro-inflammation 
(Liu et al., 2016a; Qaisiya et al., 2016). However in a rodent model examining inflamm-
aging specifically, mild hyperbilirubinemia was suggested to be protective against 
inflamm-aging (Zelenka et al., 2016), and another study found a negative association 
between serum bilirubin and the number of pro-inflammatory CD8+ T cells (Moreno-Otero 
et al., 1994). SGOT/AST has also previously been associated with inflammation (Tiwari 
et al., 2016), with experimentally-induced reductions in inflammation likewise being 
associated with decreases in SGOT/AST (Seif El-Din et al., 2016), which is in contrast to 
the negative correlation between SGOT/AST and inflammation found in this study. The 
relationship of inflammation to liver disease as a whole is complex in that increasing age 
and inflamm-aging in humans have been associated with an increased prevalence of liver 
disease; however, in the very elderly (>70 years), the incidence of liver disease is very low 
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(Sheedfar et al., 2013). The complexity of the relationship between liver disease and 
inflammation may to some degree explain these seemingly contradictory results for 
bilirubin and SGOT/AST in relation to inflammation. Furthermore, SGOT/AST is not a 
specific biomarker for liver damage, as it can also reflect muscle (and other soft tissue) 
damage, which may further explain the inconclusiveness of these results. Creatine kinase 
(CK), a common biomarker of muscle damage, exhibited an inverse relationship with 
inflammation as well. This was somewhat surprising, considering myositis and myopathies 
are generally associated with inflammation. However, studies have also shown decreased 
levels of CK in association with several inflammatory rheumatic diseases as well as with 
inflammatory bowel disease tissue (Kitzenberg et al., 2016; Lee et al., 2000; Sanmarti et 
al., 1996), supporting the results of the current study. Furthermore, CK and SGOT/AST 
values were greater than the reference range for over half of the horses sampled, suggesting 
that old horses may exhibit elevated levels of the muscle damage biomarkers, potentially 
due to sarcopenia. White blood cell counts being positively correlated with inflammation 
is well-documented. Eosinophils (percentage of WBC count) being negatively correlated 
with inflammation is not surprising given that elevated levels of eosinophils, which are 
associated with parasitic infections, elicit a TH-2 immune response that could be decreasing 
the inflammatory response associated with aging. However, the horses had been dewormed 
within a month prior to the study. 
Body composition parameters showed few correlations with the systemic 
inflammatory markers examined. This was somewhat unexpected, given the association of 
both inflamm-aging and sarcopenia with aging. And no relationships between 
inflammation and muscle measurements remained after adjusting for age, and in the case 
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of FFM estimated by ultrasound, adjusting for body weight as well. This indicates that 
some other aspect of the aging process may be contributing to sarcopenia aside from 
systemic inflamm-aging; however, if investigated in a population of both old and young 
horses, a relationship between inflamm-aging and sarcopenia may become apparent.  
Muscle composition as determined by D2O analysis (for n=10 horses) did not 
exhibit strong correlations when compared to ultrasound methods after modeling with body 
weight and age as covariates. This may give further reasons for the general lack of 
relationships between inflammation and body composition parameters discussed 
previously for the n=42 horses. However, the strong positive correlation between D2O 
analysis and muscle scoring even after taking body weight and age into account suggests 
muscle scoring as a valuable method of muscle assessment. 
PPID measures, including basal ACTH and PPID status as defined by TRH testing, 
were also associated with some of the various parameters analyzed in this study. Notably, 
vitamin B12 exhibited a negative correlation with PPID status regardless of including age 
as a covariate and also exhibited a negative correlation with basal ACTH. Vitamin B12 is 
key to proper functioning of the brain and nervous system, with case studies showing 
improvements in nervous system function after treatment with B12 for those deficient in 
this vitamin (Kumar, 2004; Shyambabu et al., 2008). A recent human study has shown 
vitamin B12 to be negatively associated with inflammation (Al-Daghri et al., 2016), 
similarly to the current study in which vitamin B12 was negatively correlated with CRP. 
Studies have also found that B12 deficiencies may be associated with Parkinson’s disease 
(Orozco-Barrios et al., 2009) and with increased risk for white matter hyperintensities (de 
van der Schueren et al., 2016), a predictor of Alzheimer’s disease (Provenzano et al., 2013). 
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Human patients with active Cushing’s disease have exhibited decreased levels of vitamin 
B12, while recovered patients did not, suggesting a role of vitamin B12 in disease state 
(Faggiano et al., 2005). In the present study, vitamin B12 levels for all horses were within 
the normal range except for two horses that exceeded normal range; thus the horses did not 
appear to be deficient in this nutrient. However, the results of the present study showing a 
negative relationship of PPID (or equine Cushing’s disease) with vitamin B12 support 
those previously published in the human with Cushing’s disease (Faggiano et al., 2005). 
Eosinophils were also positively correlated with PPID status, which is not surprising due 
to the fact that PPID horses exhibit higher levels of IL-8 (McFarlane and Holbrook, 2008), 
a chemoattractant of eosinophils (Erger and Casale, 1995).  Furthermore, PPID horses tend 
to have higher fecal egg counts than do similarly aged healthy horses, which may also 
account for the higher percentage of eosinophils in PPID horses (McFarlane et al., 2010). 
Age itself was examined in relation to the various parameters to determine where 
it might have the strongest associations. The modeling for other parameters incorporated 
age as a covariate due to: 1) the number of relationships it appeared to impact and 2) the 
fact that inflammation was the primary focus of this study within a group of senior horses, 
and it was not desired to have the potentially confounding variable of age as a component 
of inflamm-aging. It is known that the body undergoes various changes when entering 
senior years, which may have effects on numerous variables. However, to better understand 
the process of aging in the senior horse, relationships between age and the various 
parameters were determined. When examining the various inflammatory measures, many 
parameters were positively correlated with age as expected, based on previous studies 
regarding inflamm-aging in the horse and other species (Adams et al., 2008; Franceschi et 
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al., 2007). Numerous fatty acids being negatively correlated with age was also 
unsurprising, as these results are similar to those found in humans (Ferrucci et al., 2006). 
The positive correlation between age and both vitamin E and selenium may suggest either 
a protective effect in which horses with higher levels of vitamin E and selenium tend to 
live longer, or an inability of senescent cells to uptake these nutrients, thereby leaving them 
sequestered in circulation. A recent mouse model publication found that selenium 
deficiency was associated with longevity, despite having decreased healthspan (delayed 
wound healing as well as earlier onset of age-associated decreased glucose tolerance, 
decreased insulin sensitivity, and osteoporosis, etc.) (Wu et al., 2016).  This demonstrates 
that the relationship between age and selenium may be rather complex. Numerous body 
composition parameters including muscle measures were negatively correlated with age as 
expected, since horses experience sarcopenia. PPID measures (including basal ACTH and 
PPID status, as defined by TRH testing) were also associated with increased age, which is 
expected, as PPID is generally an endocrinopathy of the senior horse (McFarlane, 2011), 
and presumably would become more common with increasing age. 
This exploratory study demonstrates the various complex relationships between 
inflammatory parameters and various vitamin, mineral, fatty acid, hematological, 
biochemical, body composition, and PPID parameters in senior horses. Further study of 
the various relationships determined, particularly the relationship of inflammatory markers 
with fatty acids and folate as well as the relationship of PPID status with vitamin B12 and 
eosinophils, will aid understanding of the process of aging in the horse, with the goal of 
promoting longevity and healthspan.  
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      Table 3.1. Nutrient composition (DM basis) of feed and hay1 
Component Oats 
Alfalfa 
Pellets 
Grass 
Hay 
DM, % 92 90.8 92.6 
DE, Mcal/kg 3.34 3.01 1.94 
CP, % 12.6 13.6 14.7 
ADF, % 11.1 21.6 43.8 
NDF, % 24.7 37.3 66.1 
Ca, % 0.13 0.82 0.54 
P, % 0.4 0.59 0.42 
Mg, % 0.14 0.33 0.29 
K, % 0.53 1.13 1.46 
Na, % 0.028 0.206 0.078 
Fe, ppm 91 313 265 
Zn, ppm 35 128 36 
Cu, ppm 9 56 11 
Mn, ppm 49 128 115 
1Analyzed by Equi-Analytical Laboratories (Ithaca, NY). 
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Table 3.2. Comparisons of various inflammatory measures to serum levels of vitamins, 
minerals, and fatty acids1,2 
Inflammatory 
Parameter 
Comparison 
Parameter 
Pearson correlations Age-adjusted 
Correlation 
Coefficient p-value 
Correlation 
Coefficient p-value 
%
 IF
N
-γ
 
C16:0 -0.343 0.028† -0.177 0.275 
C18:1n9c -0.327 0.048† -0.225 0.186 
C20:2n6c 0.333 0.031† 0.276 0.081 
C20:4n6c 0.380 0.013† 0.276 0.081 
C22:2n6c 0.335 0.030† 0.407 0.008* 
C22:5n3c 0.405 0.009† 0.357 0.024* 
C24:1n9c 0.364 0.019† 0.216 0.181 
Folate 0.309 0.047† 0.222 0.164 
Iron -0.351 0.023† -0.281 0.075 
Selenium 0.386 0.013† 0.263 0.101 
IF
N
-γ
 M
F
I 
C16:0 -0.361 0.020† -0.256 0.111 
C20:2n6c 0.320 0.039† 0.277 0.080 
C20:4n6c 0.345 0.025† 0.272 0.085 
C22:2n6c 0.286 0.066 0.349 0.025* 
C22:5n3c 0.405 0.009† 0.369 0.019* 
C24:1n9c 0.338 0.031† 0.226 0.160 
Folate 0.347 0.024† 0.290 0.066 
Selenium 0.362 0.020† 0.277 0.083 
Zinc 0.244 0.135 0.316 0.050* 
%
 T
N
F-
α 
C16:0 -0.432 0.005† -0.269 0.093 
C18:1n9c -0.390 0.017† -0.252 0.138 
C20:2n6c 0.368 0.016† 0.310 0.048* 
C22:2n6c 0.362 0.018† 0.445 0.004* 
C22:5n3c 0.458 0.003† 0.412 0.008* 
C24:1n9c 0.342 0.028† 0.151 0.354 
Folate 0.398 0.009† 0.313 0.046* 
Selenium 0.339 0.030† 0.182 0.262 
TN
F-
α 
M
FI
 C16:0 -0.330 0.038† -0.214 0.191 
C22:2n6c 0.366 0.019† 0.459 0.003* 
Folate 0.410 0.008† 0.357 0.024* 
Ln
(I
FN
-γ
 R
Q
) C16:0 -0.377 0.015† -0.210 0.194 
C18:1n9c -0.381 0.020† -0.255 0.133 
C20:4n6c 0.313 0.044† 0.182 0.254 
C22:2n6c 0.257 0.101 0.331 0.035* 
C22:5n3c 0.455 0.003† 0.409 0.009* 
Folate 0.404 0.008† 0.322 0.040* 
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Table 3.2. (cont.) Comparisons of various inflammatory measures to serum levels of 
vitamins, minerals, and fatty acids1,2 
Inflammatory 
Parameter 
Comparison 
Parameter 
Pearson correlations Age-adjusted 
Correlation 
Coefficient p-value 
Correlation 
Coefficient p-value 
Ln
(I
L-
10
 R
Q
) 
C16:0 -0.312 0.047† -0.120 0.461 
C18:1n9c -0.386 0.018† -0.250 0.142 
C20:2n6c 0.339 0.028† 0.277 0.080 
C20:4n6c 0.322 0.038† 0.189 0.236 
C22:5n3c 0.417 0.007† 0.366 0.020* 
C24:1n9c 0.320 0.041† 0.136 0.404 
Folate 0.460 0.002† 0.384 0.013* 
Iron -0.305 0.050† -0.219 0.168 
Selenium 0.365 0.019† 0.215 0.183 
Ln
(I
L-
1β
 
R
Q
) C16:0 0.258 0.118 0.327 0.048* 
Zinc -0.354 0.031† -0.352 0.035* 
Ln
(I
L-
6 
R
Q
) C16:0 -0.311 0.048
† -0.212 0.189 
C16:1n7c 0.241 0.150 0.354 0.034* 
C18:0 0.364 0.018† 0.333 0.033* 
C18:1n9c -0.484 0.002† -0.421 0.011* 
C18:3n3c 0.300 0.060 0.356 0.026* 
C22:5n3c 0.455 0.003† 0.421 0.007* 
Ln
(T
N
F-
α 
R
Q
) C20:2n6c 0.407 0.008† 0.363 0.020* 
C22:2n6c 0.468 0.002† 0.537 <0.001* 
C22:4n6c 0.335 0.032† 0.305 0.056 
C22:5n3c 0.370 0.017† 0.324 0.042* 
Folate 0.401 0.008† 0.336 0.032* 
Selenium 0.356 0.023† 0.245 0.128 
Ln
(C
R
P 
EL
IS
A
) Copper 0.417 0.006† 0.368 0.018* 
Selenium -0.338 0.031† -0.249 0.121 
Vitamin B12 -0.321 0.038† -0.374 0.016* 
Ln
(I
L-
6 
EL
IS
A
) C16:1n7c 0.342 0.038† 0.465 0.004* 
C18:3n6c 0.339 0.028† 0.354 0.023* 
C20:1n9c 0.361 0.020† 0.479 0.002* 
C20:3n3c -0.222 0.164 -0.315 0.048* 
C22:2n6c 0.289 0.063 0.318 0.043* 
C22:3n3c 0.329 0.036† 0.334 0.035* 
Folate 0.351 0.023† 0.316 0.044* 
1A cross (†) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote 
P≤0.05 for age-adjusted models. 
2Spearman correlations and age-adjusted non-parametric analysis were performed for C22:2n6c 
and IL-6 ELISA due to non-normal distribution. 
3IFN-γ = interferon-γ; % gated = percent of lymphocytes producing the cytokine; MFI = mean 
fluorescence intensity; TNF-α = tumor necrosis factor-α; IL = interleukin; CRP = C-reactive 
protein; ELISA = enzyme-linked immunosorbent assay 
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Table 3.3. Comparisons of various inflammatory measures to complete blood count and 
chemistry panel measures1-3 
Inflammatory 
Parameter 
Comparison 
Parameter 
Pearson correlations Age-adjusted 
Correlation 
Coefficient p-value
Correlation 
Coefficient p-value 
%
 IF
N
-γ
 D. Bili 0.413 0.006† 0.352 0.024* 
Hgb 0.350 0.025† 0.319 0.045* 
T. Bili 0.416 0.007† 0.352 0.026* 
WBC 0.470 0.002† 0.416 0.007* 
IF
N
-γ
 M
F
I 
Calcium 0.312 0.050† 0.280 0.084 
D. Bili 0.378 0.014† 0.330 0.035* 
Eosinophils -0.419 0.006† -0.432 0.005* 
Lymphocytes 0.377 0.015† 0.418 0.007* 
Seg -0.293 0.063 -0.336 0.034* 
T. Bili 0.408 0.008† 0.359 0.023* 
%
 T
N
F-
α D. Bili 0.372 0.015† 0.297 0.059 
Eosinophils -0.329 0.033† -0.359 0.021* 
T. Bili 0.424 0.006† 0.356 0.024* 
WBC 0.404 0.008† 0.336 0.032* 
TN
F-
α 
M
F
I D. Bili 0.358 0.022† 0.310 0.052 
Sodium -0.319 0.042† -0.263 0.101 
SDH -0.374 0.025† -0.311 0.069 
SGOT/AST -0.345 0.027† -0.321 0.043* 
T. Bili 0.423 0.007† 0.378 0.018* 
Ln
(I
FN
-γ
 R
Q
) D. Bili 0.404 0.008† 0.336 0.032* 
Eosinophils -0.322 0.038† -0.348 0.026* 
Lymphocytes 0.288 0.068 0.365 0.021* 
T. Bili 0.365 0.019† 0.292 0.068 
WBC 0.452 0.003† 0.392 0.011* 
Ln
(I
L-
10
 R
Q
) D. Bili 0.368 0.017† 0.293 0.063 
Eosinophils -0.299 0.054 -0.326 0.038* 
SDH -0.325 0.050† -0.181 0.290 
T. Bili 0.330 0.035† 0.251 0.119 
WBC 0.389 0.011† 0.318 0.043* 
Ln
(I
L-
1β
 R
Q
) CK -0.362 0.028† -0.356 0.033* 
Creatinine -0.289 0.074 -0.337 0.038* 
Hgb -0.397 0.014† -0.429 0.008* 
Lymphocytes -0.448 0.004† -0.443 0.005* 
Seg 0.431 0.006† 0.425 0.008* 
Ln
(I
L-
6 
R
Q
) 
Lymphocytes 0.384 0.013† 0.422 0.007* 
SDH -0.401 0.014† -0.344 0.040* 
Seg -0.350 0.025† -0.391 0.013* 
WBC 0.321 0.038† 0.268 0.090 
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Table 3.3. (cont.) Comparisons of various inflammatory measures to serum levels of 
vitamins, minerals, and fatty acids1,2 
Inflammatory 
Parameter 
Comparison 
Parameter 
Pearson correlations Age-adjusted 
Correlation 
Coefficient p-value 
Correlation 
Coefficient p-value 
Ln
(T
N
F-
α 
R
Q
) 
D. Bili 0.317 0.041† 0.254 0.109 
LDH -0.363 0.018† -0.307 0.051 
SDH -0.387 0.018† -0.291 0.086 
SGOT/AST -0.468 0.002† -0.446 0.004* 
Ln
(C
R
P 
EL
IS
A
) BUN -0.447 0.003† -0.405 0.010* 
Creatinine -0.505 0.001† -0.473 0.002* 
SDH 0.331 0.045† 0.205 0.230 
SGOT/AST -0.285 0.067 -0.348 0.026* 
Ln
(I
L-
6 
EL
IS
A
) 
Alk. 
Phosphatase 
-0.433 0.005† -0.449 0.004* 
CK -0.417 0.008† -0.411 0.009* 
LDH -0.426 0.005† -0.407 0.008* 
Phosphorus 0.311 0.045† 0.410 0.008* 
RBC -0.296 0.057 -0.337 0.031* 
Seg 0.378 0.015† 0.363 0.021* 
SGOT/AST -0.514 0.001† -0.511 0.001* 
Total Protein 0.401 0.008† 0.406 0.008* 
1Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY). 
2 A cross (†) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote 
P≤0.05 for age-adjusted models. 
3 Spearman correlations and age-adjusted non-parametric analysis were performed for IL-6 ELISA 
due to non-normal distribution. 
4IFN-γ = interferon-γ; % = percent of lymphocytes producing the cytokine; MFI = mean 
fluorescence intensity; TNF-α = tumor necrosis factor-α; IL = interleukin; CRP = C-reactive 
protein; ELISA = enzyme-linked immunosorbent assay; D. Bili = direct bilirubin; Hgb = 
hemoglobin; T. Bili = total bilirubin; WBC = white blood cells; Seg = mature neutrophils; SDH = 
sorbitol dehydrogenase; CK = creatine kinase; LDH = lactate dehydrogenase; SGOT/AST = 
serum glutamic oxaloacetic transaminase/aspartate aminotransferase; BUN = blood urea nitrogen; 
Alk. Phosphatase = alkaline phosphatase; RBC = red blood cells. 
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Table 3.4. Comparisons of measures of PPID to various inflammatory, vitamin, mineral, 
fatty acid, complete blood count, chemistry panel, and body composition measures1-3 
PPID 
Parameter 
Comparison 
Parameter 
Pearson correlations Age-adjusted 
Correlation 
Coefficient p-value 
Correlation
Coefficient p-value 
PP
ID
 S
ta
tu
s 
RBC -0.205 0.193 -0.311 0.048* 
Eosinophils 0.269 0.084 0.311 0.048* 
Creatinine -0.228 0.146 -0.383 0.013* 
Ln(CRP ELISA) 0.185 0.240 0.368 0.018* 
Vitamin B12 -0.547 <0.001† -0.556 <0.001* 
Folate 0.307 0.048† 0.201 0.208 
C20:4n6c -0.078 0.621 -0.308 0.050* 
Ln(Basal 
ACTH) 0.595 <0.001
† 0.482 0.002* 
Ln
(B
as
al
 
A
C
TH
) C16:0 0.113 0.486 0.527 0.001* 
D. Bili -0.165 0.304 -0.331 0.037* 
Vitamin B12 -0.333 0.033† -0.300 0.060 
1Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY). 
2Pituitary pars intermedia dysfunction (PPID) status is determined by thyrotropin releasing 
hormone stimulation, with adrenocorticotropin hormone (ACTH) ≥110 pg/mL being considered 
PPID and ACTH<110 pg/mL considered non-PPID. 
3A cross (†) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote 
P≤0.05 for age-adjusted models. 
4PPID = Pituitary par intermedia dysfunction; ACTH = adrenocorticotropin hormone; RBC = red 
blood cells; CRP = C-reactive protein; ELISA = enzyme-linked immunosorbent assay; D. Bili = 
direct bilirubin 
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Table 3.5. Comparisons of various inflammatory, vitamin, mineral, fatty acid, complete 
blood count, chemistry panel, body composition, and PPID measures to age1-3 
Comparison 
Parameter 
Pearson correlations with Age 
Correlation 
Coefficient p-value
% IFN-γ 0.382 0.013* 
% TNF-α 0.436 0.004* 
Ln(IFN-γ RQ) 0.423 0.005* 
Ln(IL-10 RQ) 0.434 0.004* 
Ln(TNF-α RQ) 0.330 0.033* 
C16:0 -0.529 <0.001* 
C16:1n7c -0.332 0.044* 
C18:1n7c -0.410 0.008* 
C18:1n9c -0.501 0.002* 
C18:2n6c 0.551 <0.001* 
C20:1n9c -0.372 0.017* 
C20:4n6c 0.377 0.014* 
C24:1n9c 0.454 0.003* 
Selenium 0.438 0.004* 
Vitamin E 0.491 0.001* 
SDH -0.410 0.012* 
BCS -0.454 0.003* 
Body weight  -0.607 <0.001* 
FFM (ultrasound) -0.602 <0.001* 
Muscle Score -0.309 0.047* 
PPID Status 0.462 0.002* 
Ln(Basal ACTH) 0.454 0.003* 
1Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY). 
2All parameters with P≤0.05 are shown in this table. 
3IFN-γ = interferon-gamma; % = percent of lymphocytes producing the cytokine; TNF-α = tumor 
necrosis factor-α; IL = interleukin; SDH = sorbitol dehydrogenase; BCS = body condition 
score; FFM = fat free mass; PPID = pituitary pars intermedia dysfunction; ACTH = 
adrenocorticotropin hormone   
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Table 3.6. Comparison of deuterium oxide methods of body composition determination 
with body composition determinations via ultrasound and muscle scoring1,2 
Body 
Composition 
Parameter 
Comparison Parameter 
Pearson correlations adjusted for Age 
& Body weight 
Correlation 
Coefficient p-value 
M
us
cl
e 
Sc
or
e 
% Body Fat (ultrasound) 0.035 0.929 
% Body Fat (D2O) -0.529 0.143 
FFM (ultrasound) -0.031 0.937 
FFM (D2O) 0.895 0.001* 
%
 B
od
y 
Fa
t 
(u
ltr
as
ou
nd
) % Body Fat (D2O) -0.618 0.076§ 
FFM (ultrasound) -0.651 0.057§ 
FFM (D2O) 0.375 0.321 
FF
M
 (D
2O
) % Body Fat (ultrasound) 0.375 0.321 
% Body Fat (D2O) -0.683 0.043* 
FFM (ultrasound) -0.124 0.751 
1Correlations with age and body weight as covariates are displayed; correlation p-values 
denoted with (*) indicate P≤0.05, while (§) indicate P≤0.10. 
2BCS= body condition score; D2O = deuterium oxide; FFM = fat free mass 
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CHAPTER 4 
PERIPHERAL BLOOD MONONUCLEAR CELL-MEDIATED INFLAMM-
AGING AND IMMUNOSENESCENCE OF AGED HORSES WITH VS. 
WITHOUT PITUITARY PARS INTERMEDIA DYSFUNCTION (PPID). 
Abstract 
 Pituitary pars intermedia dysfunction (PPID) is an endocrine disorder commonly 
affecting senior equids (≥20 years). This endocrine disease results in various clinical signs, 
including hypertrichosis and immunosuppression. The senior horse population is also 
affected by immune changes associated with advanced age, including immunosenescence 
(decreased immune response) and inflamm-aging (low-grade, systemic inflammation). 
These age-associated changes occur both systemically and specifically mediated by 
peripheral blood mononuclear cells (PBMC). To determine whether the presence of PPID 
affects these already immune-compromised senior horses, PBMC-mediated cytokine 
expression and production as well as lymphocyte proliferation were compared in age-
matched PPID and non-PPID horses. It was hypothesized that PPID affects cell-mediated 
immunity differentially from the process of aging alone. 
Heparanized blood was collected from n=6 PPID (mean age ± SEM = 24.7±0.9 
years) and n=6 non-PPID horses (23.3±1.0 years) of mixed breeds and sex. PPID Status 
was determined using thyrotropin releasing hormone (TRH) stimulation testing, with 
adrenocorticotropin hormone (ACTH) levels <110 pg/mL at 10 minutes post TRH 
injection (i.v.) being considered non-PPID horses. Ficoll gradient centrifugation was used 
to isolate PBMC from heparinized blood. Intracellular staining for pro-inflammatory 
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cytokines and flow cytometry were then performed on cells stimulated with Phorbol 12-
myristate 13-acetate (PMA; 4 hr, 5% CO2, 37oC) and phytohemagglutinin (PHA; 72 hr, 
5% CO2, 37oC). Reverse transcription and real time-polymerase chain reaction (RT-PCR) 
were also performed on PMA-stimulated PBMC to determine gene expression of 
interleukin(IL)-2, IL-4, IL-6, interferon(IFN)-γ, and tumor necrosis factor(TNF)-α. 
Lymphocyte proliferation was also analyzed using flow cytometry for PBMC stained with 
carboxyfluorescein succinimidyl ester (CFSE) and stimulated with concanavalin A (96 hr, 
5% CO2, 37oC). SigmaPlot version 12.3 was used to perform t-tests between PPID and 
non-PPID horses for the various immune measures, with a two-way ANOVA with repeated 
measures used to perform lymphocyte proliferation analysis. Data with p<0.05 were 
considered significant. 
No significant differences between PPID and non-PPID horses were found for any 
of the various immune measures including intracellular staining, gene expression, and 
lymphocyte proliferation (p>0.05). Therefore, the immunosuppression and increased 
susceptibility to infections associated with PPID do not appear to affect lymphocyte-
mediated inflamm-aging or immunosenescence in the senior horse. Further research is 
warranted to elucidate the mechanisms underlying PPID in order to better manage and even 
prevent PPID in the horse. 
Introduction 
Pituitary pars intermedia dysfunction (PPID) is an endocrine disease prevalent among 
equids, in which 15-30% of the senior horse population is affected (≥20 years) (McFarlane, 
2011). This endocrine disease is caused by dopaminergic neurodegeneration of the 
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pituitary pars intermedia, leading to elevated levels of circulating adrenocorticotropin 
hormone (ACTH), α-melanocyte stimulating hormone (α-MSH), and other peptides 
cleaved from the prohormone pro-opiomelanocortin (POMC) (McFarlane, 2011). The 
elevated levels of these hormones and peptides are then thought to contribute to the clinical 
signs of PPID, although the exact mechanisms remain largely unclear (Hart et al., 2016). 
These clinical signs of PPID include: hypertrichosis, polydipsia, polyuria, hyperhidrosis, 
muscle atrophy, laminitis, abnormal fat distribution, immunosuppression and opportunistic 
infections, behavioral abnormalities, reproductive infertility, and neurologic impairment 
(McFarlane, 2011).  
Senior horses are also known to exhibit age-related immune changes including: 
inflamm-aging (increased low-grade inflammation systemically) and immunosenescence 
(decreased immune response) (Adams et al., 2008). Many of these age-related immune 
changes occur not only in circulation but also are specifically mediated by peripheral blood 
mononuclear cells (PBMC) (Adams et al., 2015; Adams et al., 2008). Given that senior 
horses are already immune-compromised, the concurrent presentation of the PPID in these 
senior horses may further decrease their ability to respond effectively to pathogens, leading 
to the immunosuppression and susceptibility to opportunistic infections characteristic of 
the PPID horse.  
Furthermore, given the high prevalence of this endocrine disease within the senior 
horse population, understanding how the disease affects immunity of the aged horse 
already experiencing inflamm-aging and immunosenescence, may improve management 
of these immune-compromised horses. According to McFarlane et al. (2015), PPID horses 
have exhibited decreased neutrophil function (McFarlane et al., 2015). However, effects of 
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PPID on PBMC function have not yet been determined. Thus, whether cell-mediated 
immunity differs between age-matched PPID and non-PPID horses was examined, 
particularly in relation to PBMC cytokine gene expression, lymphocyte inflammatory 
cytokine production, and lymphocyte proliferation. It was hypothesized that PPID affects 
cell-mediated immunity differentially from the process of aging alone. 
Methods and Materials 
2.1. Animals 
Six aged, PPID horses (mean age ± SEM = 24.7±0.9 years) and six aged, non-PPID 
horses (23.3±1.0 years) of mixed breeds and sex were used in this study. PPID status was 
determined by thyrotropin releasing hormone (TRH) stimulation testing, examining ACTH 
concentration in EDTA plasma 10 minutes post intravenous injection, with horses with 
ACTH levels above 110 pg/mL being considered PPID, as recommended by the Equine 
Endocrinology Group (Restifo et al., 2016). The ACTH analysis was performed by Cornell 
Animal Health Diagnostic Center, Endocrinology Laboratory using chemiluminescence 
immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et al., 2010). All PPID 
horses had ACTH responses to TRH stimulation of at least 500 pg/mL during non-fall 
testing as well as clinical signs of PPID, an indication these horses had more advanced 
stages of PPID. Mean ACTH levels ± SEM were 875.3±127.2 and 61.3±6.9 pg/mL for 
PPID and non-PPID horses, respectively. None of the horses in this study had received 
treatment for PPID during or within a year prior to sampling. Horses were maintained on 
pasture and mixed grass hay at the University of Kentucky, Department of Veterinary 
Science Maine Chance Farm. To maintain body weight, all non-PPID and three PPID 
horses regularly received a mixture of 50% oats, 50% alfalfa pellets, while the other three 
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PPID horses received only hay. Differences in diet were taken into consideration with 
statistical analysis below. All procedures were approved by the University of Kentucky 
Institute of Animal Care and Usage Committee. 
2.2. Sample Collection & Culture Preparation. 
All horses were screened using TRH testing in May in order to determine PPID 
status using the established ACTH reference range for non-fall months (Restifo et al., 
2016). Four months following endocrine testing, peripheral blood samples were collected 
from all horses to evaluate immune measures. Heparinized blood was collected aseptically 
by jugular venipuncture to isolate peripheral blood mononuclear cells using a Ficoll-Paque 
Plus™ (Amersham Biosciences, Piscataway, NJ) density gradient. A VICELLTM Counter-
XR (Beckman Coulter, Miami, FL) was used to enable plating of cells at a concentration 
of 4x106 and stimulating with phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) 
and ionomycin (1 μM; Sigma) for 4 hours, 37oC, 5% CO2, prior to intracellular staining 
and RNA isolation (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard 
et al., 2016).  
Cells used for proliferation analysis were fluorescently tagged with 
carboxyfluorescein succinimidyl ester (CFSE), plated at a concentration of 2x106/mL 
media, and stimulated with concanavalin A (2.5, 5, and 10 µL) for 96 hours, 37oC, 5%CO2, 
as previously described (Adams et al., 2008). The only exception was the use of fetal equine 
serum (Biowest, Nuaillé, France) instead of fetal bovine serum (FBS) to quench the CFSE 
reaction and for subsequent washes. 
PBMC were also frozen in liquid nitrogen in media containing FBS and dimethyl 
sulfoxide (DMSO) for later analysis, at which point they were thawed, washed, stimulated 
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with phytohemagglutinin (PHA; 50 µg/mL), and incubated for 72 hours, 37oC, 5%CO2 (the 
last 4 hr of which, Brefeldin A was added) prior to intracellular staining. The concentration 
of PHA used for stimulation was based on titrations performed prior to sample analysis. 
2.3. IFN-γ and TNF-α Intracellular Staining 
PMA-stimulated PBMC were fixed with 2% paraformaldehyde (Sigma), and 
incubated at 4oC overnight prior to intracellular staining. Cells were then treated with 
saponin buffer [PBS supplemented with 1% fetal bovine serum, 0.1% saponin (Sigma), 
and 0.1% sodium azide (Sigma)] and stained for IFN-γ and TNF-α using IFN-γ FITC 
mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg; 1:100 dilution) or TNF-
α anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay, 
University of Florida; 1:10 dilution) and secondary antibody FITC-conjugated goat F(ab’)2 
anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL; 1:1000 dilution) respectively, as previously 
described (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 
2016). PHA-stimulated PBMC were likewise intracellularly stained according to the same 
protocol for IFN-γ. 
2.4. Flow Cytometry 
For PMA-stimulated, intracellularly-stained PBMC, a Becton Dickenson 
FASCalibur Flow cytometer and Cell Quest® software were used to determine percent of 
lymphocytes producing each cytokine and to determine mean fluorescence intensity 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016).  
For PHA-stimulated, intracellularly-stained PBMC, a flow cytometer (Becton 
Dickenson) was also used to determine percent of lymphocytes producing IFN-γ and to 
determine IFN-γ MFI. 
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For lymphocyte proliferation, a flow cytometer (Becton Dickenson) and ModFit 
LT™ 3.0 were used to determine lymphocyte proliferation index, based on generational 
divisions (Adams et al., 2008). 
2.5. RNA Isolation, Reverse Transcription, and Real-Time Polymerase Chain Reaction  
Following the 4 hour stimulation with PMA/ionomycin, PBMC were resuspended 
in Trizol® solution and stored at -80oC until RNA isolation. RNA isolation was performed 
using a phenol-chloroform extraction (Breathnach et al., 2006). An Epoch microplate 
spectrophotometer (BioTek, Winooski, VT) was used to determine amounts of RNA in 
each sample, prior to RNA reverse transcription. To perform reverse transcription, a 
thermocycler (Applied Biosystems, Foster City, CA) and master mix reagents (16 μL avian 
myeloblastosis virus [AMV] buffer 5X, 16 μL MgCl2, 4 μL dNTP, 1 μL RNasin, 1 μL 
oligo dT primer, and 0.5 μL AMV reverse transciptase per sample; Promega, Madison, 
WI) were used, incubating samples at 42oC for 15 minutes and 95oC for 5 minutes (Adams 
et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Following reverse transcription, 
samples were stored at -20oC. Real-time polymerase chain reaction was then performed, 
implementing use of an epMotion 5070 (Eppendorf) to automatically aliquot cDNA 
samples and 5 equine specific intron-spanning primers and probes, in addition to using the 
7900HT Fast RT-PCR System (Applied Biosystems), which incubated samples for 10 min 
at 95oC, followed by 40 cycles of 95oC for 15s and 60oC for 1 min (Adams et al., 2008; 
Adams et al., 2009; Breathnach et al., 2006). The primers and probes analyzed included: 
IFN-γ, IL-2, IL-4, IL-6, and TNF-α, in addition to Beta-glucuronidase (β-GUS), the 
housekeeping gene (Applied Biosystems) (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). Following linear regression, the ΔΔCT method was used to 
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determine relative quantities for each cytokine (RQ = 2 –ΔΔCT)(Livak and Schmittgen, 
2001). The calibrator for each cytokine was the average ΔCT of all the unstimulated 
samples (one per horse).  
2.5. Statistical Analysis.  
Statistical analysis was performed using SigmaPlot version 12.3 (Systat Inc., 
Richmond, CA). T-tests comparing PPID and non-PPID horses were performed to 
determine any differences in inflammation due to PPID status. (PHA-stimulated 
inflammatory data only included n=5 PPID horses due to one horse having insufficient 
cells to stimulate with PHA as well as perform the other assays.) Proliferation data was 
analyzed using a two-way ANOVA with repeated measures to determine any differences 
between PPID and non-PPID horses at the three different concentrations of concanavalin 
A mitogen used to stimulate the PBMC. Bar graphs (mean +/- standard deviation) were 
used when comparing PPID and Non-PPID horses for the various parameters. T-tests were 
also used to evaluate differences between the n=3 PPID horses receiving feed and n=3 
PPID horses not receiving feed. (As there were no differences between fed and non-fed 
horses in various parameters, all data for PPID horses were grouped together for analysis 
when making comparisons with Non-PPID horses.) All data was normally distributed 
according to the Shapiro-Wilk normality test, with some data requiring log-transformation 
to achieve normality. Data with p<0.05 were considered statistically significant, while 
p<0.10 were considered trends.  
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Results 
3.1. Inflammatory Cytokine Intracellular Staining 
Various comparisons of immune measures mediated by PBMC were compared in 
PPID and age-matched non-PPID horses. After examining flow cytometry data for PPID 
and non-PPID horses, no significant differences were seen for either PMA or PHA-
stimulated lymphocytes in regard to the percent of lymphocytes producing inflammatory 
IFN-γ (Fig. 4.1A&C) and mean fluorescence intensity (Fig. 4.1B&D) (p>0.05). Likewise, 
flow cytometry data for PPID and non-PPID horses did not significantly differ for 
percentage of lymphocytes producing pro-inflammatory TNF-α or for TNF-α MFI (Fig. 
4.2A&B) (p>0.05). 
3.2. Lymphocyte Proliferation 
Lymphocyte proliferation also did not show significant differences between PPID 
and non-PPID horses (p=0.282); however, a difference in proliferation in relation to 
mitogen concentration was present (p<0.001), as expected, with the 2.5 µL concentration 
of Con A yielding significantly lower lymphocyte proliferation than the other two 
concentrations (Fig. 4.3).  
3.3. Real-Time Polymerase Chain Reaction Gene Expression 
PCR results also did not display differences between PPID and non-PPID horses 
(p>0.05); however, due to the variation associated with PCR data, it is possible that in a 
larger data set differences may occur (Fig. 4.4A-E). 
3.4. Feeding Status Analysis of PPID Horses 
Within the PPID horse group, n=3 horses received feed (50% alfalfa pellets, 50% 
oats) regularly while n=3 horses were fed hay alone, in order to maintain body weight. T-
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tests were run between fed horses and those that did not receive feed, and again, no 
significant differences were found. This may be in part due to the sample size; however, in 
order to sample a group of healthy horses with naturally occurring signs of PPID and TRH 
stimulation testing results to support advanced PPID status, sample size was limited. And, 
in order not to change their diets for the purposes of this study, which may elicit changes 
in immune parameters, horses were sampled while continuing maintenance diets. 
Discussion 
The PPID horse is known to experience immunosuppression and increased 
susceptibility to opportunistic infections as one of the clinical manifestations of this 
endocrinopathy. Despite the reported increases in bacterial infections, such as 
dermatophilosis, pneumonia, and abscesses found in PPID horses (McFarlane, 2011), few 
studies have been performed to determine the specific mediators for these deficiencies in 
immunity. Furthermore, senior horses (the demographic in which PPID primarily occurs) 
exhibit inflamm-aging and immunosenescence, which are specifically mediated by PBMC 
as well as occurring systemically (Adams et al., 2008). Thus, PBMC were examined as a 
potential source of immunosuppression in the PPID, aged horse.  
In this study, no differences were observed in any of the immune parameters 
analyzed in which PBMC were specifically examined regarding: intracellular staining, 
cytokine gene expression, and proliferation. Thus, the cell-mediated responses of adaptive 
immunity do not seem to be affected by PPID status of the horse. Although PPID has been 
associated with immunosuppression, it appears this compromise of immunity is not 
mediated by PBMC. Some work has shown total leukocyte cytokine dysregulation in PPID 
horses (McFarlane and Holbrook, 2008) as well as evidence that neutrophils contribute to 
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the effects of PPID on immune function of the aged horse (McFarlane et al., 2015). 
Specifically, neutrophils from aged, PPID horses have exhibited decreased oxidative burst 
activity and decreased adhesion, which may contribute to immunosuppression (McFarlane 
et al., 2015).  
Of note, PMA-stimulated neutrophils from PPID and control horses did not 
significantly differ in the McFarlane et al, 2015 study, although neutrophils that were 
unstimulated or stimulated submaximally exhibited significantly decreased adhesion in 
PPID horses compared to non-PPID horses (McFarlane et al., 2015). In the current study, 
using an optimal dose of PHA to stimulate PBMC also does not identify significant 
differences between PPID and non-PPID horses in flow cytometry measures of either 
percentage of lymphocytes producing IFN-γ or IFN-γ MFI. Additionally, the proliferation 
assay was performed using concanavalin A at various concentrations, and likewise no 
significant differences were found between PPID and non-PPID horses regarding 
lymphocyte proliferation. Therefore, the lack of significant differences between PPID and 
non-PPID horses in relation to lymphocyte function is likely not a matter of the type of 
mitogen.  
Some of the peptides produced by cleavage of POMC have established 
immunomodulatory effects, which may help compose a neuro-endocrine-immune axis 
(Bohm and Luger, 2004; Brazzini et al., 2003). Alpha-MSH particularly has long been 
established as a potent anti-inflammatory, anti-oxidant agent (Bhardwaj et al., 1996; 
Catania et al., 1999; Luger and Brzoska, 2007; Oktar et al., 2004). Mechanistically, α-MSH 
downregulates nuclear factor (NF)-κβ activity stimulated by lipopolysaccharide (LPS) 
(Luger et al., 2000). Furthermore, this hormone has specifically exhibited anti-
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inflammatory effects on PBMC in humans through increasing IL-10 gene expression and 
protein production; however monocytes, not T lymphocytes, were responsible for the anti-
inflammatory response elicited by the addition of α-MSH (Bhardwaj et al., 1996). Since 
only the PCR data in the current study included monocytes as well as lymphocytes, this 
may in part explain the lack of differences between PPID and non-PPID horses. In regards 
to PCR data, as mentioned previously, no significant differences were found for PPID vs. 
non-PPID; however, due to the variability of PCR data, some differences may become 
significant if the sample size were increased. Studies examining monocytes in the PPID 
horse specifically have not yet been performed to determine whether the increased levels 
of α-MSH in the PPID horse may yield monocyte-mediated anti-inflammatory effects 
similar to studies examining human monocytes (Bhardwaj et al., 1996; Catania et al., 1999; 
Yang et al., 2015). In addition to direct anti-inflammatory effects of α-MSH alone, 
McFarlane et al. (2015) found that in horses the ratio of insulin to α-MSH was positively 
correlated with oxidative burst activity (McFarlane et al., 2015), indicating that a 
relationship of relative hormone amounts may influence immunity of the PPID horse. 
ACTH, the other key hormone cleaved from POMC, has been positively associated with 
IL-6 expression in septic foals (Gold et al., 2012); however the relationship between ACTH 
and inflammation has not been clearly established. Additionally, much of the circulating 
ACTH is thought to be biologically inactive due to the fact that PPID horses do not appear 
to exhibit elevated cortisol levels despite their increased levels of ACTH (McFarlane et al., 
2015).  
Still, more research is needed regarding the pathogenesis of PPID and its effects on 
the immune system, particularly how this endocrinopathy is associated with 
96 
immunosuppression and susceptibility to opportunistic infections in the aged horse. 
Furthermore, it is not yet understood what causes the dopaminergic neurodegeneration of 
the pituitary pars intermedia. A variety of factors including oxidative stress, infectious 
disease, nutritional deficiencies, or even inflammation may play a role in the development 
of this endocrine dysfunction, but clearly more research is warranted. 
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Figure 4.1. Lymphocyte production of IFN-γ in vitro for PPID vs. Non-PPID horses. 
Percentage of PMA-stimulated lymphocytes (A) producing IFN-γ and (B) mean 
fluorescence intensity of IFN-γ for n=6 PPID and n=6 age-matched non-PPID horses. 
Percentage of PHA-stimulated lymphocytes (C) producing IFN-γ and (D) mean 
fluorescence intensity of IFN-γ for n=5 PPID and n=6 age-matched non-PPID horse. 
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Figure 4.2. Lymphocyte production of TNF-α in vitro for PPID vs. Non-PPID horses. 
Percentage of lymphocytes (A) producing TNF-α and (B) mean fluorescence intensity of 
TNF-α for n=6 PPID and n=6 age-matched non-PPID horses. 
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Figure 4.3. Lymphocyte proliferation index of PPID vs. Non-PPID horses. Peripheral 
blood mononuclear cells (PBMC) from n=6 PPID and n=6 age-matched Non-PPID horses 
were stained with CFSE and stimulated with various concentrations (2.5, 5, 10 µl/mL) of 
concanavalin A mitogen for 96 hours to determine proliferation. A two-way ANOVA with 
repeated measures was performed. PPPID refers to the p-value for the difference between 
PPID and non-PPID horses; Ptrt refers to the p-value for the differences between 
concanavlin A mitogen concentrations for stimulation of PBMC.  
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Figure 4.4. PBMC-mediated 
cytokine gene expression of PPID vs. 
Non-PPID horses. RT-PCR was 
performed on PMA/ionomycin-
stimulated PBMC from n=6 PPID 
and n=6 Non-PPID horses to 
determine gene expression of (A) 
IFN-γ, (B) IL-2, (C) IL-4, (D) IL-6, 
and (E) TNF-α (logged).  
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CHAPTER 5 
EFFECTS OF POLYPHENOLS INCLUDING CURCUMINOIDS, 
RESVERATROL, QUERCETIN, PTEROSTILBENE, AND 
HYDROXYPTEROSTILBENE ON LYMPHOCYTE PRO-INFLAMMATORY 
CYTOKINE PRODUCTION OF SENIOR HORSES IN VITRO 
Veterinary Immunology and Immunopathology, 2016: 173, 50-59 
Abstract 
Senior horses (aged ≥20 years) exhibit increased chronic, low-grade inflammation 
systemically, termed inflamm-aging. Inflammation is associated with many afflictions 
common to the horse, including laminitis and osteoarthritis, which are commonly treated 
with the non-steroidal anti-inflammatory drugs (NSAIDs) flunixin meglumine and 
phenylbutazone. Although these NSAIDs are effective in treating acute inflammatory 
problems, long-term treatment with NSAIDs can result in negative side effects. Thus, 
bioactive polyphenols including curcuminoids, resveratrol, quercetin, pterostilbene, and 
hydroxypterostilbene were investigated to determine their effectiveness as anti-
inflammatory agents in vitro. Heparinized blood was collected via jugular venipuncture 
from senior horses (n=6; mean age=26 ± 2 years), and peripheral blood mononuclear cells 
(PBMC) were isolated using a Ficoll density gradient. PBMC were then incubated 22 hours 
at 37oC, 5% CO2 with multiple concentrations (320, 160, 80, 40, 20, 10 µM) of all five 
polyphenols (curcuminoids, resveratrol, quercetin, pterostilbene, and 
hydroxypterostilbene), dissolved in DMSO to achieve the aforementioned concentrations. 
PBMC were stimulated the last 4 hours of the incubation period with phorbol 12-myristate 
13-acetate (PMA)/ionomycin and Brefeldin A (BFA). A Vicell-XR counter evaluated cell 
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viability following incubation. PBMC were stained intracellularly for interferon gamma 
(IFN-γ) and tumor necrosis factor alpha (TNF-α) and analyzed via flow cytometry. Data 
was analyzed by one-way analysis of variance (ANOVA). Viability of PBMC incubated 
with various compound concentrations were compared with PBMC incubated with DMSO 
alone (positive control) to determine at what concentration each compound caused 
cytotoxicity. The highest concentration at which cell viability did not significantly differ 
from the positive control was: 20 µM for curcuminoids, 40 µM for hydroxypterostilbene, 
80 µM for pterostilbene, and 160 µM for quercetin and resveratrol. Flunixin meglumine 
and phenylbutazone were then evaluated within this range of optimal concentrations for 
the polyphenol compounds (160, 80, 40, 20 µM) to compare the polyphenols to NSAIDs 
at equivalent concentrations. The highest concentration at which viability did not 
significantly differ from the positive control was: 40 µM for flunixin meglumine and 160 
µM for phenylbutazone. All five polyphenols and flunixin meglumine significantly 
decreased lymphocyte production of IFN-γ, while only hydroxypterostilbene, 
pterostilbene, quercetin, and resveratrol significantly reduced lymphocyte production of 
TNF-α compared to the positive control (p<0.05). Polyphenols performed similarly to or 
more effectively than common NSAIDs in reducing lymphocyte production of 
inflammatory cytokines of the senior horse in vitro. This study therefore supports the 
further investigation of polyphenols to determine whether they may be effective anti-
inflammatory treatments for chronic inflammation in the horse.    
Introduction 
The senior horse population is growing globally, with horses 20 years or older 
comprising an estimated 7.6% of the population in the United States (USDA., 2006) and 
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horses ≥15 years old comprising 29% of the population in the United Kingdom (Ireland et 
al., 2011a). In addition to increasing lifespan, healthspan must be taken into account. With 
increased age, an increase in inflammation at both the gene expression [interleukin (IL)-
1β, IL-15, IL-18 and TNF-α] and protein levels [tumor necrosis factor-alpha (TNF-α)] has 
been characterized in the horse (Adams et al., 2008; Katepalli et al., 2008). This increased 
inflammation with aging indicates that horses, like many other species, exhibit inflamm-
aging or low-grade, chronic inflammation that occurs systemically with aging (Franceschi 
et al., 2007). Although clearly established clinical conditions of the horse associated with 
inflamm-aging have not yet been discovered, human studies have shown that inflammation 
is characterized as a risk factor for developing various diseases and is associated with 
increased morbidity and mortality (Freund et al., 2010). Inflamm-aging in the horse 
therefore likely has detrimental effects.  
In addition to systemic inflamm-aging, many horses develop various chronic 
inflammatory conditions over the course of their lives, ranging from laminitis to 
osteoarthritis. These conditions are frequently treated with common non-steroidal anti-
inflammatory drugs (NSAIDs), such as flunixin meglumine and phenylbutazone. NSAIDs 
are quite useful for treating acute inflammatory conditions; however, long-term use can 
result in various harmful side effects, such as stomach ulcers, gastric oxidative stress, 
hypoalbuminemia, neutropenia, liver damage, and kidney damage (Bessone, 2010; 
Ingrasciotta et al., 2015; Martinez Aranzales et al., 2015; McConnico et al., 2008; Monreal 
et al., 2004; Reed et al., 2006). Thus, various anti-inflammatory polyphenols including 
curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene were 
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investigated to determine their effects on inflammation of the senior horse in vitro as an 
alternative to the use of NSAIDs in treating chronic inflammation. 
Polyphenol compounds have been shown to exhibit anti-inflammatory properties 
in various capacities both in vitro and in vivo, including decreasing peripheral blood 
mononuclear cell (PBMC) inflammatory gene expression, as reviewed by Afman et al. 
(Afman et al., 2014). Furthermore, the polyphenolic compound curcumin has decreased 
PBMC production of pro-inflammatory IL-8 (Literat et al., 2001). Curcumin has 
traditionally been used in Asia since ancient times to treat various maladies including many 
inflammatory conditions (Jeenger et al., 2015); moreover, this polyphenol has recently 
gained popularity in research and the health market, for its various anti-inflammatory, 
antioxidant, anti-tumorigenic properties (Franck et al., 2008; Schaaf et al., 2009; 
Venkatesan and Chandrakasan, 1995). Curcumin is derived from the root of Curcuma 
longa, and comprises 77% of the curcuminoids found in turmeric, making curcumin the 
primary curcuminoid (Kumar et al., 2010). Resveratrol is a phytoalexin found most notably 
in red wine, which has shown anti-inflammatory activities both dependent and 
independently of NF-κB activation (a key transcription factor in pro-inflammatory 
cytokine expression) (Birrell et al., 2005; Kumar and Sharma, 2010; Samsami-Kor et al., 
2015). Moreover, resveratrol supplementation has decreased NF-kB activity in PBMC as 
well as decreasing pro-inflammatory high sensitivity C-reactive protein (hs-CRP) and 
TNF-α in plasma (Samsami-Kor et al., 2015). Resveratrol has been found specifically to 
act as an antioxidant in equine neutrophils in vitro, as well (Kohnen et al., 2007). Quercetin 
is an antioxidant flavonoid found in various plants including teas and onions and has been 
shown to decrease inflammation in high-fat diet mice (Das et al., 2013) and high-fructose 
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diet rats (Vazquez Prieto et al., 2015). Pterostilbene, an analog of resveratrol and the 
primary antioxidant component of blueberries, has demonstrated anti-inflammatory 
properties, decreasing inflammation produced by adipocytes as well as decreasing 
inflammation produced as a result of myocardial ischemia and reperfusion (Hsu et al., 
2013; Lv et al., 2015; Wang et al., 2015). Hydroxypterostilbene, an analog of pterostilbene 
found in the plant Sphaerophysa salsula, has recently been shown to decrease the pro-
inflammatory enzyme COX-2 and to downregulate multiple pro-inflammatory pathways 
including PI3K/Akt and MAPK signaling (Cheng et al., 2014). These various polyphenol 
compounds possessing anti-inflammatory properties are of interest as alternative anti-
inflammatory therapies to the traditional long-term use of NSAIDs in treating chronic 
inflammatory conditions.  
Thus, we hypothesize that polyphenols including curcuminoids, resveratrol, 
quercetin, pterostilbene, and hydroxypterostilbene will significantly reduce inflammation 
of the senior horse in vitro, similarly to common NSAIDs phenylbutazone and flunixin 
meglumine. PBMC will particularly be examined for the following reasons: PBMC have 
been shown to contribute to chronic, low-grade inflammation (Adams et al., 2008); are 
easily accessible (Literat et al., 2001); and previous research has demonstrated the effects 
of polyphenols on PBMC (Afman et al., 2014; Literat et al., 2001; Samsami-Kor et al., 
2015). This study is the first step in determining the ability of polyphenols to decrease 
inflammation in the horse in vivo.  
Thus far, clearly established clinical conditions of the horse associated with 
inflamm-aging have not been discovered. Based on human studies, however, it is 
anticipated that decreasing inflamm-aging may be beneficial to healthspan and lifespan. 
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Furthermore, the horse exhibiting inflamm-aging was used as a model to determine 
whether polyphenols could decrease chronic inflammation of the horse. NSAIDs were used 
as a comparison to polyphenols in determining how various anti-inflammatory treatments 
(including both nutraceuticals and pharmaceuticals) affected circulating inflammatory 
cytokine production by PBMCs in the horse. The use of polyphenols could then potentially 
have further implications for the management of chronic inflammatory conditions, such as 
osteoarthritis and recurrent laminitis in the horse. 
Methods and Materials 
2.1. Animals 
Six senior horses (mean age = 26 ± 2 years) were used in this study, exhibiting no 
clinical abnormalities (eg nasal discharge, cough) upon physical assessment. When 
examining basal adrenocorticotropin hormone (ACTH), three of the horses were pituitary 
pars intermedia dysfunction (PPID) negative [with plasma levels within normal range (9-
35 pg/mL) as measured by Cornell Animal Health Diagnostic Center, Endocrinology 
Laboratory], and three were PPID positive (plasma levels >35 pg/mL) (Place et al., 2010); 
however, no significant differences in inflammatory parameters were found between PPID 
and non-PPID horses.  
2.2. Sample Collection, PBMC Isolation, and Culture Preparation 
Heparinized blood was collected via jugular venipuncture from n=6 senior horses, 
and PBMCs were isolated using a Ficoll-Paque Plus™ (Amersham Biosciences, 
Piscataway, NJ) density gradient and purified with sterile Phosphate Buffered Saline (PBS) 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). A VICELLTM Counter-
XR (Beckman Coulter, Miami, FL) counted cells and determined cell viability using 
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Trypan blue staining prior to plating. PBMCs were plated at a concentration of 4x106 
cells/mL with cRPMI media [RPMI 1640 (Gibco, Grand Island, NY) supplemented with 
2.5% fetal equine serum (FES; Sigma-Aldrich, St. Louis, MO), 55 μM 2-mercaptoethanol 
(Gibco), and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL streptomycin (HyClone 
Pen/Strep/Glutamine solution; Thermo Scientific)] (Adams et al., 2008; Adams et al., 
2009; Breathnach et al., 2006). 
2.3. Compound Preparation  
The day prior to peripheral blood collection, stock solutions (0.16 M) of 
polyphenolic compounds [curcuminoids (Natsol Laboratories Pvt. Ltd., Hyderabad, India), 
resveratrol (Biological Prospects® LLC, Lexington, KY), pterostilbene (Biological 
Prospects® LLC), 3-hydroxypterostilbene (Natsol Laboratories), and quercetin (Natsol 
Laboratories)] and NSAIDs [flunixin meglumine (Phoenix Pharmaceuticals, Inc., St. 
Joseph, MO; 50 mg/mL injectable solution) and phenylbutazone paste (Phoenix 
Pharmaceutical, Inc.; 0.33 g/mL)] were prepared in dimethyl sulfoxide (DMSO; Sigma-
Aldrich). The stock solution for each of the polyphenols and NSAIDS were diluted with 
DMSO to make a total of 6 working solutions (such that an addition of 2 μL/mL media 
would yield final concentrations of 320, 160, 80, 40, 20, and 10 μM) for each of the 
polyphenolic compounds and NSAIDs (Qureshi et al., 2012). The working solutions were 
then frozen at -20oC overnight until use the following day.    
The compound concentrations were determined based on previous work (Quereschi 
et al 2013) in which resveratrol, pterostilbene, and quercetin at concentrations ranging 320-
10 µM were shown to significantly inhibit macrophage inflammatory cytokine production. 
In vivo these optimal concentrations ranging from 20-160 µM would equate to 76.7-614.0 
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µM concentration in plasma, (given that the 20-160 µM was for 4x106 PBMC/mL, old 
horses tend to have ~2.5x107 PBMC per 15 mL blood, and previous work showing that 
horses have 6.33 L plasma/100 kg BW and 10.31 L blood total/100 kg BW (Marcilese et 
al., 1964)). 
2.4. Cell Viability after Incubation with Compounds 
After plating the PBMCs with c-RPMI, DMSO (2 μL/mL media) was added to two 
wells per horse to act as controls, while the polyphenol and NSAID stock solutions (2 
μL/mL media) were each added to a well to achieve final concentrations of 320, 160, 80, 
40, 20, and 10 μM for each compound. PBMCs were incubated with the compounds 22 
hours at 37oC, 5% CO2. At 18 hours, Brefeldin A (10 μg/mL; Sigma) was added to all 
wells, and all wells except one of the DMSO controls per horse  were stimulated with 
phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma) 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Cell counts and viability 
for each well were then determined using the Vicell Counter-XR to determine whether 
cells treated with the various compounds differed from those treated with DMSO and PMA 
(positive control). The highest compound concentration at which viability did not differ 
from the positive control was determined to be the optimal concentration. 
2.5. IFN-γ and TNF-α Intracellular Staining and Flow Cytometry  
Following incubation, aliquots (200 μL each) of cells from each well were placed 
into duplicate 96-well V-bottom plates. Both plates were centrifuged, resuspended in 2% 
paraformaldehyde (Sigma), and stored at 4oC overnight. Cells were then washed in saponin 
buffer [PBS supplemented with 1% fetal bovine serum (FBS), 0.1% saponin, and 0.1% 
sodium azide (Sigma)] and IFN-γ FITC mouse anti-bovine antibody (AbD Serotec, 
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Raleigh, NC; 0.1 mg) was added at a 1:100 dilution in saponin buffer to one plate, while 
TNF-α anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay, 
University of Florida) at a 1:10 dilution in saponin buffer was added to the other plate 
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Both plates were 
incubated 30 minutes on ice and washed in saponin buffer. The cells in the IFN-γ –stained 
plate were then resuspended in FACS Flow (Becton Dickinson, San Jose, CA), while those 
in the TNF-α plate were stained with secondary antibody FITC-conjugated goat F(ab’)2 
anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL) at a 1:1000 dilution in saponin buffer and 
incubated an additional 30 minutes on ice (Adams et al., 2008; Adams et al., 2009; 
Breathnach et al., 2006). Following incubation, the plate was washed in saponin buffer and 
resuspended in FACS Flow. Both plates were transferred to 5-mL round-bottom tubes for 
flow cytometric analysis. Using a FACS Calibur flow cytometer (Becton Dickinson) and 
Cell Quest® software (Becton Dickinson), samples were analyzed, and lymphocyte 
populations were gated on cell size and granularity to determine percent IFN-γ- and percent 
TNF-α-positive lymphocytes as well as mean fluorescence intensities (MFI) of 
lymphocytes (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). 
 2.6. Statistical Analysis.  
SigmaPlot version 10.0 and SigmaStat version 3.5 (Systat Inc., Richmond, CA) 
were used for data analysis. Data not normally distributed was log-transformed first in an 
effort to achieve a normal distribution; however, if normality still could not be achieved, 
data was analyzed on ranks. Normally distributed data was shown using bar graphs (mean 
+/- standard deviation), while data not achieving normal distribution was shown with box 
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plots (median, 25th, and 75th percentile).  For all analyses performed, data with p<0.05 was 
considered statistically significant. 
One-way analysis of variance (ANOVA) tests were performed to determine cell 
viability using the Holm-Sidak method for normally distributed data, while Kruskal-Wallis 
one-way ANOVA on ranks using the Tukey test was implemented for data not normally 
distributed. Two-way ANOVA tests using the Holm-Sidak method was employed to 
analyze inflammatory cytokine data at the various concentrations for each compound.  
For comparisons of the optimal concentrations of each polyphenol and NSAID to 
each other, one-way ANOVAs with Holm-Sidak method were used to measure the viability 
and the various inflammatory cytokine parameters for normally distributed data, while 
Kruskal-Wallis one-way ANOVAs on ranks using Dunn’s method were implemented for 
data not normally distributed.  
Results 
3.1. Cell viability for polyphenols at varying concentrations 
Polyphenolic compounds curcuminoids, hydroxypterostilbene, pterostilbene, 
quercetin, and resveratrol exhibit anti-inflammatory properties but can also be cytotoxic at 
high concentrations, thus Vicell counting was performed to determine cell viability after 
the incubation with compounds and stimulation with PMA and ionomycin. Results show 
that with increased compound concentrations, cell viability decreased for all compounds, 
as expected (Fig. 5.1). Each of the concentrations of compound for all six horses were 
compared to the positive control DMSO PMA in an effort to determine the highest non-
cytotoxic concentration for each compound, designated the optimal concentration. Results 
show that the highest non-cytotoxic concentrations for each of the compounds were the 
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following: (A) curcuminoids 20 µΜ, (B) hydroxypterostilbene 40 µΜ, (C) pterostilbene 
80 µΜ, (D) quercetin 160 µΜ, and (E) resveratrol 160 µΜ (Fig. 5.1).  
3.2. Intracellular staining and flow cytometry for polyphenols at varying concentrations  
The effect of polyphenols (at concentrations ranging from 320 to 10 µM in two-
fold dilutions) on percentages of lymphocytes producing IFN-γ and TNF-α when 
stimulated with PMA and ionomycin were examined. No significant interactions were 
observed between % IFN-γ and % TNF-α for any of the polyphenols except curcuminoids, 
thus the asterisks in Figure 5.2B-E are grouped over the bars for % IFN-γ and % TNF-α 
for each concentration, as there was an overall comparison of inflammatory cytokines for 
each of the compound concentrations to the positive control (DMSO/PMA). Results 
indicate that a concentration-dependent effect was present, with higher concentrations of 
compounds yielding decreased pro-inflammatory cytokine production, (some of which is 
due to the decreased cell viability with increasing concentration exhibited in Figure 5.1). 
Significant differences (p<0.05) relative to the positive control for inflammatory cytokines 
IFN-γ and TNF-α were found for (A) curcuminoids at all concentrations but 10 µΜ; (B) 
hydroxypterostilbene at all concentrations but 10 µΜ; (C) pterostilbene at 320, 160, 80 
µΜ; (D) quercetin at 160 µΜ; and (E) resveratrol at 320, 160 µΜ (Fig. 5.2). Data for 
curcuminoids (Fig. 5.2A) and hydroxypterostilbene (Fig. 5.2B) were log-transformed to 
achieve equal variance and normal distribution, respectively; however, for comparison to 
the other compounds, these data are represented graphically without log-transformation.  
3.3. Cell viability and intracellular staining for NSAIDs 
Since NSAIDs are often used to treat inflammation, the polyphenol compounds 
were also compared with the NSAIDs flunixin meglumine and phenylbutazone commonly 
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used in the horse. In the same manner as previously described, cell viabilities were 
determined and intracellular staining and flow cytometry for IFN-γ and TNF-α production 
by lymphocytes was quantified. Parameters for NSAIDs were only measured at 
concentrations ranging from 20 to 160 µΜ in two-fold dilutions, since the optimal 
concentrations for the various polyphenols had fallen within this range. Results are shown 
for n=5 horses, as one horse was excluded as an outlier. Results for flunixin meglumine 
showed a significant difference (p<0.05) in cell viability at 80 and 160 µΜ compared to 
the positive control (Fig. 5.3A), while phenylbutazone did not exhibit a difference in cell 
viability at any of the concentrations tested (Fig. 5.3C). For lymphocyte production of IFN-
γ and TNF-α, a significant difference (p<0.05) was exhibited for flunixin meglumine at 40, 
80, and 160 µΜ compared to the positive control (Fig. 5.3B), while phenylbutazone did 
not have any significant differences for the concentrations tested (Fig. 5.3D). Again, no 
significant interactions were observed between % IFN-γ and % TNF-α for either of the 
NSAIDs, thus the asterisks in Figure 5.3B are grouped over the bars for % IFN-γ and % 
TNF-α for each concentration, as there was an overall comparison of inflammatory 
cytokines for each of the compound concentrations to the positive control (DMSO/PMA).  
3.4. Intracellular staining for optimal concentrations 
Optimal concentrations, as determined by the highest concentrations of each 
compound at which cell viability did not significantly differ (p>0.05) from the positive 
control, were compared among the various compounds to highlight the effects of the 
compounds relative to each other. Optimal concentrations for each of the compounds and 
NSAIDs were:  phenylbutazone – 160 µΜ, flunixin meglumine – 40 µΜ, curcuminoids – 
20 µΜ, hydroxypterostilbene – 40 µΜ, pterostilbene – 80 µΜ, quercetin – 160 µΜ, and 
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resveratrol – 160 µΜ. All compounds except phenylbutazone significantly reduced 
(p<0.05) IFN-γ compared to the positive control, both by decreasing the percent of 
lymphocytes producing IFN-γ (Fig. 5.4A) and the amount of IFN-γ produced on average 
per cell [mean fluorescence intensity (MFI)] (Fig. 5.4B). The percent of lymphocytes 
producing TNF-α was reduced (p<0.05) for hydroxypterostilbene (40 µΜ), pterostilbene 
(80 µΜ), quercetin (160 µΜ), and resveratrol (160 µΜ) (Fig. 5.4C). TNF-α MFI was 
significantly decreased (p<0.05) for all compounds including both NSAIDs when 
compared to the positive control (Fig. 5.4D).  
For comparisons among the compounds for percent of lymphocytes producing IFN- 
γ (%IFN- γ), DMSO/PMA (the positive control) and phenylbutazone exhibited similar 
levels (p>0.05) (Fig. 5.4A). Phenylbutazone and flunixin meglumine did not differ 
statistically (p>0.05), although flunixin did decrease % IFN- γ significantly compared to 
the positive control (p<0.05) (Fig. 5.4A). Flunixin meglumine, curcuminoids, and 
quercetin performed similarly in reduction of % IFN- γ (Fig. 5.4A). Curcuminoids also 
performed statistically similarly to hydroxypterostilbene, pterostilbene, and resveratrol 
(p>0.05), which exhibited the greatest reductions in % IFN- γ (Fig. 5.4A). 
Among the compounds for IFN-γ MFI, the positive control DMSO/PMA and 
phenylbutazone produced similar amounts of IFN- γ on average per cell (p>0.05) (Fig. 
5.4B). Phenylbutazone also performed statistically similarly to flunixin meglumine, 
curcuminoids, hydroxypterostilbene, and quercetin (p>0.05) (Fig. 5.4B). The latter four 
compounds additionally exhibited similar reductions in IFN- γ MFI to pterostilbene and 
resveratrol, decreasing IFN- γ MFI most significantly (Fig. 5.4B). 
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For comparisons among the compounds for percent of lymphocytes producing 
TNF-α (% TNF-α), the positive control (DMSO/PMA), phenylbutazone, flunixin 
meglumine, and curcuminoids performed statistically similarly (p>0.05) (Fig. 5.4C). 
However, phenylbutazone, flunixin meglumine, curcuminoids, hydroxypterostilbene, 
pterostilbene, quercetin, and resveratrol also did not differ significantly (p>0.05) from each 
other for % TNF-α (Fig. 5.4C). 
Among the compounds for TNF-α MFI, all polyphenols and NSAIDs decreased 
TNF-α MFI compared to DMSO/PMA (p<0.05) (Fig 5.4D). Phenylbutazone, flunixin 
meglumine, and quercetin similarly decreased TNF-α MFI, while flunixin meglumine also 
exhibited similar levels of TNF-α MFI to curcuminoids and hydroxypterostilbene (Fig. 
5.4D). Curcuminoids, hydroxypterostilbene, pterostilbene, and resveratrol produced 
similar amounts of TNF-α on average per cell, decreasing TNF-α MFI most significantly 
compared to the positive control (p<0.05) (Fig. 5.4D). 
3.5. Viability of optimal concentrations  
Optimal concentrations were determined as the highest concentration within each 
compound titration at which the percent viability of PBMC did not differ (p>0.05) from 
the control, DMSO/PMA. However, since optimal concentrations were then selectively 
analyzed in comparison to the positive control for IFN-γ and TNF-α, PBMC viability for 
the chosen optimal concentrations was also evaluated to determine whether they still did 
not significantly differ from the positive control when collectively analyzed. 
Hydroxypterostilbene (40 µM) and pterostilbene (80 µM) significantly differed (p<0.05) 
in viability when compared to the positive control (Fig. 5.5). No other differences in 
viability between treatments were found. 
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Discussion 
Polyphenols and other nutraceuticals have recently gained popularity in many 
species including horses for garnering health benefits without many of the side effects 
associated with pharmaceuticals (Belcaro et al., 2010a; Horohov, 2012; Paller et al., 2015; 
Reed et al., 2006). Polyphenols including curcuminoids, hydroxypterostilbene, 
pterostilbene, quercetin, and resveratrol have demonstrated anti-inflammatory activity in 
previous studies. Although various in vitro and in vivo studies have been performed in other 
species demonstrating the anti-inflammatory effects of polyphenols (Luna et al., 2007; 
Qureshi et al., 2012; Vazquez Prieto et al., 2015; Venkatesan and Chandrakasan, 1995), 
little research has been performed in the horse despite the common occurrence of 
inflammatory-associated conditions (Goodrich and Nixon, 2006). Furthermore, senior 
horses, like elderly humans, exhibit inflamm-aging, and thus provide an excellent model 
of elevated inflammation in which to test the efficacy of anti-inflammatory compounds.  
In the present study, the effects of polyphenols on inflammatory cytokine 
production in vitro have been examined. Results indicate that lymphocyte production of 
pro-inflammatory cytokines decreased when treated with polyphenols compared to the 
positive control of cells stimulated with PMA/ionomycin and treated with DMSO. All 
optimal concentrations of compounds (highest concentration at which viability was not 
diminished within each compound titration curve when compared to the positive control) 
decreased lymphocyte production of inflammatory cytokines (p<0.05). This demonstrates 
that curcuminoids, hydroxypterostilbene, pterostilbene, quercetin, and resveratrol can 
significantly reduce inflammation in vitro without becoming toxic to PBMCs.  
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Other studies have found similar results, with resveratrol, pterostilbene, and 
quercetin decreasing TNF-α, IL-1β, IL-6, and iNOS expression as well as TNF-α secretion 
upon stimulation of macrophage cell line RAW264.7 with LPS (Qureshi et al., 2012). The 
same study found that resveratrol, pterostilbene, and quercetin decreased NF-κΒ activation 
of the human kidney line HEK293 cells, as well (Qureshi et al., 2012). This study exhibited 
similar findings to our results in that resveratrol and pterostilbene decreased inflammation 
similarly to or better than quercetin (Qureshi et al., 2012). Notably, in the present study, 
pterostilbene (80 µM) at half the concentration of resveratrol and quercetin (160 µM) still 
decreased inflammation significantly. Curcumin and resveratrol have been shown to 
decrease inflammation through modulating the NF-κΒ pathway at various stages 
(Buhrmann et al., 2011; Duarte et al., 2010; Samsami-Kor et al., 2015). Additionally, 
curcumin has exhibited more potent anti-inflammatory activity than resveratrol in equine 
neutrophils (Derochette et al., 2013), which supports our results in which curcuminoids (20 
µM) reduced inflammation similarly to resveratrol (160 µM). Although little research has 
been performed thus far on hydroxypterostilbene, it has been found to decrease production 
of pro-inflammatory COX-2, as well as downregulating upstream PI3K/Akt and MAPK, 
more effectively than its counterpart pterostilbene (Cheng et al., 2014). This aligned with 
our results, showing potent anti-inflammatory action of hydroxypterostilbene (40 µM), 
even at half the concentration of pterostilbene (80 µM). The variation observed in optimal 
compound concentrations suggests that compounds exhibiting anti-inflammatory effects at 
lower concentrations have greater bioactivity in vitro, such as curcuminoids and 
hydroxypterostilbene, while those exhibiting anti-inflammatory effects at higher 
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concentrations like quercetin and resveratrol may be less bioactive in reducing 
inflammation.  
 Furthermore, these polyphenols reduced inflammation at least as effectively as 
common NSAIDs flunixin meglumine and phenylbutazone. In fact, phenylbutazone did 
not significantly reduce lymphocyte production of IFN-γ or TNF-α at any of the 
concentrations tested, whereas all polyphenols did. Phenylbutazone did, however, reduce 
TNF-α MFI when compared to the positive control. Phenylbutazone may not have 
performed as well as expected due to the fact that phenylbutazone paste was suspended in 
DMSO before addition to PBMCs (since paste is the formulation most commonly used in 
the horse). Using an intravenous formulation of phenylbutazone, however, may have 
yielded significant decreases in inflammation on more parameters, since the effects of 
PBMC incubation with paste may exhibit masked effects when compared to a more pure 
form.  
Additionally, the mechanisms of action for these polyphenols suppress 
inflammation by inhibiting the gene expression of inflammatory cytokines and other 
proteins, while NSAIDs primarily work to treat the symptoms of inflammation, inhibiting 
the pro-inflammatory COX enzyme (Beretta et al., 2005). Polyphenols particularly 
modulate inflammation via NF-κΒ and MAPK signaling (Buhrmann et al., 2011; Busch et 
al., 2012; Comalada et al., 2005; Kumar and Sharma, 2010; Vazquez Prieto et al., 2015). 
Curcumin, quercetin, and resveratrol have also been shown to activate Sirtuin 1 (SIRT1), 
which is involved in deacetylation of histones and transcription factors. (Busch et al., 2012; 
Chung et al., 2010). One study compared phenylbutazone with curcumin and resveratrol, 
finding that both of the polyphenols decreased NF-kB activation at far smaller 
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concentrations than phenylbutazone, thereby suggesting the greater potency of polyphenols 
to modulate the source of inflammation when compared to phenylbutazone (Takada et al., 
2004). Another study compared flunixin meglumine and phenylbutazone, determining that 
while both NSAIDs inhibited COX-1, flunixin meglumine also decreased NF-kB 
activation to some degree, indicating that flunixin meglumine may function to decrease 
inflammation by a COX-independent pathway as well (Bryant et al., 2003). This may also 
explain why our study found flunixin meglumine to be the more effective NSAID. 
Nevertheless negative side effects, particularly gastrointestinal problems, have been 
associated with long-term NSAID use (Luna et al., 2007; Reed et al., 2006; Yoon and Baek, 
2005). Thus, polyphenol nutraceuticals may provide a more proactive approach to treating 
inflammation, without the various side effects, though more research is needed in this area, 
particularly in vivo.   
 Although these results suggest significant anti-inflammatory activity of the 
polyphenols examined in vitro, bioavailability and bioactivity of these compounds in the 
horse in vivo must also be taken into account. Little research has been performed thus far 
in this area, as the use of these naturally-occurring polyphenols as anti-inflammatory 
treatments in the horse is novel. From research in other species, oral bioavailability of the 
polyphenol compounds are as follows: curcuminoids – 0.47% (Gutierres et al., 2015), 
pterostilbene – 35-80% (Azzolini et al., 2014; Kapetanovic et al., 2011), quercetin – 17% 
(Ader et al., 2000), resveratrol – 20% (Kapetanovic et al., 2011), and hydroxypterostilbene 
– yet to be determined. For NSAIDs phenylbutazone and flunixin meglumine, the common 
routes of administration (and the formulations used in this study) were oral paste and i.v. 
injectable, respectively; the bioavailability of oral phenylbutazone in the horse is 
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approximately 70% (Tobin et al., 1986), while flunixin meglumine was assumed to be 
100%, as it is administered intravenously. Upon taking the bioavailability of these 
compounds into account, the extrapolated amount of the compounds needing to be 
administered orally based on our results would be the following: curcuminoids – 269.36, 
pterostilbene – 4.40-10.07, quercetin – 48.89, resveratrol – 31.37, flunixin meglumine (i.v.) 
– 3.38, and phenylbutazone – 12.11 mg/kg body weight.  These extrapolated 
concentrations, while shown to be anti-inflammatory in vitro, need to be examined in vivo 
to determine their anti-inflammatory effects in the horse.  
Furthermore, some of these amounts may appear formidable, however it is 
necessary to note that studies have been conducted in vivo with much smaller amounts 
yielding biologically beneficial effects. Curcumin administered orally (90 mg/kg) to 
diabetic rats has improved glucose tolerance and insulin sensitivity (Gutierres et al., 2015), 
and curcumin given at a low dose of 8 mg/kg in pigs has been shown to decrease transport 
stress in various biological markers (Wei et al., 2010). Pterostilbene (40 mg/kg) 
administered orally has yielded powerful antioxidant results in diabetic rats (Amarnath 
Satheesh and Pari, 2006), and our results suggest that the dose could potentially be lowered 
and still exhibit beneficial effects. Quercetin (20 mg/kg) given to rats has been shown to 
decrease adipose inflammation (Vazquez Prieto et al., 2015). Resveratrol administered at 
a dose of 20 mg/kg to diabetic rats decreased blood lipid and sugar levels (Balata et al., 
2016). Although hydroxypterostilbene has been researched little thus far, a study in mice 
found that hydroxypterostilbene (10 mg/kg, i.p.) exhibited anti-tumor properties including 
decreased levels of COX-2 (Cheng et al., 2014). Flunixin meglumine has exhibited 
analgesic properties at a dose of only 1.1 mg/kg i.v. (Foreman and Ruemmler, 2011). 
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Phenylbutazone at the clinical dose of 4.4 mg/kg has been shown to decrease lameness in 
the horse when administered i.v. (Foreman and Ruemmler, 2011) as well as decreasing 
clinical signs of osteoarthritis when administered orally (Doucet et al., 2008). Given the 
body of literature in other species regarding the biological effects of polyphenols in vivo, 
it is anticipated that doses lower than those anticipated by the results of this in vitro study 
may be effective biologically, and perhaps reduce chronic inflammation. Some of these 
effects may be mediated by polyphenol metabolites not taken into account when studies 
have examined bioavailability of these compounds previously. Furthermore, many of these 
polyphenols are known to have poor bioavailability, thus research is currently underway to 
formulate more bioavailable versions or targeting systems of many of these polyphenolic 
compounds (Balata et al., 2016; Belcaro et al., 2010a; Nahar et al., 2015; Swaminathan et 
al., 2016).   
In vivo research in the horse examining the anti-inflammatory effects of these 
polyphenols is clearly warranted. Future research should focus on determining the 
pharmacokinetics of these compounds in the horse. This will make possible the 
establishment of a recommended dose, which can then be examined for anti-inflammatory 
and antioxidant effects in vivo. Safety of the polyphenols should also be monitored in the 
horse when establishing dose, although long-term tolerability has already been reportedly 
high in other species for some polyphenols, such as curcumin and resveratrol (Belcaro et 
al., 2010a; Tome-Carneiro et al., 2012).   
 In conclusion, our research suggests the polyphenol compounds curcuminoids, 
resveratrol, quercetin, pterostilbene, and hydroxypterostilbene show potential as anti-
inflammatory therapies for chronic inflammation in the horse. More research is warranted 
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in vivo in the horse to determine the extent to which these compounds may be effective as 
alternatives to the use of NSAIDs when treating long-term inflammatory conditions. 
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Figure 5.3. Effect of compound concentration on cell viability and lymphocyte production of IFN-
γ and TNF-α for the common NSAIDs flunixin meglumine (FM) and phenylbutazone (Bute). 
Concentrations ranged from 20 – 160 µΜ in two-fold dilutions and were compared with DMSO 
PMA as a positive control. Bar graphs show mean +/- SD, while box plots show the median, 
25th, and 75th percentile. Bars denoted with an asterisk (*) signify a significant difference 
(p<0.05) in that concentration relative to DMSO/PMA, the positive control. Bars denoted with an 
asterisk  (  *  ) indicate no interaction between the cytokines, but an overall significant difference 
(p<0.05) of inflammatory cytokine production when comparing the FM to the positive control. 
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Figure 5.4. Comparison of the positive control of DMSO/PMA to optimal concentrations for each 
compound in examining inflammation. Optimal concentrations were determined as the highest 
concentration of each compound where viability was not significantly different from the positive 
control. Comparisons of the percentage of lymphocytes producing IFN-γ (A) and TNF-α (C) as 
well as the mean fluorescence intensity (MFI) for IFN-γ (B) and TNF-α (D) were compared for the 
optimal concentrations of each compound to the positive control. Bar graphs show mean +/- SD, 
while box plots show the median, 25th, and 75th percentile. Bars denoted with different letters 
significantly differ from each other (p<0.05), while those with the same letters do not differ 
statistically. Compounds are abbreviated [Phenylbutazone  (Bute), Flunixin meglumine (FM), 
Curcuminoids (Cur), Hydroxypterostilbene (Hyd), Pterostilbene (Pter), Quercetin (Quer), and 
Resveratrol (Res)] followed by the concentration (μM). 
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Figure 5.5. Effect of optimal compound concentrations on % viability of PBMC following 
incubation with PMA/ionomycin. Bars denoted with different letters are significantly different 
from each other (p<0.05), while those with the same letters do not statistically differ. Compounds 
are abbreviated [Phenylbutazone  (Bute), Flunixin meglumine (FM), Curcuminoids (Cur), 
Hydroxypterostilbene (Hyd), Pterostilbene (Pter), Quercetin (Quer), and Resveratrol (Res)] 
followed by the concentration (μM). 
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CHAPTER 6 
EFFECTIVENESS OF CURCUMIN IN MODULATING CHRONIC 
INFLAMMATION OF THE SENIOR HORSE 
Abstract 
Senior horses (≥20 years) exhibit inflamm-aging, or systemic, chronic, low-grade 
inflammation associated with aging, similarly to senior humans. In humans, inflamm-aging 
is associated with morbidity and mortality, with many diseases having underlying 
inflammatory components. In addition to inflamm-aging, many horses exhibit chronic 
inflammation, but treating these conditions with non-steroidal anti-inflammatory drugs 
(NSAIDs) long-term can have negative side effects. As a potential alternative to NSAIDs, 
an in vivo study was conducted to examine the effects of dietary polyphenolic compound 
curcumin, found in the root of Curcuma longa, on inflammation in horse, particularly the 
senior horse experiencing inflamm-aging,. Senior horses (n=30) were supplemented with 
either curcumin (5.6 mg/kg BW of Longvida® containing 20% optimized curcumin) or 
placebo (4.48 mg/kg BW of background components of Longvida® without curcumin) for 
90 days. The effects of curcumin were examined to determine peripheral blood 
mononuclear cell (PBMC)-mediated cytokine production & gene expression using flow 
cytometry & RT-PCR, respectively. Prostaglandin E2 (PGE2) production was determined 
using ELISA to examine the effects of curcumin on the inflammatory cyclooxygenase-2 
pathway. Endocrine function was examined as well, specifically basal insulin, basal 
adrenocorticotropin hormone (ACTH), and ACTH in response to thyrotropin releasing 
hormone stimulation (a test to determine whether horses exhibit pituitary pars intermedia 
dysfunction, a common endocrinopathy in older horses). Horses were clinically examined 
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pre and post study to examine body temperature, heart rate, respiratory rate, and overall 
health status. Horse body weight and body condition score was also monitored monthly 
throughout the study. Complete blood count & blood chemistry panels were run pre and 
post study to monitor health status, as well. Blood was also collected post study to 
determine curcumin and curcumin metabolite concentrations. No significant differences 
(p>0.05) were seen between treatment groups over the course of the study for any of the 
parameters measured. Curcumin and metabolites were only detected in quantifiable 
amounts for 2/15 horses supplemented with curcumin. In this study, horses supplemented 
with curcumin did not appear to experience anti-inflammatory effects in relation to the 
placebo group. These negative results may be due to any number of factors including low 
dosage and/or low bioavailability of curcumin. Further research is needed to determine if 
a higher dosage of curcumin can demonstrate bioactive effects in the horse, particularly in 
regards to decreasing chronic inflammation. 
Introduction 
Senior horses comprise a significant percentage of the equine population, with 
estimates ranging from 11.4 to 15% in the United States (≥20 years old) (Malinowski et 
al., 1997; USDA, 2016) and estimates as large as 29% in the United Kingdom (≥15 years) 
(Ireland et al., 2011a). However, like humans, senior horses tend to exhibit both inflamm-
aging (chronic, low-grade systemic inflammation systemically with aging) and 
immunosenescence (deterioration of the immune system with aging, particularly adaptive 
immunity), leading to a generally immune-compromised state (Adams et al., 2008; 
Franceschi et al., 2000; Franceschi et al., 2007). Inflamm-aging has been characterized in 
both gene expression and proteins in whole blood as well as specifically being mediated 
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by lymphocytes and monocytes (Adams et al., 2008; Adams et al., 2009). Thus far, clearly 
established clinical conditions of the horse associated with inflamm-aging have not been 
discovered. Based on human studies, however, inflamm-aging is associated with morbidity 
and mortality (Adriaensen et al., 2015; Franceschi and Campisi, 2014).  
 Common treatments for localized and chronic inflammation of the horse include 
non-steroidal anti-inflammatory drugs (NSAIDs), such as phenylbutazone and flunixin 
meglumine. These NSAIDs are a non-specific cyclooxygenase (COX) inhibitors, meaning 
that they inhibit both COX-1 and COX-2; this has specifically been shown in horses 
(Brideau et al., 2001; Duz et al., 2015). Inhibition of COX-1 is frequently associated with 
secondary problems, most notably gastric ulcers (Carvajal et al., 2004; Monreal et al., 
2004), since COX-1 protects the glandular lining of the stomach. Phenylbutazone 
specifically has created oxidative stress in the stomach mucosa of horses (Martinez 
Aranzales et al., 2014). Other adverse effects of NSAIDs may include liver and kidney 
damage, hypoalbuminemia, and neutropenia (Bessone, 2010; Ingrasciotta et al., 2015; 
McConnico et al., 2008; Reed et al., 2006).NSAIDs targeting COX-2 have been developed; 
however, even these NSAIDs are not intended for ongoing use. For example, firocoxib 
(Equioxx®, Merial), one of the most commonly used COX-specific NSAIDs in horses, has 
a maximum of 14 days of intended use and must be prescribed by a veterinarian, according 
to the manufacturer.  
Despite the benefits of using NSAIDs for treating acute inflammatory conditions, 
long-term use of NSAIDs in treating chronic conditions can have detrimental effects. Thus, 
the potential of anti-inflammatory phytonutrient curcumin to mitigate chronic 
inflammation of the senior horse was examined. 
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Curcumin has been used in traditional Asian medicine for treating various 
inflammatory diseases (Jeenger et al., 2014; Jurenka, 2009); however, recently curcumin 
has gained a scientific reputation as a potent anti-inflammatory, antioxidant, and anti-
tumorigenic compound (Franck et al., 2008; Schaaf et al., 2009; Venkatesan and 
Chandrakasan, 1995). This polyphenol comprises 0.3% to 5.4% of raw turmeric, the 
cooking spice which is derived from the rhizomes of Curcuma longa (Jeenger et al., 2015; 
Khan and Abourashed, Hoboken, New Jersey). In food-grade curcumin, the compound 
curcumin itself constitutes 77%, while other curcuminoids demethoxycurcumin (DMC) 
and bisdemethoxycurcumin (BDMC) only make up 17% and 6%, respectively (Kumar et 
al., 2010).  
The number of mechanisms by which curcumin is thought to act is vast (Di Pierro 
et al., 2013). However, many anti-inflammatory activities of curcumin are thought to be 
orchestrated through down-regulating the nuclear factor–kappa B (NF-κB) and COX 
pathways. For the NF-κB pathway: Curcumin has been found to decrease IκB kinase (IKK) 
activity, thereby decreasing IκBα phosphorylation, which in turn decreases NF-κB 
activation, thus decreasing its gene products, such as IκBα, interleukin(IL)-6, IL-12, tumor 
necrosis factor-alpha (TNF-α), and COX-2 (Bharti et al., 2003; Nanji et al., 2003). The 
COX pathway may actually be a specific cascade of the NF-κB pathway, as it has been 
suggested that NF-κB upregulates COX-2 expression (Kim et al., 2006). COX-2 catalyzes 
the conversion of arachidonic acid into pro-inflammatory prostaglandin E2 (PGE2) 
(Chizzolini and Brembilla, 2009; Park and Conteas, 2010). COX-1 is constitutively 
expressed, while COX-2 is inducible. Curcumin has been shown to selectively inhibit 
COX-2, without interfering with COX-1 (Goel et al., 2001).  
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The effectiveness of curcumin as an anti-inflammatory agent has been extensively 
exemplified in vitro. Since curcumin is a lipophilic molecule, it can easily penetrate the 
phospholipid bilayer of cells and may even be capable of mediating some of its actions 
through influencing lipid rafts of cell membranes (Derochette et al., 2013; Lin et al., 2014). 
Some studies have shown that curcumin decreases inflammation and oxidative stress when 
taken orally (Venkatesan and Chandrakasan, 1995). However, curcumin is rapidly 
metabolized into curcumin sulfate or curcumin glucuronide after oral administration 
(Kumar et al., 2010). Thus, it is often unable to reach immune cells while still in its 
bioactive state.  
Since this issue of bioavailability is a known hurdle, various studies have been 
conducted in an endeavor to generate more bioactive analogs of curcumin. Stabilizing 
curcumin by solid lipid curcumin particle (SLCP) ™ technology has met with success in 
the formulation of Longvida® optimized curcumin, which employs a lipophilic matrix to 
deliver curcumin into the bloodstream and target tissues (Gota et al., 2010). Longvida® 
has been shown to improve mood and working memory (Cox et al., 2015) and to decrease 
pathophysiology associated with Alzheimer’s disease (decreasing amyloid plaques, 
insoluble β-amyloid peptide, and soluble Tau dimers)(Begum et al., 2008; Ma et al., 2013), 
while decreasing inflammation [interleukin(IL)-1β, inducible nitric oxide synthase (iNOS), 
and upstream c-Jun N-terminal kinase (JNK)](Begum et al., 2008). In vitro studies have 
also shown that Longvida® decreases inflammation by decreasing nitric oxide, 
prostaglandin E2, and IL-6 via downregulating NF-κB activity(Nahar et al., 2014). 
Recently, oral supplementation with Longvida® has also demonstrated anti-inflammatory 
effects, decreasing the degree of systemic inflammation (IL-8, TNF-α) associated with 
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exercise-induced muscle damage (McFarlin et al., 2016). This body of evidence taken 
together asserts that solid lipid particle curcumin has great potential as an anti-
inflammatory treatment.   
In relation to the potential of curcumin use in the horse specifically, a few studies 
have been performed examining curcumin as an anti-inflammatory and antioxidant. Most 
studies have primarily focused on its in vitro effects, which have yielded favorable results, 
suggesting the use of curcumin for its anti-inflammatory and anti-oxidant properties 
(Derochette et al., 2013; Franck et al., 2006; Franck et al., 2008). Our lab has found 
curcumin to have potent anti-inflammatory effects in vitro specifically in the senior horse 
(Siard et al., 2016). One small scale study in vivo has been performed in the horse with 
some beneficial effects, showing decreased IL-1β and IL-1RN expression and apparent, 
though not statistically significant, reductions in COX-2, TNF-α, and IL-6 expression in 
osteoarthritic mares (Farinacci et al., 2009a). However, numerous limitations were present, 
including a short study duration of only fifteen days, small sample size (n=7), and no 
placebo group to serve as a control (Farinacci et al., 2009a). Moreover, no studies have 
been conducted in the senior horse. 
Thus, we performed the first large-scale study to determine the effectiveness of 
curcumin in the senior horse in vivo, comparing its anti-inflammatory action to a control 
placebo group. It was hypothesized that treatment with curcumin would decrease 
inflammation at both the gene expression and protein levels in senior horses. Specifically, 
this study was performed to determine the effects of curcumin supplementation on PBMC-
mediated inflammatory cytokine expression and production, COX-1 and COX-2 gene 
expression, and PGE2 production in senior horses. It is anticipated that decreasing 
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inflamm-aging may be beneficial to healthspan and lifespan. Furthermore, the horse 
exhibiting inflamm-aging was used as a model to determine whether polyphenols could 
decrease chronic inflammation. 
Methods and Materials 
2.1. Animals and Supplementation. 
Thirty senior horses (mean age = 26.2±3.2 years) of mixed breeds and both sexes 
were fed a mixture of 50% alfalfa pellets and 50% oats twice per day (at 0830 and 1400 
hours) at maintenance. The horses were housed on pasture (with mixed grass hay 
supplemented during early spring) at the University of Kentucky, Department of 
Veterinary Science, Woodford Farm. The study was conducted from late March to late 
June 2016. 
Treatment groups were determined by blocking horses based on body condition 
score (BCS), age, inflammatory status as determined by percent of lymphocytes producing 
IFN-γ (see Sections 2.3 & 2.4), and pituitary function using a thyrotropin releasing 
hormone (TRH) test (see 2.7). BCS was determined using the Henneke scale of 1-9 
(Henneke et al., 1983).  
The horses daily received 5.6 mg/kg BW of Longvida® supplement (containing 
20% of optimized curcumin; Verdure Sciences, Noblesville, IN) (n=15) (Farinacci et al., 
2009a) or 4.48 mg/kg BW of background placebo (n=15) for 90 days. This dose of 
Longvida® curcumin was chosen by extrapolating from human Longvida® studies with 
biological effects (Cox et al., 2015; McFarlin et al., 2016). Longvida® and placebo were 
provided by Verdure Sciences. Longvida® and placebo supplements were suspended in 
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soybean oil (approximately 25 mL) and administered orally by syringe once per day with 
the morning meal.  
A veterinarian who was blinded in regard to treatment groups examined the horses 
prior to and post study to determine heart rate, respiratory rate, rectal temperature, and 
overall health status. All procedures were in accordance with the University of Kentucky’s 
Institute of Animal Care and Usage Committee. 
2.2. Sample Collection. 
Heparinized blood was collected from horses for PBMC isolation prior to receiving 
any treatments (Day 0) and on Days 15, 30, 60, and 90 after receiving treatment. Serum 
also collected pre and post study prior to feeding and treatment to determine basal insulin 
concentrations. TRH stimulation testing was performed pre and post study, with EDTA 
plasma collected pre and 10 minutes post TRH injection to determine ACTH 
concentrations. Blood was also collected into citrate tubes post study to determine 
curcumin and curcumin metabolite concentrations. All blood sampling (except serum for 
basal insulin, as noted) occurred approximately 1.5 hours after being fed (similar to a 
previous study in the horse (Farinacci et al., 2009a)). Horse body weights and BCS (by 
three assessors) were also recorded pre study and monthly thereafter for the duration of the 
study.  
2.3. PBMC Isolation & Culture.  
Peripheral blood mononuclear cells (PBMC) were isolated and purified from 
heparinized blood using a Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ) 
density gradient and Phosphate Buffered Saline (PBS), respectively (Adams et al., 2008; 
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Breathnach et al., 2006; Siard et al., 2016). PBMC were counted using a VICELLTM 
Counter-XR (Beckman Coulter, Miami, FL) in order to plate cells at a concentration of 
4x106 cells/mL media [RPMI 1640 (Gibco, Grand Island, NY) supplemented with 2.5% 
fetal equine serum (FES; Sigma-Aldrich, St. Louis, MO), 100 μM 2-mercaptoethanol 
(Gibco), and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL streptomycin (HyClone 
Pen/Strep/Glutamine solution; Thermo Scientific)] (Adams et al., 2008; Breathnach et al., 
2006; Siard et al., 2016). PBMC were plated in duplicate, with all wells receiving Brefeldin 
A (10 μg/mL; Sigma), while only one well per sample was stimulated with phorbol 12-
myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma) (Adams et 
al., 2008; Breathnach et al., 2006; Siard et al., 2016). The cells were then incubated at 37oC, 
5% CO2 for 4 hours prior to intracellular staining and RNA isolation (Adams et al., 2008; 
Breathnach et al., 2006; Siard et al., 2016).  
2.4. Intracellular Staining and Flow Cytometry. 
Following incubation, PBMC were transferred into duplicate 96-well V-bottom 
plates, fixed with 2% paraformaldehyde (Sigma), and stored overnight at 4oC. Cells were 
then perforated and washed with saponin buffer [PBS supplemented with 1% fetal bovine 
serum (FBS), 0.1% saponin, and 0.1% sodium azide (Sigma)). One plate was intracellularly 
stained with IFN-γ FITC mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg). 
The second plate was stained with TNF-α anti-equine monoclonal antibody (HL801; kindly 
provided by Dr. Rob MacKay, University of Florida) and secondary antibody FITC-
conjugated goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL). Following 
intracellular staining, cells from both plates were resuspended in FACS Flow and analyzed 
using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA) and Cell Quest® 
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software (Becton Dickinson). Data were gated on lymphocyte populations to determine 
lymphocyte mediated production of IFN-γ and TNF-α.   
2.5. RNA Isolation, Reverse Transcription, and Real- Time Polymerase Chain Reaction. 
Following the 4 hour incubation, PBMC were resuspended in Trizol® solution and 
stored at -80oC until RNA was isolated using phenol-chloroform extraction. Following 
quantification with an Epoch microplate spectrophotometer (BioTek, Winooski, VT), 
RNA (1 μg) was reverse transcribed in a thermocyler (Bio-Rad, Hercules, CA) after the 
addition of master mix (16 μL avian myeloblastosis virus (AMV) buffer 5X, 16 μL MgCl2, 
4 μL dNTP, 1 μL RNasin, 1 μL Oligo dT primer, and 0.5 μL AMV Reverse Transciptase 
per sample; Promega, Madison, WI) to the samples. The thermocycler incubated samples 
at 42oC for 15 minutes and 95oC for 5 minutes. The cDNA samples then underwent RT-
PCR after the epMotion 5070 (Eppendorf) loaded plates with the samples and 11 equine 
specific intron-spanning primers and probes (Applied Biosystems), specifically IFN-γ, 
TNF-α, Il-1β, IL-6, IL-12, IL-4, IL-10, Tbet, GATA3, COX-1, and COX-2 in addition to 
Beta-glucuronidase (BGUS), the housekeeping gene. During RT-PCR, samples were 
incubated at 95oC for 10 minutes, followed by 40 cycles of 95oC for 15s and 60oC for 60s 
using the 7900HT Fast RT-PCR System (Applied Biosystems, Foster City, CA). The 
ΔΔCT method (Livak and Schmittgen 2001) will be used to determine relative changes in 
cytokine gene expression, with data being reported as relative quantity (RQ) values 
according to the equation RQ = 2 -ΔΔCT. The average ΔCT of all media alone samples on 
Day 0 will serve as the calibrator for each cytokine.  
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2.6. PGE2 ELISA. 
Serum was collected on Days 0, 30, and 90 to determine prostaglandin E2 content. 
Serum was assayed using a Parameter PGE2 competitive ELISA (R&D Systems, 
Minneapolis, MN), according to manufacturer protocol (Shah et al., 2010). This PGE2 
ELISA has previously been used to analyze equine samples due to the consistency of 
arachidonic acid derivative PGE2 among species (de Grauw et al., 2006; de Grauw et al., 
2009; Lucia et al., 2013). 
Briefly, calibrator diluent was added to non-specific binding wells (200 µL) and 
zero standard wells (150 µL). Standards, controls, and samples (ranging from undiluted 
serum to 1:18, with most samples being diluted 1:3) were added to wells in duplicate (150 
µL), followed by primary antibody solution (50 µL; in all wells but non-specific binding). 
Plates were shaken for 1 hour (500 ± 50 rpm; 0.12” orbit), followed by the addition of 
PGE2 conjugate (50 µL) and an additional 2 hour incubation on a shaker. Plates were then 
washed four times, and substrate solution (200 µL) was added, with plates being incubated 
at room temperature in the dark for 30 minutes. Stop solution (100 µL) was then added, 
and absorbance of each sample was measured at 450 nm with a 540 nm correction using a 
colorimetric ELISA microplate reader (Bio-Rad Laboratories, Inc., Philadelphia, PA). The 
mean intra-assay coefficient of variation was 7.2%. 
2.7. Endocrine Function. 
The horses were sampled to determine pituitary function, particularly examining 
the presence of pituitary pars intermedia dysfunction (PPID), an endocrinopathy caused by 
hyperplasia of the pituitary pars intermedia. Thyrotropin releasing hormone (TRH) 
stimulation was performed to determine pituitary function by exogenous injection of TRH 
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(1 mg/mL saline per horse; i.v.; Sigma-Aldrich) and analyzing EDTA plasma ACTH 
concentrations prior to and at 10 minutes post injection with TRH. EDTA plasma was 
shipped to the Cornell Animal Health Diagnostic Center (AHDC) for ACTH analysis using 
chemiluminescence immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et 
al., 2010). TRH stimulation was performed prior to and post study, approximately 1.5 hours 
post feeding and supplementation with curcumin or placebo.  
The horses were also sampled prior to feeding to determine serum basal insulin pre 
and post study, with serum samples being analyzed by Cornell AHDC using a 
commercially available radioimmunoassay for human insulin (RIA) (EMD Millipore Corp, 
Billerica, MA) that has previously been validated for use in equine samples. 
2.8. Plasma Amyloid-β ELISA. 
EDTA plasma was collected on Days 0 and 90 and frozen at -80oC until analyzed 
for amyloid-β (Aβ) peptide concentrations by Dr. Michael Paul Murphy, Sanders-Brown 
Center on Aging, University of Kentucky. A two-site sandwich ELISA was used to 
measure Aβx-42 in plasma samples, as previously described (Beckett et al., 2010). (Aβ is 
well-conserved among higher mammals (Johnstone et al., 1991), thus a human ELISA was 
used.) Briefly, an Immulon 4HBX plate (Dynex-Thermo Fisher) coated with 0.5 µg/well 
of 2.1.3 monoclonal (end specific for Aβ42) capture antibody (Das et al., 2001; Kukar et 
al., 2005), was incubated at 4° C overnight prior to blocking with Synblock (AbD Serotec, 
Raleigh, NC), according to manufacturer protocol. Biotinylated 4G8 (against Aβ17-24; 
BioLegend, San Diego, CA) antibody was used for antigen detection, followed by 
incubation with 0.1 μg / ml of neutravidin-HRP (Pierce Biotechnologies; Rockford, IL). 
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TMB reagent (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and 6% o-phosphoric 
acid solution were used to develop and stop the reaction, sequentially. A multi-well plate 
reader (Bio Tek, Winooski, VT) read the plates at 450 nm. The Aβ peptide standard curve 
samples and plasma samples were run at least in duplicate.   
2.9. CBC with Differential & Chemistry Panel. 
Lithium heparinized whole blood was collected at Day 0 and Day 90 and sent to 
Rood and Riddle Equine Hospital Laboratory to analyze complete blood count with 
differential and blood chemistry panel pre and post study to examine overall health of the 
horses. This specifically measured hemoglobin (Hgb), packed cell volume (PCV), red 
blood cells (RBC), white blood cells (WBC), total protein, mature neutrophils (seg), 
immature neutrophils (bands), lymphocytes (lymph), monocytes (mono), eosinophils (eos), 
sodium, potassium, chloride, albumin, serum glutamic oxaloacetic 
transaminase/aspartate aminotransferase (SGOT/AST), alkaline phosphatase, total 
bilirubin (T. Bili), direct bilirubin (D. bili), creatine kinase (CK), creatinine, glucose, 
gamma-glutamyl transferase (GGT), blood urea nitrogen (BUN), phosphorus, calcium, 
sorbitol dehydrogenase (SDH), and lactate dehydrogenase (LDH). 
2.10. Curcumin and Curcumin Metabolite Measurement. 
Plasma, buffy coat, and red blood cells were collected post study approximately 1.5 
hours post treatment and feeding using tubes containing acid citrate dextrose additives 
(Solution A - 22.0 g/L trisodium citrate, 8.0 g/L citric acid, 24.5 g/L dextrose; BD 
Vacutainer®, Franklin Lakes, NJ) and immediately placed on ice. Within 1 hour of 
collection, blood was centrifuged at 1500g for 15 minutes at 4oC. Aliquots of plasma, buffy 
140 
coat, and red blood cell samples were then stored at -80oC until shipped to Dr. Navindra 
Seeram at the University of Rhode Island for analysis via ultra fast liquid chromatography 
tandem mass spectrometry (UFLC-MS/MS). UFLC-MS/MS was used to determine 
content of curcumin, demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), 
curcumin sulfate, curcumin glucuronide, and ferulic acid for n=3 placebo and all n=15 
curcumin-receiving horses.  
Briefly, UFLC-MS/MS was performed with a modified protocol from analyzing 
polyphenol quantities in maple-dervied foods (Liu et al., 2016b) to determine curcumin 
and curcumin metabolite concentrations in buffy coat and red blood cells. Prominence 
UFLC (SHIMADZU, Marlborough, MA) with a Waters XBridge® BEH C18 column (100 
mm × 2.1 mm i.d., 2.5 μm. Milford, MA, USA) were used to perform chromatography, 
while mass spectrometry was performed using a QTRAP 4500 system (Applied 
Biosystems, Framingham, MA) with electrospray ionization. Samples were analyzed in 
Multiple Reaction Monitoring mode using Analyst 1.6.3 software and MultiQuant 3.0.1 
software. The calibration curve ranged from 1-1000 ng/mL for curcumin and ferulic acid 
and from 0.1-1000 ng/mL for DMC, BDMC, curcumin sulfate, and curcumin glucuronide 
and were analyzed using linear regression following x-2 transformation. Urolithin B was 
used as the internal standard. Acetonitrile was used to denature proteins. Curcumin 
compounds were extracted from 200 µL of sample (buffy coat or RBC). The mobile phase 
consisted of 43% acetonitrile with 0.1% formic acid. The flow rate was 0.2 mL/min with a 
total run time of 9 min and an injection volume of 10 µL. The assay validation was 
performed in a forthcoming publication in regards to specificity, accuracy and precision 
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(intra-day and inter-day), recovery and matrix effect, and stability using n=6 horses and all 
three blood fractions (plasma, buffy coat, and red blood cells).  
2.11. Statistical Analysis. 
To determine sample size for treatment groups, SigmaPlot version 10.0 and 
SigmaStat version 3.5 were employed using mean difference and standard deviation from 
a data set in a previous study in which a group receiving supplement was compared to a 
group receiving placebo. The power level was set at 0.8 and alpha was 0.05.  
In this study SigmaPlot version 12.0 was used to perform two-way analysis of 
variance (ANOVA) tests with repeated measures to compare treatment groups over time 
for Aβ, ACTH, insulin, PGE2, flow cytometry, and normally-distributed CBC/Chem data. 
SAS 9.4 software was used to analyze body weight, PCR gene expression, and 
some CBC/Chem parameters (Bands, Monocytes, Potassium, SGOT/AST, CK, 
Phosphorous, SDH, and GGT), as these data were not normally distributed when analyzed 
in SigmaPlot. However, SAS is more robust and met skewness and kurtosis requirements 
for each of the variables, (although some required log-transformation).  Data was analyzed 
using a mixed procedure examining time point, treatment group, and time point x treatment 
group as fixed effects, with time point as the repeated variable. PGE2 analysis only 
included data from n=12 curcumin and n=11 placebo-receiving horses, as some were 
excluded due to high coefficients of variation.  
For all analyses, data with p<0.05 were considered statistically significant and 
p<0.10 were considered trends. 
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Results 
3.1. Inflammatory cytokine and PGE2 production. 
Inflammatory cytokine production by lymphocytes was determined using flow 
cytometry. Specifically, percent of lymphocytes producing IFN-γ (Fig. 6.1A) and TNF-α 
(Fig. 6.1C) as well as mean fluorescence intensity of lymphocytes for each of each of these 
cytokines (Fig. 6.1B&D) was examined. Similar patterns in results for these cytokine 
measures were observed. Particularly, no differences between curcumin and placebo-
treated horses were found (p>0.05). Significant differences over time were observed 
(p<0.001) with an overall increase in inflammatory cytokine production over the course of 
the study. However, no significant interactions between treatment group and time were 
found (p>0.05).  
Curcumin and placebo-treated groups were also compared in relation to serum 
concentrations of pro-inflammatory prostaglandin E2 (Fig. 6.2) using a commercial ELISA 
kit (R&D Systems), and no differences were seen between treatment groups (p=0.509) or 
over time (p=0.673), as well as no interaction of treatment group with time (p=0.877).  
3.2. Real-Time Polymerase Chain Reaction Gene Expression. 
Gene expression mediated by PBMC was determined by RT-PCR (Table 6.1). 
Many variables showed significant differences over time, including: Log(COX-1), 
GATA3, Log(IFN-γ), IL-1β, IL-4, Log(IL-6), Log(IL-10), Log(IL-12), Log(Tbet), and 
Log(TNF-α) (p<0.05) (Table 6.1). Overall, these variables tended to decrease at Day 30 
and increase again thereafter. Log(COX-2) and Log(IL-6) also showed differences between 
treatment groups (p<0.05) (Fig. 6.3A&B); however, there were no treatment over time 
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interactions (p>0.05) (Table 6.1). Additionally, the differences in treatment groups for 
Log(COX-2) and Log(IL-6) appeared to largely be present at the beginning of the study, 
prior to supplementation (Fig. 6.3A&B). 
3.3. Endocrine Parameters. 
Endocrine measures were also examined pre and post study to determine any 
differences in regards to supplementation with curcumin. Plasma ACTH was analyzed both 
basally and 10 minutes post TRH injection (T-10). No differences between curcumin and 
placebo treatment groups were found (p>0.05) (Fig. 6.4). Basal ACTH exhibited a trend 
over time (p=0.066) (Fig. 6.4A), and T-10 ACTH exhibited significant differences over 
time (p=0.020), with both these measures of ACTH increasing during the study (Fig. 6.4B); 
however, no interactions between treatment groups over time were observed (p>0.05). 
No significant differences in treatment groups were seen for serum insulin 
concentrations (p>0.05) (Fig. 6.5). Over time, insulin concentrations significantly 
increased (p<0.001), but no interactions between treatment group and time were observed 
(p>0.05) (Fig. 6.5). 
3.4. Plasma Aβ concentrations. 
Plasma Aβ was also examined as it has been associated with Alzheimer’s disease 
in humans, and some similarities have been suggested between PPID of the horse and 
Alzheimer’s disease in humans, as both are neurodegenerative diseases occurring primarily 
in the elderly. Additionally, Longvida® curcumin has helped decrease some 
pathophysiology associated with Alzheimer’s disease in a mouse model (Ma et al., 2013). 
No differences in plasma Aβ concentrations were seen in treatment groups overall (p>0.05) 
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(Fig. 6.6). Significant differences were observed over time (p<0.001), with Aβ 
concentrations increasing after 90 days of treatment with curcumin or placebo (Fig. 6.6). 
A trend was observed for differences between treatment groups over time (p=0.094) (Fig. 
6.6). Plasma Aβ concentrations at baseline of placebo-receiving horses were marginally 
less than those for curcumin-treatment horses, while post-study Aβ values were slightly 
greater for placebo-treated horses than for curcumin-treated horses, suggesting that 
curcumin may decrease the extent to which Aβ values would otherwise increase. However, 
this interaction was only a trend with no significant differences between treatment group 
either pre or post study and no significant overall treatment effect (p>0.05). 
3.5. Complete Blood Count and Blood Chemistry Analysis. 
For CBC and blood chemistry panel parameters, no differences were found in 
regard to treatment group alone (p>0.05). Many variables among CBC and blood chemistry 
significantly differed with time (p<0.05) including: PCV, RBC, WBC, Log(GGT), 
phosphorus, total protein, calcium, sodium, albumin, alkaline phosphatase, direct bilirubin, 
total bilirubin, glucose, BUN, and LDH. Among these, albumin was the only variable 
exhibiting a significant interaction with treatment group over time (p<0.05), with placebo-
receiving horses having increased albumin levels over time, while curcumin-receiving 
horses did not (Fig. 6.7A). Direct bilirubin also exhibited a trend (p=0.066) for interactions 
between treatment groups and time point (Fig. 6.7B). The placebo group appeared to have 
elevated direct bilirubin prior to the study, but these concentrations dropped during the 
study, while the curcumin-supplemented horses remained at similar levels (Fig. 6.7B). 
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3.6. Body Weight, BCS, TPR, and Overall Health Parameters. 
No significant changes were seen in body weight either over time or in regard to 
treatment group (p>0.05) (Fig. 6.8A). Average body condition scores differed only in 
regard to time (p<0.05) and not treatment group (p>0.05), with BCS increasing over time 
(Fig. 6.8B). No adverse side effects were observed for horses supplemented with curcumin 
in comparison to the placebo group regarding body temperature, respiratory rate, heart rate, 
nasal discharge, or overall health (data not shown).  
3.7. Curcumin & Curcumin Metabolite Measurement. 
Buffy coat and red blood cell (RBC) fractions of the blood were each analyzed to 
determine curcumin, DMC, BDMC, curcumin sulfate, curcumin glucuronide, and ferulic 
acid for n=3 placebo and all n=15 curcumin-receiving horses. The placebo horses were 
analyzed post study to ensure that they were negative for curcumin and metabolites, and as 
expected, the horses were negative for all 6 compounds in both blood fractions. 
Additionally, the curcumin-receiving horses were all analyzed post study, and only 2 
horses had quantifiable levels of curcumin, DMC, and BDMC (detected in the RBC 
fraction from one horse, and both RBC and buffy coat from the other horse). 
Discussion 
Curcumin has exhibited anti-inflammatory effects in a multitude of studies; 
however, very few studies have been performed in the horse examining curcumin as an 
anti-inflammatory. Previously our lab has characterized the in vitro anti-inflammatory 
effects of curcumin on PBMC from senior horses (≥20 years) experiencing chronic, 
systemic inflammation known as inflamm-aging (Siard et al., 2016). However, only two 
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small-scale studies (without control groups) have previously explored the anti-
inflammatory effects of dietary curcumin on the horse in vivo (Farinacci et al., 2009a; 
Schell, 2009). Thus, the present study was undertaken to determine the effectiveness of 
dietary curcumin as an anti-inflammatory supplement in the senior horse. 
No appreciable differences were seen in various inflammatory markers for senior 
horses administered curcumin compared to placebo in this study. Specifically, horses 
supplemented with curcumin were expected to have decreased lymphocyte-mediated pro-
inflammatory cytokine expression and production compared to horses receiving placebo; 
however no differences between groups were found. Anti-inflammatory cytokines were 
also expected to potentially increase, as curcumin has many anti-inflammatory 
mechanisms of action, but again, no differences in treatment groups were present. Gene 
expression of inflammatory cytokine IL-6 exhibited an overall treatment group effect 
(p<0.05); however, there was no interaction between treatment group and time (p>0.05). 
Additionally, the difference in IL-6 between treatment groups appeared to be present prior 
to the beginning of the supplementation study; thus, the overall difference in treatment 
group is likely not due to curcumin supplementation, especially since the difference of 
means at the culmination of the study on Day 90 is numerically less than at Day 0 (0.06 
and 0.11, respectively).  
Curcumin is known to selectively inhibit pro-inflammatory COX-2 (Goel et al., 
2001), thus the curcumin-supplemented group was expected to decrease COX-2 gene 
expression compared to the placebo group without inhibiting COX-1 expression. As 
expected, there were no differences in COX-1 between treatment groups. In regard to 
COX-2, overall differences in treatment group were present; however, no interaction effect 
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of treatment group over time was present for COX-2. Since there was no treatment by time 
point interaction, and since COX-2 in placebo-treated horses was numerically greater 
(0.16) prior to the beginning of the study, the overall significant difference in COX-2 
between treatment groups is likely not due to treatment with curcumin. Additionally, horses 
in the two groups appear to have equalized COX-2 expression by Day 90, (with the placebo 
group even having a slightly lower mean of 2.34 as compared to the curcumin group mean 
of 2.40). Thus, COX-2 in the curcumin-supplemented group did not decrease in relation to 
the placebo group, which was unexpected. 
Furthermore, pro-inflammatory PGE2 in serum also did not exhibit significant 
differences in regards to treatment group or over time. Again, this was not originally 
anticipated, as the horses supplemented with curcumin were expected to have decreased 
levels of inflammatory PGE2 when compared to the placebo group. However, since no 
appreciable differences were seen in the interaction of treatment group over time for COX-
2, which is upstream of PGE2 in the pro-inflammatory signaling cascade as a catalyst for 
the conversion of arachidonic acid to PGE2 (Chizzolini and Brembilla, 2009; Park and 
Conteas, 2010), the lack of a treatment effect for the horses supplemented with curcumin 
is not surprising.   
In previous studies, many of the anti-inflammatory effects of curcumin were 
demonstrated in vitro, where the known hurdle of bioavailability is not an issue. However, 
due to the enhanced bioavailability of Longvida® curcumin (Gota et al., 2010), the 
effectiveness of curcumin as an in vivo anti-inflammatory was not expected to be impeded 
due to bioavailability. Furthermore, several in vivo studies with curcumin-containing 
products with enhanced bioavailability including Longvida® have demonstrated biological 
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effects (Cox et al., 2015; Ma et al., 2013). However, few dietary Longvida® curcumin 
studies have focused on anti-inflammatory effects of curcumin. One study found lower 
exercise-induced inflammation (TNF-α and IL-8) in subjects receiving Longvida® 
curcumin in comparison to placebo (McFarlin et al., 2016). However, another study found 
serum inflammatory cytokine levels were below detection limits for most parameters 
analyzed, and C-reactive protein levels did not differ in Longvida® curcumin-receiving 
subjects (Cox et al., 2015). 
In addition to determining effects of curcumin supplementation on inflammation, 
this study examined the effects of curcumin supplementation on endocrine function, 
specifically regarding basal insulin, basal ACTH, and ACTH response to TRH stimulation. 
Horses experience various endocrine disorders, with two of the most common being equine 
metabolic syndrome (EMS) and pituitary pars intermedia dysfunction (PPID). EMS is 
similar to metabolic syndrome in humans in that it involves regional adiposity, insulin 
resistance (which may include hyperinsulinemia), and sometimes heightened levels of 
triglycerides (Frank et al., 2010b). EMS is particularly problematic due to its associated 
predisposition to laminitis, an inflammatory condition of the hoof that can be fatal to horses 
(Frank et al., 2010b; Johnson et al., 2012). Curcumin has been shown to decrease 
triglycerides and insulin resistance (Ghorbani et al., 2014; Panahi et al., 2014; Song et al., 
2015b), thus it was thought that curcumin may be able to mitigate EMS in the horse. PPID 
is common in the senior horse, caused by dopaminergic neurodegeneration of the pars 
intermedia lobe of the pituitary and frequently resulting in hypertrichosis, polydipsia, 
polyuria, hyperhidrosis, laminitis, muscle atrophy, and abnormal fat distribution 
(McFarlane, 2011). Endocrinologically, this frequently results in increased levels of basal 
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circulating adrenocorticotropin hormone (ACTH), while also resulting in decreased ability 
of horses to return to resting levels of ACTH after intravenous injection of thyrotropin 
releasing hormone (TRH) (Beech et al., 2007). Curcumin has been shown to exhibit anti-
tumor activity, including in the pituitary (Bangaru et al., 2010; Curic et al., 2013; Schaaf 
et al., 2009; Shan et al., 2012), specifically decreasing hormone levels associated with 
pituitary tumors (Miller et al., 2008a; Schaaf et al., 2009). Thus, it was expected that senior 
horses supplemented with curcumin would have improved endocrine function, both 
increasing insulin sensitivity and decreasing excessive production of ACTH in response to 
TRH stimulation. However, no differences in endocrine function were found for horses 
supplemented with curcumin in comparison to placebo.  
In addition to examining endocrine dysfunctions in the horse, plasma Aβ was also 
examined. Amyloid-β production and deposition is one of the two primary pathologies 
associated with Alzheimer’s disease (Murphy and LeVine, 2010). Since Longvida® 
curcumin has previously decreased various Alzheimer’s-associated pathologies (Begum et 
al., 2008; Ma et al., 2013), and since both the PPID horse and Alzheimer’s patients 
experience age-related neurodegeneration, examining plasma Aβ was of interest. However, 
no differences in plasma Aβ were seen between treatment groups in this study. A trend was 
present in the interaction between time point and treatment group for Aβ, but no significant 
differences between treatment groups occurred. There was, however, a significant overall 
time effect. Variations in Aβ with season have not yet been investigated, although in this 
study, it appears that season or some other condition experienced by this group of senior 
horses in general seems to influence levels of circulating Aβ. Although horses would most 
likely be more apt to exhibit seasonal changes than humans due to their outdoor housing, 
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it may bear investigation to determine how easily plasma Aβ may be influenced by 
conditions aside from the presence of Alzheimer’s disease.  
Many inflammatory and metabolic parameters increased over the course of the 
study for horses regardless of treatment group, which may be due to seasonal effects. 
Insulin has previously been shown to vary seasonally in equids, particularly for those 
grazing on pasture, as insulin was correlated with grass carbohydrate composition (Borer-
Weir et al., 2013; Frank et al., 2010a). Likewise, ACTH has known seasonal rhythms in 
the horse as well (Cordero et al., 2012; Frank et al., 2010a). Inflammatory markers have 
exhibited seasonal rhythms in other species (Bilbo et al., 2002; Bowden et al., 2007; 
McFarlane et al., 2012), though work in the horse regarding seasonal inflammatory 
parameters is limited thus far with only a few studies showing seasonal fluctuations in 
unhealthy animals (Beadle et al., 2002; Hamza et al., 2007). Although this study was 
conducted in spring/summer (from late March to late June) to control for changes in season 
as much as possible, the results of this study show an overall increase in many 
inflammatory and metabolic parameters, suggesting that similarly to other species, 
seasonal variation of inflammatory markers may occur in the healthy horse as well. 
Additionally, these increases in inflammatory markers over the course of the study may at 
least in part be due to the increased body condition scores, which indicate an increase in 
body fat. And, increased body fat in the horse specifically has been associated with 
increased PBMC-mediated inflammation (Adams et al., 2009). 
Regarding the lack of curcumin and curcumin metabolites in blood fractions for all 
but two of the horses supplemented with curcumin, several factors may contribute. First, 
the curcumin may truly not have reached the bloodstream, in which case it would be 
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expected that curcumin glucuronide and curcumin sulfonate would be present (Kumar et 
al., 2010); however, this does not appear to be the case. Second, the timing of the blood 
collection may not have been ideal to detect curcumin and metabolites for most of the 
horses despite the fact that quantifiable levels were present for two of the horses. Studies 
have shown that some curcumin formulations are rapidly absorbed into tissues and spend 
very little time in the bloodstream, yielding bioactive effects even at undetectable plasma 
levels (Pawar et al., 2012). This is entirely possible however does not explain the lack of 
biological effects seen in this study. Third, the dose and/or formulation of curcumin was 
not effective to reach peak levels in the blood for most horses and thereby have biological 
effects in the horse.  
The dose of curcumin certainly may be the primary reason that supplementation 
did not demonstrate biological anti-inflammatory effects. In many previous studies where 
oral curcumin has been used to correct pathophysiology, the dose was often larger in 
relation to mg/kg body weight (Kumar et al., 2011; Maithilikarpagaselvi et al., 2016; 
Venkatesan and Chandrakasan, 1995). Additionally, previous work in our lab showing in 
vitro anti-inflammatory effects of curcumin on PBMC from senior horses indicated a much 
higher concentration of curcumin (without enhanced bioavailability) needed to achieve 
biological effects (Siard et al., 2016). However, the dose used in the current study was 
originally thought to be sufficient due to: 1) the enhanced bioavailability of Longvida® 
curcumin (Gota et al., 2010), 2) the length of study (90 days, whereas several other studies 
were shorter term), and 3) the quantity of curcumin already being given to horses, even at 
a lower mg/kg body weight dose. 
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Another potential reason anti-inflammatory effects of curcumin were not seen in 
this study may be that naturally-occurring basal inflamm-aging alone was not the best 
model in which to evaluate the effectiveness of curcumin as an anti-inflammatory 
supplement. Perhaps inflamm-aging of the senior horse was not as readily responsive to 
anti-inflammatory supplements as experimental models. Most studies showing curcumin 
to have effects on inflammation, metabolism, oxidative stress, senescence, etc. involve 
induced models in experimental animals (Kinney et al., 2015; Kumar et al., 2011; Ma et 
al., 2013; Maithilikarpagaselvi et al., 2016; Nanji et al., 2003; Venkatesan and 
Chandrakasan, 1995). For example, D-galactose-induced senescence in mice was 
attenuated by oral treatment with curcumin, improving memory dysfunction and oxidative 
damage (Kumar et al., 2011). However, perhaps because senescence was induced, 
curcumin may not have the same degree of effectiveness in naturally-occurring senescence. 
Additionally, some models of inflammation that have shown the effectiveness of curcumin 
and particularly Longvida® involve some type of physiological challenge, such as 
exercise, in which the degree of inflammation and muscle damage was modulated in 
comparison to a group receiving placebo (McFarlin et al., 2016). 
While the expected anti-inflammatory effects of curcumin were not exhibited in 
this study at the dose given, negative side effects were not present either, which were 
monitored by clinical examination and CBC with differential and chemistry panels prior to 
and post treatment. This aligns with a multitude of previous work, showing that curcumin 
in generally regarded as safe even at much higher dosages than those given in the present 
study (Cox et al., 2015; Nanji et al., 2003).  
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In conclusion, senior horses (≥20 years) supplemented with curcumin compared to 
placebo did not differ in regard to modulation of inflamm-aging. Treatment with curcumin 
also did not appear to affect endocrine function. Numerous parameters showed overall time 
effects, but these did not appear to be due to treatment. Since a low dose of curcumin 
supplementation was unable to mitigate age-associated inflammation, potentially 
increasing the dose of curcumin may be able to mediate anti-inflammatory effects. 
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Figure 6.1. Peripheral blood mononuclear cell (PBMC)-mediated production of interferon(IFN)- 
γ and tumor necrosis factor(TNF)-α from n=15 curcumin and n=15 placebo-receiving senior horses 
(≥20 years). PBMC were stimulated with PMA and analyzed via intracellular staining and flow 
cytometry to determine both percent of lymphocytes producing (A) IFN-γ and (C) TNF-α and 
mean fluorescence intensity (MFI) for each of these cytokines (B&D). P-values for significant 
(p<0.05) data are denoted on the figures. Ptime refers to the p-value for overall effects of time. 
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Figure 6.2. Serum Prostaglandin E2 (PGE2) production in curcumin and placebo supplemented 
senior horses. Serum from n=12 curcumin and n=11 placebo-receiving horses was analyzed via 
ELISA to determine pro-inflammatory PGE2 production.  
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Figure 6.3. PBMC-mediated inflammatory gene expression of curcumin (n=15) and placebo 
(n=15)-receving senior horses (≥20 years).  Gene expression is reported as the log of relative 
quantity (RQ) values of (A) cyclooygenase(COX)-2 and (B) interleukin(IL)-6. P-values for 
significant (p<0.05) data are denoted on the figures. Ptrt refers to the p-value for treatment group 
overall, while Ptime refers to the p-value for overall time effects. 
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Figure 6.4. Thyrotropin releasing hormone (TRH) stimulation testing in senior horses (≥20 years) 
pre and post 90-day supplementation with curcumin (n=15) or placebo (n=15). Plasma was 
analyzed both for (A) basal ACTH and for (B) ACTH 10 minutes post intravenous injection with 
TRH, as measures of pituitary function. Data with p<0.05 were considered significant, while those 
with p<0.10 were considered trends. P-values for significant and trending data are denoted on the 
figures. Ptime refers to the p-value for overall effects of time (pre vs. post study). 
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Figure 6.5. Basal insulin pre vs. post study for curcumin (n=15) vs. placebo-receiving (n=15) 
horses. P-values for significant (p<0.05) data are denoted on the figure. Ptime refers to the p-value 
for overall effects of time (pre vs. post study). 
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Figure 6.6. Plasma Aβ pre vs. post study for curcumin (n=15) and placebo-receiving (n=15) senior 
horses (≥ 20 yrs). Data with p<0.05 were considered significant, while those with p<0.10 were 
considered trends. P-values for significant and trending data are denoted on the figures. Ptime refers 
to the p-value for overall effects of time (pre vs. post study), while Ptrt x time refers to the p-value 
for the interaction between treatment group and time point. Bars with different lettering 
significantly differ (p<0.05) from each other. 
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Figure 6.7. Blood chemistry panel parameters with significant (p<0.05) or trending 
(p<0.10) interactions between time point and treatment group (n=15 curcumin and n=15 
placebo-treated horses). P-values for significant and trending data are denoted on the 
figures. Ptime refers to the p-value for overall time effects (pre vs. post study), while Ptrt x
time refers to the p-value for the interaction between treatment group and time point. Bars 
with different lettering significantly differ (p<0.05) from each other. 
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Figure 6.8. Body weights and body condition scores (BCS) for senior (≥20 yrs) horses 
supplemented with curcumin (n=15) or placebo (n=15) for 90 days. Body weights (A) and 
BCS (B) were monitored approximately every 30 days throughout the duration of the study. 
P-values for significant (p<0.05) data are denoted on the figures. Ptime refers to the p-value 
for overall time effects. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS 
Inflamm-aging, the chronic low-grade inflammation occurring systemically with 
advanced age, is well-characterized in the horse. Lymphocyte-mediated inflamm-aging has 
specifically been demonstrated in the horse, which is not surprising given that a vast body 
of literature in various species has shown lymphocytes to be particularly affected by 
advanced aging. In humans, inflamm-aging is associated with various age-related diseases 
as well as morbidity and mortality; however, clearly defined clinical effects in the horse 
have not yet been determined. Given that senior horses (≥20 years) comprise a substantial 
component of the equine population, with many continuing to be used for competition and 
recreation into their senior years, understanding the implications of inflamm-aging for the 
horse is key to promote healthspan as well as lifespan. 
In this research, senior horses exhibiting inflamm-aging and adult horses exhibited 
seasonal variations in inflammatory cytokine production. Specifically, lymphocyte-
mediated production of pro-inflammatory cytokines was decreased in winter and elevated 
during spring and summer. Similarly, PBMC-mediated gene expression of TNF-α was 
elevated in summer, while IL-6 expression was actually decreased in summer. Some of 
these seasonal inflammatory changes appeared to be associated with body weight and may 
be associated with temperature and/or photoperiod, but likely a complex array of neuro-
endocrine-immune signaling pathways is involved. Future research should focus on 
understanding what these seasonal changes may mean for the health of the senior horse, 
already immune-compromised due to immunosenescence and inflamm-aging.  
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 Inflamm-aging was also examined in relation to the common age-associated 
endocrinopathy, pituitary pars intermedia dysfunction (PPID), which has been associated 
with immunosuppression and increased susceptibility to opportunistic infections. Senior 
PPID horses and age-matched non-PPID horses do not appear to differentially experience 
lymphocyte-mediated inflamm-aging. Specifically, no differences were found between 
PPID and non-PPID horses regarding lymphocyte-mediated inflammatory cytokine 
production or PBMC-mediated inflammatory cytokine gene expression. Likely, the aspects 
of PPID impacting immunity are primarily mediated by neutrophils, as some previous 
research has demonstrated, and not lymphocytes. Future research should examine what 
stimulates the initiation of the dopaminergic neurodegeneration associated with PPID, 
particularly examining any relationships with inflammation and/or the immune system. 
 Relationships of inflamm-aging with overall health of the senior horse were also 
examined, particularly in regard to nutrition status, body composition, 
hematology/biochemistry, and PPID status. Inflamm-aging appears to be associated with 
increased levels of serum docosadienoic acid (C22:2n6c), docosapentaenoic acid 
(C22:5n3c), and folate, which may be due to a compensatory effect, given that these 
nutrients are generally considered to be anti-inflammatory. No relationships between 
inflamm-aging and markers of body composition were found. However, within the group 
of senior horses, age itself was inversely associated with multiple markers of body 
composition, indicating the incidence of decreased muscle, body condition, and weight 
with advanced age. Further research should focus on elucidating implications of the 
relationships found, with the goal of promoting the health and longevity of the senior horse.  
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The ability of phytonutrient polyphenols to mitigate lymphocyte-mediated 
inflamm-aging of the senior horse was also examined in vitro. Curcumin, resveratrol, 
quercetin, pterostilbene, and hydroxypterostilbene all significantly reduced lymphocyte-
mediated inflamm-aging of the senior horse in vitro. These anti-inflammatory results were 
achieved at concentrations that were not cytotoxic. Additionally, the anti-inflammatory 
capacity of polyphenols was compared to common NSAIDs, and polyphenols were found 
to significantly reduce inflamm-aging similarly. In fact, curcumin decreased inflammation 
at a concentration lower than the NSAIDs or any of the other polyphenols, demonstrating 
its potent anti-inflammatory capacity. Thus, polyphenols were found to mitigate inflamm-
aging of the senior horse in vitro.  
As a follow-up to our in vitro polyphenol work, curcumin was evaluated in vivo as 
a potential anti-inflammatory supplement for the senior horse exhibiting inflamm-aging. 
Senior horses receiving enhanced-bioavailability curcumin and placebo did not 
significantly differ in regard to degree of inflamm-aging after being supplemented for 90 
days. Specifically, no differences were found between curcumin and placebo-receiving 
horses in regards to lymphocyte-mediated inflammatory cytokine production or PBMC-
mediated inflammatory gene expression. This lack of anti-inflammatory response in horses 
supplemented with curcumin may be due to an inadequate dose, as only two of the fifteen 
horses administered curcumin showed quantifiable levels of curcumin and/or metabolites 
in blood, or a poor response of the senior horse to the specific formulation. Future research 
should be conducted to determine whether a higher dose or different formulations of 
curcumin delivery systems may enable curcumin to function as an effective anti-
inflammatory agent in the senior horse. Furthermore, some previous research suggests that 
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curcumin in combination with other polyphenols may act synergistically, which would be 
of interest to test in the inflamm-aging horse in vivo. 
As a whole, this body of research demonstrates that various factors are associated 
with lymphocyte-mediated inflamm-aging of the senior horse. Furthermore, this inflamm-
aging may potentially be modulated by anti-inflammatory polyphenols; however, further 
research is necessarily to determine dosage and formulations effective as anti-
inflammatory supplements in the horse. Additionally, future research to better understand 
the implications of inflamm-aging on overall health of the senior horse should be 
undertaken in an effort to promote healthspan in addition to longevity of horse. 
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